Targeted linear conjugates containing polyethyleneimine and polymethylene glycol and polyplexes containing same
Chemoselective conjugation of LPEI-PEG fragments forms stable, targeted polyplexes with defined structures, addressing inefficiencies in tumor uptake and aggregation issues, enhancing antitumor activity and reducing toxicity.
Patent Information
- Application Number
- JP2024526541
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-05
- Filing Date
- 2022-11-07
- Publication Date
- 2024-11-13
AI Technical Summary
Current chemotherapeutic agents face inefficiencies in targeting and uptake by tumors, leading to non-specific uptake by healthy cells and toxicity due to inadequate tumor accessibility, and existing cationic polymer-nucleic acid polyplexes suffer from aggregation and interaction with serum proteins, hindering their potential as delivery agents.
The development of chemoselective conjugation methods to form linear LPEI-PEG conjugates with defined structures, allowing for consistent and predictable ratios of LPEI to PEG fragments, which are then combined with targeting ligands and polyanions like poly(IC) to create targeted polyplexes for selective delivery to cancer cells.
The linear LPEI-PEG conjugates with defined chemoselective binding enhance the stability and biological activity of polyplexes, improving tumor targeting and reducing non-specific uptake, thereby maintaining or increasing antitumor activity while minimizing toxicity.
Smart Images

Figure 2024542076000487 
Figure 2024542076000488 
Figure 2024542076000489
Abstract
Description
[Technical Field]
[0001] Cancer remains a leading cause of death worldwide. For most solid tumors after surgical removal, chemotherapy is an important treatment option for managing remaining cancer cells. The main reason for chemotherapy failure is inefficient targeting and uptake of chemotherapeutic agents by tumors (Vasir & Labhasetwar Technology in Cancer Research & Treatment 4(4), 363-374(2005)). Insufficient accessibility to tumors requires higher doses, and due to the nature of chemotherapeutic agents, this leads to nonspecific uptake and toxicity in healthy cells. Targeted drug delivery strategies, in which therapeutic agents reversibly bind to targeting ligands and are selectively delivered to cells for treatment, are currently applied to many chemotherapeutic agents in clinical use. This strategy shows promise for maximizing the safety and efficacy of a given chemotherapeutic agent, as their selective delivery to target cells avoids nonspecific uptake and associated toxicity in healthy cells, which can result in a higher maximum tolerated dose (Srinivasarao & Low, Chem. Rev., 117, 12133-12164, (2017)).
[0002] Cationic polymers are known to form supramolecular polyplexes with negatively charged nucleic acids in solution. For example, linear polyethyleneimine (LPEI) is protonated at physiological pH and therefore has a net positive charge. When LPEI is incubated with nucleic acids, which have a net negative charge at physiological pH, the LPEI and nucleic acids can form polyplexes held together by electrostatic interactions. These supramolecular polyplexes can be taken up by cells in vivo and can deliver nucleic acid sequences into cells. Therefore, supramolecular polyplexes containing cationic polymers and nucleic acids can be used as vectors for therapy.
[0003] Despite their promise, technical challenges remain regarding the formation of homogeneous, well-characterized cationic polymers. Polyplexes containing only LPEI are prone to aggregation and interactions with serum proteins, potentially limiting their potential as nucleic acid delivery agents. To overcome these challenges, the polymer LPEI can be conjugated or copolymerized with polyethylene glycol (PEG). PEG fragments can help shield LPEI from the surrounding matrix, improving the biocompatibility and blood circulation of the resulting polyplexes.
[0004] However, coupling of PEG to LPEI generally occurs via the formation of a covalent bond between an electrophilic PEG fragment and a secondary amine embedded within the LPEI backbone fragment, resulting in branched, heterogeneous conjugates that randomly incorporate PEG fragments, characterized based on the average PEG inclusion density. In such conjugates, the PEG fragments, whether single or multiple, are generally orthogonally attached to the LPEI fragment without site specificity. Such random synthesis and inaccurate characterization of LPEI-PEG conjugates can make it difficult to establish a clear structure-activity relationship (SAR) between the conjugate structure and the activity of the resulting supramolecular polyplex. Therefore, there is a need for homogeneous LPEI-PEG conjugates with well-defined chemical structures. Summary of the Invention
[0005] Instead of the random and uncontrolled attachment of an electrophilic PEG fragment to one of the multiple nucleophiles of an LPEI backbone fragment, the present invention provides conjugates comprising an LPEI and a PEG fragment connected by a distinct linkage formed by a defined chemoselective reaction. The distinct linkage not only ensures a consistent and predictable ratio of LPEI to PEG fragment, but also ensures a defined linear conjugate instead of a random branched conjugate. Thus, the LPEI fragment is attached to a single PEG fragment in a linear, end-to-end manner. The chemoselective attachment of the LPEI fragment to the PEG fragment can be achieved using any suitable chemical precursor capable of forming a chemoselective bond. In a preferred embodiment, the chemoselective attachment of the LPEI fragment to the PEG fragment occurs via a [3 + 2] cycloaddition between an azide and an alkyne or alkene. Alternatively, the chemoselective attachment is via a thiol-ene reaction between a thiol and an alkene. When the chemoselective bond is between an azide and an alkyne or alkene, the resulting linkage is a 1,2,3-triazole (if an alkyne is coupled) or a 4,5-dihydro-1H-[1,2,3]triazole (if an alkene is coupled). When the chemoselective bond is between a thiol and an alkene, the resulting linkage is a thioether.
[0006] In preferred conjugates of the present invention, the PEG fragment is further selectively linked to a targeting fragment to target specific cell types and promote uptake of the compositions, conjugates, and / or polyplexes of the present invention in said specific cell types. Thus, preferred embodiments include one or more (e.g., one) targeting fragment, such as hEGF, a HER2 ligand, DUPA, or folate, specifically linked to an LPEI-PEG diconjugate to form an LPEI-PEG-targeting fragment triconjugate, capable of targeting corresponding receptors, such as hEGFR, HER2, PSMA, or folate, on specific cell types, typically cancer cell types. In polyplexes of the present invention, such triconjugates are combined with a polyanion, such as a nucleic acid, preferably polyinosinic:polycytidylic acid (poly(IC)), which can serve as a cytotoxic and / or immunostimulatory payload delivered to and internalized within cells.
[0007] Even more advantageously and surprisingly, the inventors have found that preferred conjugates and polyplexes obtained according to the present invention are significantly less heterogeneous due to the defined chemoselective attachment of the LPEI fragments to the PEG fragments, thus significantly reducing the number of potentially biologically active conjugates and polyplexes, and not only forming polyplexes of appropriate size, but also maintaining or even increasing their overall biological activity, such as potency and selectivity for reducing survival and inducing cell death of targeted cancer cells.
[0008] Thus, in one aspect, the present invention provides a composition comprising a conjugate, the conjugate comprising a linear polyethyleneimine (LPEI) fragment comprising an alpha end and an omega end; a polyethylene glycol (PEG) fragment, preferably a linear polyethylene glycol (PEG) fragment, comprising a first end and a second end; wherein the omega end of the LPEI fragment is connected to the first end of the PEG fragment by a covalent linking moiety; the covalent linking moiety is not an amide; preferably, the alpha end of the LPEI fragment is bonded to a methyl group or a hydrogen atom, more preferably, the alpha end of the LPEI fragment is bonded to a hydrogen atom; and preferably, the second end of the PEG fragment is bonded to a targeting fragment.
[0009] In one aspect, the invention provides a composition comprising a conjugate, the conjugate comprising a linear polyethyleneimine fragment comprising an alpha end and an omega end; a polyethylene glycol fragment comprising a first end and a second end; wherein the alpha end of the polyethyleneimine fragment is an initiating residue; the omega end of the polyethyleneimine fragment is connected to the first end of the polyethylene glycol fragment by a covalent linking moiety; the covalent linking moiety is not a single bond and is not an amide; and preferably, the second end of the polyethylene glycol fragment is capable of reacting, preferably the second end is capable of binding to a target fragment.
[0010] In one aspect, the present invention provides a composition comprising a conjugate, said conjugate comprising: a linear polyethyleneimine fragment containing an alpha end and an omega end; comprising a polyethylene glycol fragment comprising a first end and a second end; wherein the alpha terminus of the polyethyleneimine fragment is the initiating residue; The omega end of the polyethyleneimine fragment is linked to a covalent linking group -ZX 1-Z- is connected to the first end of the polyethylene glycol fragment by -Z-, where -Z- is not a single bond and -Z- is not an amide; -X 1 - is a divalent covalent linking moiety; The second end of the polyethylene glycol fragment is capable of binding to a targeting fragment, and preferably said polyethylene glycol fragment binds to a targeting fragment. In a preferred embodiment of this aspect, the composition consists of said conjugate.
[0011] In another aspect, the present invention provides a composition comprising a conjugate of formula I*: R 1 -(NR 2 -CH2-CH2) n -ZX 1 -(O-CH2-CH2) m -X 2 -L(formula I*); [In the formula, n is any integer from 1 to 1500; m is any integer from 1 to 200, preferably m is any integer from 1 to 100; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -R in 2 at least 80%, preferably 90% of which is H; X 1 and X 2 are independently a divalent covalent linking moiety; Z is a divalent covalent linking moiety, wherein Z is not a single bond and Z is not -NHC(O)-; L is a targeting fragment, wherein preferably said targeting fragment is capable of binding to a cell, and more preferably said targeting fragment is capable of binding to a cell surface receptor. or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or enantiomer thereof, and Preferably, a composition is provided that consists of the conjugate.
[0012] In another aspect, the present invention provides a conjugate of formula I*: R 1 -(NR 2 -CH2-CH2) n -ZX 1 -(O-CH2-CH2) m -X 2 -L(formula I*); [In the formula, n is any integer from 1 to 1500; m is any integer from 1 to 200, preferably m is any integer from 1 to 100; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -R in 2 at least 80%, preferably 90% of which is H; X 1 and X 2 are independently a divalent covalent linking moiety; Z is a divalent covalent linking moiety, wherein Z is not a single bond and Z is not -NHC(O)-; L is a targeting fragment, wherein preferably said targeting fragment is capable of binding to a cell, and more preferably said targeting fragment is capable of binding to a cell surface receptor. or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or enantiomer thereof.
[0013] In another aspect, the present invention provides a composition comprising a conjugate of formula I: [ka] [In the formula, [ka] is a single or double bond; n is any integer from 1 to 1500; m is any integer from 1 to 200; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -R in 2 at least 80%, preferably at least 90% of is H; Ring A may have one or more R A1 5-10 membered cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl optionally substituted with R A1 are independently selected from C1-C6 alkyl, C1-C6 alkoxy, oxo, or halogen; or two R A1 together with the atoms to which they are attached to form one or more fused C6-C 10 can form an aryl, C-C heteroaryl, or C-C cycloalkyl ring, and each fused aryl, heteroaryl, or cycloalkyl can be joined by one or more R A2 optionally substituted with R A2 is independently selected from C1-C6 alkyl, C1-C6 alkoxy, halogen, —SO3H, or OSO3H; X 1 is a divalent covalent linking moiety; X 2 is a divalent covalent linking moiety; and L is a targeting fragment, wherein preferably said targeting fragment is capable of binding to a cell, and more preferably said targeting fragment is capable of binding to a cell surface receptor. or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or enantiomer thereof.
[0014] In another aspect, the present invention provides a conjugate of formula I: [ka] [In the formula, [ka] is a single or double bond; n is any integer from 1 to 1500; m is any integer from 1 to 200; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -R in 2 at least 80%, preferably at least 90% of is H; Ring A may have one or more R A1 5-10 membered cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl optionally substituted with R A1 are independently selected from C1-C6 alkyl, C1-C6 alkoxy, oxo, or halogen; or two R A1 together with the atoms to which they are attached to form one or more fused C6-C 10 can form an aryl, C-C heteroaryl, or C-C cycloalkyl ring, and each fused aryl, heteroaryl, or cycloalkyl can be joined by one or more R A2 optionally substituted with R A2 is independently selected from C1-C6 alkyl, C1-C6 alkoxy, halogen, —SO3H, or OSO3H; X 1 is a divalent covalent linking moiety; X 2 is a divalent covalent linking moiety; and L is a targeting fragment, wherein preferably said targeting fragment is capable of binding to a cell, and more preferably said targeting fragment is capable of binding to a cell surface receptor. or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or enantiomer thereof.
[0015] In another aspect, the present invention provides a composition comprising a conjugate of formula I: [ka] [In the formula, [ka] is a single or double bond; n is any integer from 1 to 1500; m is any integer from 1 to 200, preferably m is any integer from 1 to 100; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n - the R in the part 2 at least 80%, preferably 90% of which is H; Ring A may have one or more R A1 5-10 membered cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl optionally substituted with; R A1 are independently selected from C1-C6 alkyl, C1-C6 alkoxy, oxo, or halogen; or two R A1 together with the atoms to which they are attached to form one or more fused C6-C 10can form an aryl, C-C heteroaryl, or C-C cycloalkyl ring, where each fused aryl, heteroaryl, or cycloalkyl is joined to one or more R A2 optionally substituted with; R A2 is independently selected from C1-C6 alkyl, C1-C6 alkoxy, halogen, —SO3H, or OSO3H; X 1 is the formula -(Y 1 ) p where p is an integer from 1 to 20, and Y 1 Each occurrence of represents independently a chemical bond, -CR 11 R 12 -, -C(O)-, -O-, -S-, -NR 13 -, an amino acid residue, a divalent phenyl moiety, a divalent heterocyclic moiety, and a divalent heteroaryl moiety, wherein each divalent phenyl or heteroaryl is selected from one or more R 13 and each divalent heterocycle is optionally substituted with one or more R 14 optionally substituted with R 11 , R 12 and R 13 is independently at each occurrence H or C1-C6 alkyl; and 14 is a linking moiety for (each occurrence is independently H, C1-C6 alkyl, or oxo); X 2 is the formula -(Y 2 ) q - (wherein q is an integer from 1 to 50, and Y 2 Each occurrence of represents independently a chemical bond, -CR 21 R 22 -, NR 23 -, -O-, -S-, -C(O)-, an amino acid residue, a divalent phenyl moiety, a divalent heterocyclic moiety, and a divalent heteroaryl moiety, wherein each divalent phenyl and divalent heteroaryl is selected from one or more R 23 and each divalent heterocyclic moiety is optionally substituted with one or more R 24 optionally substituted with R 21 , R 22and R 23 are each independently at each occurrence -H, -CO2H, or C1-C6 alkyl, where each C1-C6 alkyl is selected from one or more of -OH, oxo, C6-C 10 optionally substituted with aryl or 5-8 membered heteroaryl; and R 24 is a linking moiety for (each occurrence is independently -H, -COH, C-C alkyl, or oxo); and L is preferably a targeting fragment capable of binding to a cell. or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or enantiomer thereof, and preferably consisting of said conjugate.
[0016] In another aspect, the present invention provides a conjugate of formula I: [ka] [In the formula, [ka] is a single or double bond; n is any integer from 1 to 1500; m is any integer from 1 to 200, preferably m is any integer from 1 to 100; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n - the R in the part 2 at least 80%, preferably 90% of which is H; Ring A may have one or more R A1 5-10 membered cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl optionally substituted with; R A1are independently selected from C1-C6 alkyl, C1-C6 alkoxy, oxo, or halogen; or two R A1 together with the atoms to which they are attached to form one or more fused C6-C 10 can form an aryl, C-C heteroaryl, or C-C cycloalkyl ring, where each fused aryl, heteroaryl, or cycloalkyl is joined to one or more R A2 optionally substituted with; R A2 is independently selected from C1-C6 alkyl, C1-C6 alkoxy, halogen, —SO3H, or OSO3H; X 1 is the formula -(Y 1 ) p where p is an integer from 1 to 20, and Y 1 Each occurrence of represents independently a chemical bond, -CR 11 R 12 -, -C(O)-, -O-, -S-, -NR 13 -, an amino acid residue, a divalent phenyl moiety, a divalent heterocyclic moiety, and a divalent heteroaryl moiety, wherein each divalent phenyl or heteroaryl is selected from one or more R 13 and each divalent heterocycle is optionally substituted with one or more R 14 optionally substituted with R 11 , R 12 and R 13 is independently at each occurrence H or C1-C6 alkyl; and 14 is a linking moiety for (each occurrence is independently H, C1-C6 alkyl, or oxo); X 2 is the formula -(Y 2 ) q - (wherein q is an integer from 1 to 50, and Y 2 Each occurrence of represents independently a chemical bond, -CR 21 R 22 -, NR 23-, -O-, -S-, -C(O)-, an amino acid residue, a divalent phenyl moiety, a divalent heterocyclic moiety, and a divalent heteroaryl moiety, wherein each divalent phenyl and divalent heteroaryl is selected from one or more R 23 and each divalent heterocyclic moiety is optionally substituted with one or more R 24 optionally substituted with R 21 , R 22 and R 23 are each independently at each occurrence -H, -CO2H, or C1-C6 alkyl, where each C1-C6 alkyl is selected from one or more of -OH, oxo, C6-C 10 optionally substituted with aryl or 5-8 membered heteroaryl; and R 24 is a linking moiety for (each occurrence is independently -H, -COH, C-C alkyl, or oxo); and L is preferably a targeting fragment capable of binding to a cell. or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or enantiomer thereof.
[0017] In a further aspect, the present invention provides methods for synthesizing a composition comprising a conjugate of Formula I, comprising reacting an azide-containing LPEI fragment with an alkene or alkyne-containing PEG fragment at a pH below about 5, preferably below about 4. In some preferred embodiments, the LPEI fragment comprises an azide at the omega terminus and the PEG fragment comprises an alkene or alkyne at a first terminus.
[0018] In a further aspect, the present invention provides a polyplex comprising a composition described herein and a polyanion, preferably wherein the polyanion is a nucleic acid, more preferably wherein the nucleic acid is RNA, and again more preferably wherein the polyanion is polyinosinic:polycytidylic acid (poly(IC)).
[0019] In a further aspect, the invention provides a polyplex comprising a composition described herein and a nucleic acid. In a further aspect, the invention provides a polyplex comprising a composition described herein and a nucleic acid, wherein the nucleic acid is RNA. In a further aspect, the invention provides a polyplex comprising a composition described herein and polyinosinic:polycytidylic acid (poly(IC)).
[0020] In another aspect, the present invention provides a polyplex comprising a triconjugate as described herein, preferably said conjugate of Formula I* or Formula I, and a polyanion, e.g., a nucleic acid, preferably polyinosinic:polycytidylic acid (poly(IC)).
[0021] In one aspect, the present invention provides pharmaceutical compositions comprising a triconjugate described herein, preferably said conjugate of Formula I* or Formula I, and / or a polyplex, and pharmaceutically acceptable salts thereof.
[0022] In one aspect, the invention provides a polyplex as described herein, or a pharmaceutical composition comprising a polyplex as described herein, for use in the treatment of a disease or disorder, preferably cancer.
[0023] In one aspect, the invention provides the use of a polyplex as described herein for use in the manufacture of a medicament for the treatment of a disease or disorder, such as cancer.
[0024] In another aspect, the present invention provides a method of treating a disease or disorder, e.g., cancer, in a subject in need thereof, comprising administering to the subject an effective amount of a polyplex described herein.
[0025] The compositions and polyplexes of the invention, including the linear, non-random LPEI-PEG di- and tri-conjugates described herein, not only ensure a consistent and predictable ratio of LPEI fragments to PEG fragments, but also typically and preferably ensure structurally defined, linear conjugates of LPEI fragments to PEG fragments. Thus, they offer greater batch-to-batch consistency, ease of manufacturing, and more predictable SAR compared to the branched LPEI-PEG diconjugates currently prepared using the random, uncontrolled synthetic strategies described above.
[0026] Even more advantageously and surprisingly, the linear, non-random conjugates of the invention described herein can be combined with polyanions and nucleic acids, such as poly(IC), to form polyplexes. When administered to cells, the polyplexes surprisingly not only maintain but even enhance the antitumor activity of polyplexes made using random, branched conjugates. Thus, despite the significant reduction in variability and number of conjugate structures used and thus in the number of possible (biological) activities, including targeting and presentation of their target fragments to the surface of targeted cells and subsequent uptake, there is no loss in the efficacy of the linear LPEI-l-PEG:nucleic acid polyplexes described herein. In contrast, the conjugates and compositions of the invention can even increase their overall biological activity. Further features and advantages of this technology will be apparent to those skilled in the art upon reading the following detailed description of the invention, and further aspects and embodiments of the invention will become apparent as this description continues. [Brief explanation of the drawings]
[0027] [Figure 1A]DLS backscattering plot obtained for triplicate LPEI-l-[N3:DBCO]-PEG24-hEGF:poly(IC) polyplexes measuring their size distribution in HBG buffer at pH 7.2, 0.125 mg / mL, and an N / P ratio of 2.4. The z-average diameter was 306 nm and the polydispersity index (PDI) was 0.35. [Figure 1B] DLS backscattering plot obtained for triplicate LPEI-l-[N3:DBCO]-PEG24-hEGF:poly(IC) polyplexes measuring their size distribution in HBG buffer at pH 7.2, 0.125 mg / mL, and an N / P ratio of 4.0. The z-average diameter was 116 nm and the polydispersity index (PDI) was 0.08. [Figure 1C] DLS backscattering plot obtained for triplicate LPEI-l-[N3:DBCO]-PEG24-hEGF:poly(IC) polyplexes measuring their size distribution in HBG buffer at pH 7.2, 0.125 mg / mL, and an N / P ratio of 5.6. The z-average diameter was 107 nm, and the polydispersity index (PDI) was 0.109. [Figure 2] DLS backscattering plots obtained for triplicate LPEI-l-[N3:DBCO]-PEG24-hEGF:poly(Glu) polyplexes measuring size distribution and zeta potential in HBG buffer at pH 7.2, 0.1 mg / mL, 1 mL volume, and N / P ratio of 4. The z-average diameter was 121 nm and the polydispersity index (PDI) was 0.087. The zeta potential was 28.7 mV. [Figure 3] DLS backscattering plots obtained for triplicate LPEI-l-[N3:DBCO]-PEG23-OMe:poly(IC) polyplexes measuring size distribution and zeta potential in 1 mL of 50 mM acetate buffer at pH 4.3, 0.1875 mg / mL, and an N / P ratio of 4, 5% glucose. The z-average diameter was 107 nm, and the polydispersity index (PDI) was 0.139. The zeta potential was 31.4 mV. [Figure 4]DLS backscattering plots obtained for triplicate LPEI-l-[N3:DBCO]-PEG12-hEGF:poly(IC) polyplexes measuring size distribution and zeta potential in 1 mL of 50 mM acetate buffer at pH 4.3, 0.1875 mg / mL, and an N / P ratio of 4, 5% glucose. The z-average diameter was 156 nm, and the polydispersity index (PDI) was 0.144. The zeta potential was 38.3 mV. [Figure 5] DLS backscattering plots obtained for triplicate LPEI-l-[N3:DBCO]-PEG24-DUPA:poly(IC) polyplexes measuring distribution and zeta potential at 0.1875 mg / mL, 1 mL volume, and N / P of 4. The z-average diameter was 120 nm and the polydispersity index (PDI) was 0.125. The zeta potential was 31.1 mV. [Figure 6A] 1 is a plot of cell viability in MCF7 cells as a function of treatment with LPEI-1-[N3:DBCO]-PEG36-hEGF:poly(IC) and LPEI-1-[N3:DBCO]-PEG36-hEGF:poly(Glu). The X-axis shows the logarithm of the concentration of delivered poly(IC) or poly(Glu). [Figure 6B] 1 is a plot of cell viability in A431 cells as a function of treatment with LPEI-1-[N3:DBCO]-PEG36-hEGF:poly(IC) and LPEI-1-[N3:DBCO]-PEG36-hEGF:poly(Glu). The X-axis shows the logarithm of the concentration of delivered poly(IC) or poly(Glu). [Figure 7A] 1 is a plot of cell viability in MCF7 cells as a function of treatment with LPEI-1-[N3:DBCO]-PEG24-hEGF:poly(IC) and LPEI-1-[N3:DBCO]-PEG24-hEGF:poly(Glu). The X-axis shows the logarithm of the concentration of delivered poly(IC) or poly(Glu). [Figure 7B]1 is a plot of cell viability in A431 cells as a function of treatment with LPEI-1-[N3:DBCO]-PEG24-hEGF:poly(IC) and LPEI-1-[N3:DBCO]-PEG24-hEGF:poly(Glu). The x-axis shows the logarithm of the concentration of poly(IC) or poly(Glu) delivered. [Figure 8A] 1 is a plot of cell viability in MCF7 cells as a function of treatment with LPEI-l-[N3:DBCO]-PEG12-hEGF:poly(IC) and LPEI-l-[N3:DBCO]-PEG12-hEGF:poly(Glu). The X-axis shows the logarithm of the concentration of delivered poly(IC) or poly(Glu). [Figure 8B] 1 is a plot of cell viability in A431 cells as a function of treatment with LPEI-l-[N3:DBCO]-PEG12-hEGF:poly(IC) and LPEI-l-[N3:DBCO]-PEG12-hEGF:poly(Glu). The X-axis shows the logarithm of the concentration of delivered poly(IC) or poly(Glu). [Figure 9A] 1 is a plot of cell viability in MCF7 cells as a function of treatment with LPEI-l-[N3:DBCO]-PEG4-hEGF:poly(IC) and LPEI-l-[N3:DBCO]-PEG4-hEGF:poly(Glu). The X-axis shows the logarithm of the concentration of delivered poly(IC) or poly(Glu). [Figure 9B] 1 is a plot of cell viability in A431 cells as a function of treatment with LPEI-l-[N3:DBCO]-PEG4-hEGF:poly(IC) and LPEI-l-[N3:DBCO]-PEG4-hEGF:poly(Glu). The x-axis shows the logarithm of the concentration of delivered poly(IC) or poly(Glu). [Figure 10A] 1 is a plot of cell viability in MCF7 cells as a function of treatment with the nontargeted polyplexes LPEI-l-[N3:DBCO]-PEG23-OMe:poly(IC) and LPEI-l-[N3:DBCO]-PEG23-OMe:poly(Glu). The x-axis shows the logarithm of the concentration of delivered poly(IC) or poly(Glu). [Figure 10B] 1 is a plot of cell viability in A431 cells as a function of treatment with the nontargeted polyplexes LPEI-l-PEG23-OMe:poly(IC) and LPEI-l-PEG23-OMe:poly(Glu). The x-axis shows the logarithm of the concentration of delivered poly(IC) or poly(Glu). [Figure 11A] 1 is a plot of cell viability in LNCaP cells as a function of treatment with LPEI-l-[N3:DBCO]-PEG24-DUPA:poly(IC) and LPEI-l-[N3:DBCO]-PEG24-DUPA:poly(Glu). The x-axis shows the logarithm of the concentration of delivered poly(IC) or poly(Glu). [Figure 11B] 1 is a plot of cell viability in PC-3 cells as a function of treatment with LPEI-l-[N3:DBCO]-PEG24-DUPA:poly(IC) and LPEI-l-[N3:DBCO]-PEG24-DUPA:poly(Glu). The x-axis shows the logarithm of the concentration of delivered poly(IC) or poly(Glu). [Figure 11C] 1 is a plot of cell viability in DU145 cells as a function of treatment with LPEI-l-[N3:DBCO]-PEG24-DUPA:poly(IC) and LPEI-l-[N3:DBCO]-PEG24-DUPA:poly(Glu). The x-axis shows the logarithm of the concentration of delivered poly(IC) or poly(Glu). [Figure 12A] 1 is a plot of cell viability in LNCaP cells as a function of treatment with LPEI-l-[N3:DBCO]-PEG36-DUPA:poly(IC) and LPEI-l-[N3:DBCO]-PEG36-DUPA:poly(Glu). The x-axis shows the logarithm of the concentration of delivered poly(IC) or poly(Glu). [Figure 12B] 1 is a plot of cell viability in PC-3 cells as a function of treatment with LPEI-l-[N3:DBCO]-PEG36-DUPA:poly(IC) and LPEI-l-[N3:DBCO]-PEG36-DUPA:poly(Glu). The x-axis shows the logarithm of the concentration of delivered poly(IC) or poly(Glu). [Figure 12C] 1 is a plot of cell viability in DU145 cells as a function of treatment with LPEI-l-[N3:DBCO]-PEG36-DUPA:poly(IC) and LPEI-l-[N3:DBCO]-PEG36-DUPA:poly(Glu). The x-axis shows the logarithm of the concentration of delivered poly(IC) or poly(Glu). [Figure 13] 1 is a plot of cell viability in LNCaP cells as a function of treatment with LPEI-l-[N3:DBCO]-PEG36-DUPA:poly(IC); LPEI-l-[N3:DBCO]-PEG36-[(NH2)MAL-S]-DUPA:poly(IC); LPEI-l-[N3:BCN]-PEG36-DUPA:poly(IC); LPEI-l-[N3:SCO]-PEG36-DUPA:poly(IC); LPEI-l-[N3:DBCO]-PEG36-[CONH]-DUPA:poly(IC); and LPEI-l-[N3:DBCO]-PEG36-[S-MAL]-DUPA:poly(IC) polyplexes. [Figure 14] 1 is a plot of cell viability in DU145 cells as a function of treatment with LPEI-l-[N3:DBCO]-PEG36-DUPA:poly(IC); LPEI-l-[N3:DBCO]-PEG36-[(NH2)MAL-S]-DUPA:poly(IC); LPEI-l-[N3:BCN]-PEG36-DUPA:poly(IC); LPEI-l-[N3:SCO]-PEG36-DUPA:poly(IC); LPEI-l-[N3:DBCO]-PEG36-[CONH]-DUPA:poly(IC); and LPEI-l-[N3:DBCO]-PEG36-[S-MAL]-DUPA:poly(IC) polyplexes. [Figure 15] 10 is a plot of cell viability in SKOV3 and MCF7 cells treated with various concentrations of LPEI-1-[N3:DBCO]-PEG24-folate:poly(IC) polyplexes. [Figure 16A]1 is a plot of cell viability in MCF7 cells as a function of treatment with LPEI-l-[N3:DBCO]-PEG24-HER2-affibody:poly(IC) and LPEI-l-[N3:DBCO]-PEG24-HER2-affibody:poly(Glu). The x-axis shows the logarithm of the concentration of poly(IC) or poly(Glu) delivered. [Figure 16B] 1 is a plot of cell viability in SKBR3 cells as a function of treatment with LPEI-l-[N3:DBCO]-PEG24-HER2-affibody:poly(IC) and LPEI-l-[N3:DBCO]-PEG24-HER2-affibody:poly(Glu). The x-axis shows the logarithm of the concentration of poly(IC) or poly(Glu) delivered. [Figure 16C] 1 is a plot of cell viability in BT474 cells as a function of treatment with LPEI-l-[N3:DBCO]-PEG24-HER2-affibody:poly(IC) and LPEI-l-[N3:DBCO]-PEG24-HER2-affibody:poly(Glu). The x-axis shows the logarithm of the concentration of delivered poly(IC) or poly(Glu). [Figure 17] 1 is a plot of IP-10 secretion in A431 and MCF7 cells as a function of treatment with 0.125, 0.25, 0.5, and 1 μg / mL LPEI-l-PEG24-hEGF:poly(IC) polyplexes. [Figure 18] Western blot imaging analysis showing the qualitative levels of EGFR phosphorylation as a function of treatment with full serum, starved serum, LPEI- / -PEG24-EGF, LPEI- / -PEG24-hEGF:poly(IC), and hEGF. [Figure 19A] 1 is a plot of IP-10 secretion as a function of LPEI-1-[N3:DBCO]-PEG24-DUPA:poly(IC) concentration in LNCaP and PC-3 cells. [Figure 19B] 1 is a plot of IP-10 secretion as a function of LPEI-1-[N3:DBCO]-PEG36-DUPA:poly(IC) concentration in LNCaP and PC-3 cells. [Figure 19C] 1 is a plot of IP-10 secretion as a function of LPEI-1-[N3:DBCO]-PEG36-DUPA:poly(IC) concentration in LNCaP and DU145 cells. [Figure 20A] 1 is a plot of RANTES secretion as a function of LPEI-1-[N3:DBCO]-PEG24-DUPA:poly(IC) concentration in LNCaP and PC-3 cells. [Figure 20B] 1 is a plot of RANTES secretion as a function of LPEI-1-[N3:DBCO]-PEG36-DUPA:poly(IC) concentration in LNCaP and PC-3 cells. [Figure 20C] 1 is a plot of RANTES secretion as a function of LPEI-1-[N3:DBCO]-PEG36-DUPA:poly(IC) concentration in LNCaP and DU145 cells. [Figure 21A] 1 is a plot of IFN-β secretion as a function of LPEI-1-[N3:DBCO]-PEG24-DUPA:poly(IC) concentration in LNCaP and PC-3 cells. [Figure 21B] 1 is a plot of IFN-β secretion as a function of LPEI-1-[N3:DBCO]-PEG36-DUPA:poly(IC) concentration in LNCaP and PC-3 cells. [Figure 21C] 1 is a plot of IFN-β secretion as a function of LPEI-1-[N3:DBCO]-PEG36-DUPA:poly(IC) concentration in LNCaP and DU145 cells. [Figure 22] Western blot imaging analysis showing the qualitative levels of caspase 3, cleaved caspase 3, PARP, cleaved PARP, RIG-1;MDA5, and ISG15 as a function of treatment with 0, 0.0625, and 0.625 μg / mL of LPEI-l-[N3:DBCO]-PEG36-DUPA:poly(IC) and LPEI-l-[N3:DBCO]-PEG36-DUPA:poly(Glu) polyplexes. [Figure 23]SEM images of polyplex particles containing compounds 31 and 31b and poly(IC), i.e., LPEI-l-[N3:DBCO]-PEG36-DUPA:poly(IC), formed at an N / P ratio of 4 and a concentration of 0.1875 mg / mL in 20 mM HEPES buffer, 5% glucose (HBG), pH 7.2. [Figure 24A] Plot of luminescence (AU) in Renca parenteral and Renca EGFR M1 H cells treated with LPEI-l-[N3:DBCO]PEG36-hEGF:[Fluc mRNA] compared to the control delivery vehicle Messenger MAX. Luminescence was measured 24 hours after treatment at N / P ratios of 4, 6, and 12, and at concentrations of 0.125 to 1.0 mg / mL of LPEI-l-[N3:DBCO]PEG36-hEGF:[Fluc mRNA] and Lipofectamine Messenger MAX. [Figure 24B] Plot of luminescence (AU) in Renca parenteral and Renca EGFR M1 H cells treated with LPEI-l-[N3:DBCO]PEG36-hEGF:[Fluc mRNA] compared to the control delivery vehicle, jetPEI. Luminescence was measured 24 hours after treatment at N / P ratios of 4, 6, and 12, and at concentrations of LPEI-l-[N3:DBCO]PEG36-hEGF:[Fluc mRNA] and jetPEI ranging from 0.125 to 1.0 mg / mL. [Figure 24C]Figure 1 shows the luminescence (AU) ratio of Renca parenteral cells to Renca EGFR M1 H cells treated with LPEI-l-[N3:DBCO]PEG36-hEGF:[Fluc mRNA] using Messenger MAX as a comparative delivery vehicle. After 24 hours of treatment, luminescence was measured at N / P ratios of 4, 6, and 12, and at concentrations of 0.125–1.0 mg / mL of LPEI-l-[N3:DBCO]PEG36-hEGF:[Fluc mRNA] and Lipofectamine Messenger MAX. The ratio was calculated by dividing the luminescence signal from Renca EGFR M1 H cells by the luminescence signal from Renca parental cells. [Figure 24D] Figure 1 shows the luminescence (AU) ratio of Renca parenteral cells to Renca EGFR M1 H cells treated with LPEI-l-[N3:DBCO]PEG36-hEGF:[Fluc mRNA] using jetPEI as a comparative delivery vehicle. After 24 hours of treatment, luminescence was measured at N / P ratios of 4, 6, and 12, and at concentrations of LPEI-l-[N3:DBCO]PEG36-hEGF:[Fluc mRNA] and jetPEI ranging from 0.125 to 1.0 mg / mL. The ratio was calculated by dividing the luminescence signal from Renca EGFR M1 H cells by the luminescence signal from Renca parental cells. [Figure 24E] Figure 1 shows plots of percent viability in Renca parenteral and Renca EGFR M1 H cells treated with LPEI-l-[N3:DBCO]PEG36-hEGF:[Fluc mRNA] compared to the control delivery vehicle Messenger MAX. After 24 hours of treatment, percent viability was measured at N / P ratios of 4, 6, and 12, and at concentrations of 0.125 to 1.0 mg / mL of LPEI-l-[N3:DBCO]PEG36-hEGF:[Fluc mRNA] and Messenger MAX. [Figure 25A]Relative luminescence (AU) in Renca parenteral cells and Renca EGFR M1 H cells treated with LPEI-1-[N3:DBCO]PEG36-hEGF:[Fluc mRNA] 24 hours after treatment with N / P4 is shown. [Figure 25B] Relative luminescence (AU) in Renca parenteral cells and Renca EGFR M1 H cells treated with LPEI-1-[N3:DBCO]PEG36-hEGF:[Fluc mRNA] 24 hours after treatment with N / P6 is shown. [Figure 25C] Relative luminescence (AU) in Renca parenteral cells and Renca EGFR M1 H cells treated with LPEI-1-[N3:DBCO]PEG36-hEGF:[Fluc mRNA] 48 hours after treatment with N / P4 is shown. [Figure 25D] Relative luminescence (AU) in Renca parenteral cells and Renca EGFR M1 H cells treated with LPEI-1-[N3:DBCO]PEG36-hEGF:[Fluc mRNA] 48 hours after treatment with N / P6 is shown. DETAILED DESCRIPTION OF THE INVENTION
[0028] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The embodiments, preferred embodiments, and highly preferred embodiments described and disclosed herein should apply to all aspects and other embodiments, preferred embodiments, and highly preferred embodiments, whether or not specifically mentioned again.
[0029] The present invention provides linear conjugates of LPEI and PEG that can form polyplexes with polyanions and nucleic acids, such as poly(IC), as outlined herein and below. The conjugates preferably comprise an LPEI fragment, a PEG fragment, and a targeting fragment. In preferred embodiments, the LPEI fragment and the PEG fragment are coupled in a separate end-to-end manner. In some preferred embodiments, the LPEI fragment and the PEG fragment are coupled via a covalent bond of an azide to an alkene or alkyne to form a 1,2,3-triazole or a 4,5-dihydro-1H-[1,2,3]triazole.
[0030] definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.
[0031] The articles "a" and "an" are used in this disclosure to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.
[0032] The term "and / or" is used in this disclosure to mean either "and" or "or," unless otherwise indicated.
[0033] The term "about" as used herein shall mean ±10%. For example, about 50% shall mean 45% to 55%. Preferably, the term "about" as used herein shall mean ±5%. For example, about 50% shall mean 47.5% to 52.5%.
[0034] The phrase "number X to number Y" as used herein includes number X and number Y. For example, the phrase "0.01 μmol to 50 μmol" refers to 0.01 μmol and 50 μmol, as well as values therebetween. The same applies to the phrase "about number X to about number Y."
[0035] The term "optionally substituted" is understood to mean that a given chemical moiety (e.g., an alkyl group) can be (but is not required to be) bonded to other substituents (e.g., heteroatoms). For example, an optionally substituted alkyl group can be a fully saturated alkyl chain (i.e., pure hydrocarbon). Alternatively, the same optionally substituted alkyl group can have substituents other than hydrogen. For example, it can be bonded at any point along the chain to a halogen atom, an alkoxy group, or any other substituent described herein. Thus, the term "optionally substituted" means that a given chemical moiety can potentially contain other functional groups, but does not necessarily have to have additional functional groups.
[0036] The term "optionally replaced" is understood to refer to a situation in which a carbon atom of a methylene group (i.e., -CH-) may, but need not, be replaced by a heteroatom (e.g., -NH-, -O-). For example, a C alkylene (i.e., propylene) group in which one of the methylene groups is "optionally replaced" can have the structure --CH-O-CH- or O-CH-CH-. Those skilled in the art will understand that a methylene group cannot be replaced if such a replacement would result in an unstable chemical moiety. For example, those skilled in the art will understand that four methylene groups cannot be replaced simultaneously by oxygen atoms. Thus, in some preferred embodiments, when one methylene group of an alkylene fragment is replaced with a heteroatom, one or both of the adjacent carbon atoms are not replaced with a heteroatom.
[0037] The term "aryl" refers to cyclic aromatic hydrocarbon groups having one to two aromatic rings, including monocyclic or bicyclic groups such as phenyl, biphenyl, or naphthyl. 10An aryl group contains 6 to 10 carbon atoms. When containing two aromatic rings (such as bicyclic), the aromatic rings of the aryl group may be joined at a single point (e.g., biphenyl) or fused (e.g., naphthyl). The aryl group may be optionally substituted at any point of attachment with one or more substituents, for example, 1 to 5 substituents, which may themselves be optionally substituted. Furthermore, when containing two fused rings, the aryl group defined herein may have an unsaturated or partially saturated ring fused to a fully saturated ring. Exemplary ring systems of these aryl groups include indanyl, indenyl, tetrahydronaphthalenyl, and tetrahydrobenzoannulenyl. In some preferred embodiments, the aryl group is a phenyl group.
[0038] Unless otherwise specifically defined, "heteroaryl" means a monovalent monocyclic or polycyclic aromatic ring of 5 to 24 ring atoms containing one or more ring heteroatoms selected from N, S, P, or O, with the remaining ring atoms being C. A 5-10 membered heteroaryl group contains 5 to 10 atoms. Heteroaryl, as defined herein, also means a bicyclic heteroaromatic group in which the heteroatoms are selected from N, S, P, or O. Aromatic radicals are optionally substituted independently with one or more substituents described herein. Examples include, but are not limited to, furyl, thienyl, pyrrolyl, pyridyl, pyrazolyl, pyrimidinyl, imidazolyl, isoxazolyl, oxazolyl, oxadiazolyl, pyrazinyl, indolyl, thiophen-2-yl, quinolyl, benzopyranyl, isothiazolyl, thiazolyl, thiadiazole, indazole, benzimidazolyl, thieno[3,2-b]thiophene, triazolyl, triazinyl, imidazolyl, benzopyranyl, thiazolyl, thiadiazole, indazole, benzimidazolyl, thieno[3,2-b]thiophene, triazolyl, triazinyl, imidazolyl, benzopyranyl, thiazolyl, thiadiazole, indazole, benzimidazolyl, thieno[3,2-b]thiophene, thiazolyl, thiaz ...diazole, indazole, benzimidazolyl, thiadiazole, thiadiazole, indazole, benzimidazolyl, thiadiazole, thiadiazole, Zo[1,2-b]pyrazolyl, furo[2,3-c]pyridinyl, imidazo[1,2-a]pyridinyl, indazolyl, pyrrolo[2,3-c]pyridinyl, pyrrolo[3,2-c]pyridinyl, pyrazolo[3,4-c]pyridinyl, thieno[3,2-c]pyridinyl, thieno[2,3-c]pyridinyl, thieno[2,3-b]pyridinyl, benzothiazolyl, indolyl, indolinyl, indolinonyl, dihydrobenzothiophene Phenyl, dihydrobenzofuranyl, benzofuran, chromanyl, thiochromanyl, tetrahydroquinolinyl, dihydrobenzothiazine, dihydrobenzoxanyl, quinolinyl, isoquinolinyl, 1,6-naphthyridinyl, benzo[de]isoquinolinyl, pyrido[4,3-b][1,6]naphthyridinyl, thieno[2,3-b]pyrazinyl, quinazolinyl, tetrazolo[1,5-a]pyridinyl, [1,2,4]thiazolinyl Zolo[4,3-a]pyridinyl, isoindolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[3,4-b]pyridinyl, pyrrolo[3,2-b]pyridinyl, imidazo[5,4-b]pyridinyl, pyrrolo[1,2-a]pyrimidinyl, tetrahydropyrrolo[1,2-a]pyrimidinyl, 3,4-dihydro-2H-1λ2-pyrrolo[2,1-b]pyrimidine, dibenzo[b,d]thiophene, pyridin-2-one, furo[3,2-c]pyridinyl, furo[2,3-c]pyridinyl, 1H-pyrido[3,4-b][1,4]thiazinyl, benzoxazolyl, benzisoxazolyl, furo[2,3-b]pyridinyl, benzothiophenyl, 1,5-naphthyridinyl, furo[3,2-b]pyridine, [1,2,4]triazolo[1,5-a]pyridinyl, benzo[1,2,3]triazolyl, imidazo[1,2-a]pyrimidinyl, [1,2,4]triazolo[4,3-b]pyridazinyl, benzo[c [1,2,5]thiadiazolyl, benzo[c][1,2,5]oxadiazole, 1,3-dihydro-2H-benzo[d]imidazol-2-one, 3,4-dihydro-2H-pyrazolo[1,5-b][1,2]oxazinyl, 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridinyl, thiazolo[5,4-d]thiazolyl, imidazo[2,1-b][1,3,4]thiadiazolyl, thieno[2,3-b]pyrrolyl, 3H-indolyl, and derivatives thereof. Furthermore, when containing two fused rings, heteroaryl groups as defined herein can have an unsaturated or partially saturated ring fused to a fully saturated ring. Exemplary ring systems of these heteroaryl groups include indolinyl, indolinonyl, dihydrobenzothiophenyl, dihydrobenzofuran, chromanyl, thiochromanyl, tetrahydroquinolinyl, dihydrobenzothiazine, 3,4-dihydro-1H-isoquinolinyl, 2,3-dihydrobenzofuran, indolinyl, indolyl, and dihydrobenzoxanyl.
[0039] The term "alkyl" refers to a straight or branched chain saturated hydrocarbon. A C1-C6 alkyl group contains 1 to 6 carbon atoms. Examples of C1-C6 alkyl groups include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, and neopentyl.
[0040] The term "alkylene" refers to a straight-chain or branched-chain saturated divalent hydrocarbon fragment. A C0-C6 alkyl group contains 0 to 6 carbon atoms. Examples of C0-C6 alkylene groups include, but are not limited to, methylene, ethylene, propylene, butylene, pentylene, isopropylene, isobutylene, sec-butylene, tert-butylene, isopentylene, and neopentylene.
[0041] The term "C1-C6-alkoxy", as used herein, refers to a substituted hydroxyl of the formula (-OR'), where R' is an optionally substituted C1-C6 alkyl, as defined herein, and the oxygen moiety is directly attached to the parent molecule; thus, the term "C1-C6 alkoxy", as used herein, refers to a straight or branched C1-C6 alkoxy, which can be, for example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, straight or branched pentoxy, straight or branched hexyloxy. C1-C4 alkoxy and C1-C3 alkoxy are preferred.
[0042] The term "cycloalkyl" means a monocyclic or polycyclic saturated carbocyclic ring containing 3 to 18 carbon atoms. A C3-C8 cycloalkyl group contains 3 to 8 carbon atoms. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptanyl, cyclooctanyl, norboranyl, norborenyl, bicyclo[2.2.2]octanyl, or bicyclo[2.2.2]octenyl. A C3-C8 cycloalkyl is a cycloalkyl group containing 3 to 8 carbon atoms.
[0043] The term "cycloalkenyl" means a monocyclic non-aromatic unsaturated carbocyclic ring containing 5 to 18 carbon atoms. Examples of cycloalkenyl groups include, but are not limited to, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, and norborenyl. A C5-C8 cycloalkenyl is a cycloalkenyl group containing 5 to 8 carbon atoms.
[0044] The terms "heterocyclyl" or "heterocycloalkyl" or "heterocycle" refer to a monocyclic or polycyclic 3- to 24-membered ring containing carbon and heteroatoms derived from oxygen, nitrogen, or sulfur, and lacking delocalized π-electrons (aromaticity) shared between ring carbons or heteroatoms. 3- to 10-membered heterocycloalkyl groups contain 3-10 atoms. Heterocyclyl rings include, but are not limited to, oxetanyl, azetazinyl, tetrahydrofuranyl, pyrrolidinyl, oxazolinyl, oxazolidinyl, thiazolinyl, thiazolidinyl, pyranyl, thiopyranyl, tetrahydropyranyl, dioxalinyl, piperidinyl, morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S-dioxide, piperazinyl, azepinyl, oxepinyl, diazepinyl, tropanyl, and homotropanyl.
[0045] The term "heterocycloalkenyl" refers to a monocyclic or polycyclic 3- to 24-membered ring containing carbon and heteroatoms derived from oxygen, nitrogen, or sulfur, where there are no delocalized π-electrons (aromaticity) shared between ring carbons or heteroatoms, but at least one unsaturated element is present within the ring. 3- to 10-membered heterocycloalkenyl groups contain 3 to 10 atoms.
[0046] As used herein, the term "halo" or "halogen" means fluoro (F), chloro (Cl), bromo (Br), or iodo (I).
[0047] The term "carbonyl" refers to a functional group consisting of a carbon atom double-bonded to an oxygen atom. It may be abbreviated herein as "oxo," C(O), or C=O.
[0048] The term "overexpression" refers to increased expression of a gene or protein in a cell or on the cell surface compared to basal or normal expression. In a preferred embodiment, the targeting fragment is capable of binding to a cell that overexpresses a cell surface receptor. In one embodiment, the cell that overexpresses a cell surface receptor means that the level of the cell surface receptor expressed in the cell in a particular tissue is elevated compared to the level of the cell surface receptor measured in normal healthy cells of the same tissue type under similar conditions. In one embodiment, the cell that overexpresses a cell surface receptor refers to an increase in the level of the cell surface receptor in a cell compared to the level in the same cell or a closely related non-malignant cell under normal physiological conditions.
[0049] The term "polyanion," as used herein, refers to a polymer, preferably a biopolymer, having two or more negatively charged sites. Typically and preferably, the term "polyanion," as used herein, refers to a polymer, preferably a biopolymer, composed of repeating units that include residues that can carry a negative charge. In a further embodiment, the polyanion is a polymer, preferably a biopolymer, composed of repeating units that include negatively charged residues. In another preferred embodiment, the polyanion is a nucleic acid, more preferably DNA, RNA, polyglutamic acid, or hyaluronic acid.
[0050] The term "nucleic acid," as used herein, includes deoxyribonucleic acid (DNA) and / or ribonucleic acid (RNA), or a combination thereof. In preferred embodiments, the term "nucleic acid" refers to deoxyribonucleic acid (DNA) and / or ribonucleic acid (RNA), and as used herein, refers to genomic, viral, and recombinantly prepared and chemically synthesized molecules. Nucleic acids can be single- or double-stranded and in the form of linear or covalently closed circular molecules, can include chemical derivatization of the nucleic acid on the nucleotide base, sugar, or phosphate, and can contain non-natural nucleotides and nucleotide analogs.
[0051] The term "dispersity" (abbreviated as D), as used herein, refers to the distribution of molar masses in a given polymer sample, such as the polymer fragments used herein for the conjugates and polyplexes of the invention. This is defined herein as D = (M w / M n ) where D is the dispersity; M w is the weight average molecular weight of the polymer sample or polymer fragment; and M n is the number average molecular weight of the polymer sample or polymer fragment.
[0052] The term "polydispersity index" (abbreviated as PDI) as used herein refers to the polydispersity index in dynamic light scattering measurements of polyplex nanoparticles, such as the polyplexes of the present invention. This index is a number calculated from a simple two-parameter fit to correlation data (cumulant analysis). The polydispersity index is dimensionless and is scaled so that values below 0.05 are rarely found except in highly monodisperse standards. Values above 0.7 indicate a sample has a very broad size distribution and are likely unsuitable for dynamic light scattering (DLS) techniques. Various size distribution algorithms work with data that fall between these two extremes. The zeta-average diameter (z-average diameter) and polydispersity index of the polyplexes of the present invention are determined by dynamic light scattering (DLS) based on the assumption that the polyplexes are isotropic and spherical. Calculation of these parameters is defined and determined in accordance with the ISO standard document ISO 22412:2017.
[0053] The term "amino acid residue" refers to a divalent residue derived from an organic compound containing the functional groups amine (-NH) and carboxylic acid (-COOH), typically and preferably with a side chain specific to each amino acid. In a preferred embodiment of the present invention, the amino acid residue is a divalent residue derived from an organic compound containing the functional groups amine (-NH) and carboxylic acid (-COOH), the divalency being provided by the amine and carboxylic acid functional groups, and thus the -NH- and CO- moieties. In an alternative preferred embodiment of the present invention, the amino acid residue is a divalent residue derived from an organic compound containing the functional groups amine (-NH) and carboxylic acid (-COOH), the divalency being provided by the amine or carboxylic acid functional group and by further functional groups present in the amino acid residue. As a preferred example and embodiment, an amino acid residue according to the present invention derived from cysteine comprises the divalent structure -S-(CH)-CH(COOH)-NH-, where the divalency is provided by the amino functionality and the contained thiol functionality. The term "amino acid residue," as used herein, typically and preferably includes amino acid residues derived from naturally occurring or non-naturally occurring amino acids. Furthermore, the term "amino acid residue," as used herein, typically and preferably also includes amino acid residues derived from chemically synthesized non-natural amino acids, including alpha- (α-), beta- (β-), gamma- (γ-), or delta- (δ-) amino acids, as well as mixtures thereof in any ratio. Furthermore, the term "amino acid residue," as used herein, typically and preferably also includes amino acid residues derived from alpha amino acids, including any isomeric forms thereof, particularly their D- and L-stereoisomers (alternatively addressed by the (R) and (S) nomenclature), as well as mixtures thereof in any ratio, preferably a 1:1 racemic ratio. The terms "D-stereoisomer," "L-stereoisomer," "D-amino acid," or "L-amino acid" refer to the chiral alpha carbon of an amino acid. Thus, in a preferred embodiment, the amino acid residue is a divalent group of the structure -NH-CHR-C(O)-, where R is an amino acid side chain.Two or more consecutive amino acid residues preferably form a peptide (i.e., amide) bond between both the amine and carboxylic acid moieties of each amino acid residue. Di-, tri-, or polypeptide amino acid residues are typically (AA). a When described herein as a nucleotide, the sequence provided is presented from left to right in the NC direction. Thus, for example, Trp-Trp-Gly (AA) a shall refer to amino acid residues, with Trp corresponding to the N-terminus of said tripeptide having an -NH- valence and Gly corresponding to the C-terminus of said tripeptide having an -CO- valence.
[0054] The terms "peptide," "polypeptide," and "protein," as used herein, refer to a substance comprising about two or more consecutive amino acid residues linked together via peptide bonds. The terms "peptide," "polypeptide," and "protein" are used interchangeably herein to refer to polymers of amino acid residues of any length. In one embodiment, the term "protein" refers to large peptides, particularly peptides having at least about 151 amino acids, while in other embodiments, the term "peptide" refers to a substance containing about two or more, about three or more, about eight or more, or about 20 or more, and up to about 50, about 100, or about 150 amino acids.
[0055] The term "epitope," as used herein, refers to an antigenic determinant in a molecule, such as an antigen. An epitope of a protein preferably comprises a continuous or discontinuous portion of said protein and is preferably 5 to 100, preferably 5 to 50, more preferably 8 to 30, and most preferably 10 to 25 amino acids in length; for example, an epitope may be preferably 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 amino acids in length.
[0056] The term "antibody" refers to any immunoglobulin, whether natural or wholly or partially synthetically produced, as well as derivatives and characteristic portions thereof. Antibodies can be monoclonal or polyclonal. Antibodies can be members of any immunoglobulin class, including any of the human classes: IgG, IgM, IgA, IgD, and IgE. As used herein, an antibody fragment (i.e., a characteristic portion of an antibody) refers to any derivative of an antibody that is less than full-length. Generally, an antibody fragment retains at least a significant portion of the full-length antibody's specific binding ability. Examples of antibody fragments include, but are not limited to, single- and double-chain fragments, Fab, Fab', F(ab')2, scFv, Fv, dsFv diabody, and Fd fragments. Antibody fragments can be produced by any means. For example, antibody fragments can be enzymatically or chemically produced by fragmentation of an intact antibody and / or recombinantly produced from a gene encoding a partial antibody sequence. Alternatively, or additionally, antibody fragments can be wholly or partially synthetically produced. Antibody fragments may optionally include single-chain antibody fragments. Alternatively, or additionally, antibody fragments may comprise multiple chains linked together, for example, by disulfide bonds. Antibody fragments may optionally include multimolecular complexes. Functional antibody fragments typically comprise at least about 50 amino acids, more typically at least about 200 amino acids. In some embodiments, antibodies may include chimeric (e.g., "humanized") and single-chain (recombinant) antibodies. In some embodiments, antibodies may have reduced effector function and / or bispecific molecules. In some embodiments, antibodies may include fragments produced by Fab expression libraries. Single-chain Fvs (scFvs) are recombinant antibody fragments consisting only of a variable light chain (VL) and a variable heavy chain (VH) covalently connected to each other by a polypeptide linker. Either the VL or VH may comprise an NH2-terminal domain. The polypeptide linker may be of variable length and composition, so long as the two variable domains are bridged without significant steric hindrance.Typically, the linker contains primarily a stretch of glycine and serine residues, with some glutamic acid or lysine residues interspersed for solubility. Diabodies are dimeric scFvs. Diabodies typically have shorter peptide linkers than most scFvs and often preferentially associate as dimers. Fv fragments are antibody fragments consisting of one VH and one VL domain held together by noncovalent interactions. The term "dsFv" as used herein refers to an Fv with an engineered intermolecular disulfide bond to stabilize the VH-VL pair. F(ab')2 fragments are antibody fragments essentially equivalent to those obtained from immunoglobulins by digestion with the enzyme pepsin at pH 4.0-4.5. Fragments can be produced recombinantly. Fab' fragments are antibody fragments essentially equivalent to those obtained by reduction of one or more disulfide bridges joining the two heavy chain pieces in the F(ab')2 fragment. Fab' fragments can be produced recombinantly. 1. Fab fragments are antibody fragments essentially equivalent to those obtained by digesting immunoglobulins with enzymes (e.g., papain). Fab fragments can be produced recombinantly. The heavy chain segment of a Fab fragment is the Fd fragment.
[0057] The term "alpha end of a linear polyethyleneimine fragment" (α-end of an LPEI fragment), as used herein, refers to the end of an LPEI fragment at which initiation of polymerization occurs using an electrophilic initiator, as further described below for the term "initiating residue."
[0058] The term "omega end of a linear polyethyleneimine fragment" (ω end of an LPEI fragment), as used herein, refers to the end of an LPEI fragment at which polymerization termination occurs using a nucleophile, such as an azide, thiol, or other nucleophile described herein.
[0059] The term "organic residue" refers to any suitable organic group that can be bonded to a nitrogen atom embedded within an LPEI fragment. In a preferred embodiment, the organic residue is connected to the nitrogen atom via a carbonyl group to form an amide bond. Without wishing to be bound by theory, the organic residue is incorporated into the nitrogen atom of a poly(2-oxazoline) during ring-opening polymerization of the 2-oxazoline (see, e.g., Glassner et al., (2018), Poly(2-oxazoline)s: A comprehensive overview of polymer structures and their physical properties. Polym. Int, 67:32-45. https: / / doi.org / 10.1002 / pi.5457). Typically and preferably, the organic residue is cleaved from the poly(2-oxazoline) (i.e., the amide is typically cleaved), yielding the -(NH-CH-CH)- moiety embedded within the LPEI and the LPEI fragment, and thus the conjugate of the present invention. However, if the cleavage reaction is not complete, a fraction of the organic residue will not be cleaved. Thus, in a preferred embodiment of the present invention, R of the conjugates of the present invention, including those of formula I* and I 1 -(NR 2 -CH2-CH2) n -R in part 2 at least 80%, preferably 90%, of the R of the conjugates of the invention, including those of formula I* or I, are H; 1 -(NR 2 -CH2-CH2) n -R in part 2 Preferably at least 91%, more preferably 92%, more preferably 93%, more preferably 94%, more preferably 95%, more preferably 96%, more preferably 97%, more preferably 98%, and most preferably 99% of is H.
[0060] The term "initial residue" refers to the LPEI fragment and R 1 -(NR 2 -CH2-CH2) n- refers to a residue present in the - moiety, which is derived from any initiator, typically and preferably any electrophilic initiator, capable of initiating the polymerization of poly(2-oxazoline) from 2-oxazoline. As described by Glassner et al., (2018), Poly(2-oxazoline)s: A comprehensive overview of polymer structures and their physical properties. Polym. Int, 67:32-45. https: / / doi.org / 10.1002 / pi.5457, "Different initiator systems can be used, including toluenesulfonic acid (TsOH), or alkylsulfonates such as methyl p-toluenesulfonate (MeOT), most frequently found in the literature, p-nitrobenzenesulfonate (nosylate) and trifluoromethanesulfonate (triflate), alkyl halides, benzyl halides and acetyl halides, oxazolinium salts and Lewis acids." Thus, in a preferred embodiment, R 1 is -H or CH3, but those skilled in the art will recognize that R 1 is any other suitable residue, e.g., C where n is greater than 1. n Alkyl groups, typically C 1~6 It will be understood that these groups may also include, but are not limited to, alkyl groups, benzyl groups, or acetyl groups.
[0061] Thus, in one aspect, the present invention provides a composition comprising a conjugate, the conjugate comprising a linear polyethyleneimine (LPEI) fragment comprising an alpha end and an omega end; a polyethylene glycol (PEG) fragment, preferably a linear polyethylene glycol (PEG) fragment, comprising a first end and a second end; wherein the omega end of the LPEI fragment is connected to the first end of the PEG fragment by a covalent linking moiety; the covalent linking moiety is not an amide; preferably, the alpha end of the LPEI fragment is bonded to a methyl group or a hydrogen atom, more preferably, the alpha end of the LPEI fragment is bonded to a hydrogen atom; and preferably, the alpha end of the PEG fragment is bonded to a targeting fragment.
[0062] In one aspect, the invention provides a composition comprising a conjugate, the conjugate comprising a linear polyethyleneimine fragment comprising an alpha end and an omega end; a polyethylene glycol fragment comprising a first end and a second end; wherein the alpha end of the polyethyleneimine fragment is an initiating residue; and the omega end of the polyethyleneimine fragment is a covalent linking group, -ZX 1 -Z- is connected to the first end of the polyethylene glycol fragment by -Z-, where -Z- is not a single bond and -Z- is not an amide; -X 1 is a divalent covalent linking moiety; and the second end of the polyethylene glycol fragment is capable of binding to a targeting fragment, preferably said polyethylene glycol fragment binds to a targeting fragment. In a preferred embodiment of this aspect, said composition consists of said conjugate. In a preferred embodiment, the linear polyethyleneimine fragment is of formula R 1 -(NR 2 -CH2-CH2) n -, and n is any integer from 1 to 1500. In a further preferred embodiment, R 1 -(NR 2 -CH2-CH2) n The - moiety has about 115 to about 1150 repeating units n and a dispersity of about 5 or less, preferably about 280 to about 700 repeating units n with a dispersity of about 3 or less, more preferably about 350 to about 630 repeating units n with a dispersity of about 2 or less, and preferably R 1 is a dispersed polymer moiety that is —H or CH3.
[0063] In another aspect, the present invention provides a composition comprising a conjugate of formula I*: R 1 -(NR 2 -CH2-CH2) n -ZX 1 -(O-CH2-CH2) m -X 2 -L (Formula I*); wherein n is any integer from 1 to 1500; m is any integer from 1 to 200, preferably m is any integer from 1 to 100; R1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -R in 2 at least 80%, preferably 90%, of X are H; 1 and X 2 are independently a divalent covalent linking moiety; Z is a divalent covalent linking moiety, where Z is not -NHC(O)-; and L is a targeting fragment, preferably capable of binding to a cell; or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or enantiomer thereof, preferably consisting of said conjugate.
[0064] In another aspect, the present invention provides a conjugate of formula I*: R 1 -(NR 2 -CH2-CH2) n -ZX 1 -(O-CH2-CH2) m -X 2 -L (Formula I*); wherein n is any integer from 1 to 1500; m is any integer from 1 to 200, preferably m is any integer from 1 to 100; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n The R in the part 2 at least 80%, preferably 90%, of X are H; 1 and X 2 are independently a divalent covalent linking moiety; Z is a divalent covalent linking moiety, where Z is not -NHC(O)-; and L is a targeting fragment, preferably capable of binding to a cell. or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or enantiomer thereof.
[0065] In another aspect, the present invention provides a composition comprising a conjugate of formula I*: R 1 -(NR 2 -CH2-CH2) n -ZX 1 -(O-CH2-CH2) m -X 2 -L (Formula I*); wherein n is any integer from 1 to 1500; m is any integer from 1 to 200, preferably m is any integer from 1 to 100; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -R in 2 at least 80%, preferably 90%, of X are H; 1 and X 2 are independently a divalent covalent linking moiety; Z is a divalent covalent linking moiety, where Z is not a single bond and Z is not -NHC(O)-; L is a targeting fragment, where preferably said targeting fragment is capable of binding to a cell, and more preferably said targeting fragment is capable of binding to a cell surface receptor. or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or enantiomer thereof, and Preferably, a composition is provided that consists of the conjugate.
[0066] In another aspect, the present invention provides a conjugate of formula I*: R 1 -(NR 2 -CH2-CH2) n -ZX 1 -(O-CH2-CH2) m -X 2 -L (Formula I*); wherein n is any integer from 1 to 1500; m is any integer from 1 to 200, preferably m is any integer from 1 to 100; R 1 is the starting residue, where preferably R 1 is -H or CH3; R2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -R in 2 at least 80%, preferably 90%, of X are H; 1 and X 2 are independently a divalent covalent linking moiety; Z is a divalent covalent linking moiety, where Z is not a single bond and Z is not -NHC(O)-; L is a targeting fragment, where preferably said targeting fragment is capable of binding to a cell, and more preferably said targeting fragment is capable of binding to a cell surface receptor. or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or enantiomer thereof.
[0067] In another aspect, the present invention provides a composition comprising a conjugate of formula I: [ka] [In the formula, [ka] is a single bond or a double bond; n is an integer of 1 to 1500; m is an integer of 1 to 200, preferably an integer of 1 to 100; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n - the R in the part 2 at least 80%, preferably 90%, of are H; ring A is A1 5-10 membered cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl optionally substituted with R A1 are independently selected from C1-C6 alkyl, C1-C6 alkoxy, oxo, or halogen; or two RA1 together with the atoms to which they are attached to form one or more fused C6-C 10 can form an aryl, C-C heteroaryl, or C-C cycloalkyl ring, where each fused aryl, heteroaryl, or cycloalkyl is joined to one or more R A2 optionally substituted with R A2 is independently selected from C1-C6 alkyl, C1-C6 alkoxy, halogen, —SO3H, or OSO3H; X 1 is the formula -(Y 1 ) p where p is an integer from 1 to 20, and Y 1 Each occurrence of represents independently a chemical bond, -CR 11 R 12 -, -C(O)-, -O-, -S-, -NR 13 -, an amino acid residue, a divalent phenyl moiety, a divalent heterocyclic moiety, and a divalent heteroaryl moiety, wherein each divalent phenyl or heteroaryl is selected from one or more R 13 and each divalent heterocycle is optionally substituted with one or more R 14 optionally substituted with R 11 , R 12 and R 13 is independently at each occurrence H or C1-C6 alkyl; and 14 is independently, at each occurrence, H, C1-C6 alkyl, or oxo; X 2 is the formula -(Y 2 ) q - (wherein q is an integer from 1 to 50, and Y 2 Each occurrence of represents independently a chemical bond, -CR 21 R 22 -, NR 23 -, -O-, -S-, -C(O)-, an amino acid residue, a divalent phenyl moiety, a divalent heterocyclic moiety, and a divalent heteroaryl moiety, wherein each divalent phenyl and divalent heteroaryl is selected from one or more R 23 and each divalent heterocyclic moiety is optionally substituted with one or more R 24 optionally substituted with R21 , R 22 and R 23 are each independently at each occurrence -H, -CO2H, or C1-C6 alkyl, where each C1-C6 alkyl is selected from one or more of -OH, oxo, C6-C 10 optionally substituted with aryl or 5-8 membered heteroaryl; and R 24 and L is a targeting moiety that is preferably capable of binding to a cell] or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or enantiomer thereof, preferably consisting of said conjugate.
[0068] In another aspect, the present invention provides a conjugate of formula I: [ka] [In the formula, [ka] is a single bond or a double bond; n is an integer of 1 to 1500; m is an integer of 1 to 200, preferably an integer of 1 to 100; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n - the R in the part 2 at least 80%, preferably 90%, of are H; ring A is A1 5-10 membered cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl optionally substituted with R A1 are independently selected from C1-C6 alkyl, C1-C6 alkoxy, oxo, or halogen; or two R A1together with the atoms to which they are attached to form one or more fused C6-C 10 can form an aryl, C-C heteroaryl, or C-C cycloalkyl ring, where each fused aryl, heteroaryl, or cycloalkyl is joined to one or more R A2 optionally substituted with R A2 is independently selected from C1-C6 alkyl, C1-C6 alkoxy, halogen, —SO3H, or OSO3H; X 1 is the formula -(Y 1 ) p where p is an integer from 1 to 20, and Y 1 Each occurrence of represents independently a chemical bond, -CR 11 R 12 -, -C(O)-, -O-, -S-, -NR 13 -, an amino acid residue, a divalent phenyl moiety, a divalent heterocyclic moiety, and a divalent heteroaryl moiety, wherein each divalent phenyl or heteroaryl is selected from one or more R 13 and each divalent heterocycle is optionally substituted with one or more R 14 optionally substituted with R 11 , R 12 and R 13 is independently at each occurrence H or C1-C6 alkyl; and 14 is independently, at each occurrence, H, C1-C6 alkyl, or oxo; X 2 is the formula -(Y 2 ) q - (wherein q is an integer from 1 to 50, and Y 2 Each occurrence of represents independently a chemical bond, -CR 21 R 22 -, NR 23 -, -O-, -S-, -C(O)-, an amino acid residue, a divalent phenyl moiety, a divalent heterocyclic moiety, and a divalent heteroaryl moiety, wherein each divalent phenyl and divalent heteroaryl is selected from one or more R 23 and each divalent heterocyclic moiety is optionally substituted with one or more R 24 optionally substituted with R 21 , R22 and R 23 are each independently at each occurrence -H, -CO2H, or C1-C6 alkyl, where each C1-C6 alkyl is selected from one or more of -OH, oxo, C6-C 10 optionally substituted with aryl or 5-8 membered heteroaryl; and R 24 is a linking moiety of the formula: (wherein each occurrence is independently -H, -COH, C1-C6 alkyl, or oxo); and L is a targeting fragment, preferably capable of binding to a cell; or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or enantiomer thereof. In a preferred embodiment, R 1 is -H. In a preferred embodiment, 1 is -CH3.
[0069] In another aspect, the present invention provides a composition comprising a conjugate of formula I: [ka] [In the formula, [ka] is a single or double bond; n is any integer from 1 to 1500; m is any integer from 1 to 200; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -R in 2 at least 80%, preferably at least 90% of is H; Ring A may have one or more R A1 5-10 membered cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl optionally substituted with R A1are independently selected from C1-C6 alkyl, C1-C6 alkoxy, oxo, or halogen; or two R A1 together with the atoms to which they are attached to form one or more fused C6-C 10 can form an aryl, C-C heteroaryl, or C-C cycloalkyl ring, and each fused aryl, heteroaryl, or cycloalkyl can be joined by one or more R A2 optionally substituted with R A2 is independently selected from C1-C6 alkyl, C1-C6 alkoxy, halogen, —SO3H, or OSO3H; X 1 is a divalent covalent linking moiety; X 2 is a divalent covalent linking moiety; and L is a targeting fragment, wherein preferably said targeting fragment is capable of binding to a cell, and more preferably said targeting fragment is capable of binding to a cell surface receptor. or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or enantiomer thereof. 1 is -H. In a preferred embodiment, 1 is -CH3.
[0070] In another aspect, the present invention provides a conjugate of formula I: [ka] [In the formula, [ka] is a single or double bond; n is any integer from 1 to 1500; m is any integer from 1 to 200; R 1 is the starting residue, where preferably R 1 is -H or CH3; R2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -R in 2 at least 80%, preferably at least 90% of is H; Ring A may have one or more R A1 5-10 membered cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl optionally substituted with R A1 are independently selected from C1-C6 alkyl, C1-C6 alkoxy, oxo, or halogen; or two R A1 together with the atoms to which they are attached to form one or more fused C6-C 10 can form an aryl, C-C heteroaryl, or C-C cycloalkyl ring, and each fused aryl, heteroaryl, or cycloalkyl can be joined by one or more R A2 optionally substituted with R A2 is independently selected from C1-C6 alkyl, C1-C6 alkoxy, halogen, —SO3H, or OSO3H; X 1 is a divalent covalent linking moiety; X 2 is a divalent covalent linking moiety; and L is a targeting fragment, wherein preferably said targeting fragment is capable of binding to a cell, and more preferably said targeting fragment is capable of binding to a cell surface receptor. or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or enantiomer thereof. 1 is -H. In a preferred embodiment, 1 is -CH3.
[0071] In some embodiments, the covalent linking moiety Z comprises a triazole.
[0072] In some embodiments, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 99% of the LPEI in the composition are connected to the PEG fragments by a single covalent linking moiety, preferably resulting in a linear end-to-end linkage between the LPEI fragments and the PEG fragments. In some embodiments, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 99% of the LPEI fragments in the composition are contained in the conjugate, preferably as determined by UV spectroscopy or mass spectrometry. In some embodiments, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 99% of the LPEI in the composition are contained in the conjugate, preferably as determined by UV spectroscopy or mass spectrometry. In some embodiments, the composition consists essentially of the conjugate. In some embodiments, the composition consists of the conjugate.
[0073] In some embodiments, at least 60% of the LPEI fragments in the composition are connected to a single PEG fragment by a single covalent linking moiety Z, preferably, the covalent linking moiety Z creates a linear end-to-end linkage between the LPEI fragment and the PEG fragment. In some embodiments, at least 60% of the LPEI fragments in the composition are connected to a PEG fragment by a single triazole linker, preferably as determined by UV spectroscopy or mass spectrometry. In some embodiments, at least 70% of the LPEI fragments in the composition are connected to a PEG fragment by a single covalent linking moiety Z, preferably, the covalent linking moiety Z creates a linear end-to-end linkage between the LPEI fragment and the PEG fragment. In some embodiments, at least 70% of the LPEI fragments in the composition are comprised in the conjugate, preferably, as determined by UV spectroscopy or mass spectrometry. In some embodiments, at least 80% of the LPEI fragments in the composition are connected to a PEG fragment by a single covalent linking moiety Z, preferably, the covalent linking moiety Z creates a linear end-to-end linkage between the LPEI fragment and the PEG fragment. In some embodiments, at least 80% of the LPEI fragments in the composition are comprised in the conjugate, preferably as determined by UV spectroscopy or mass spectroscopy. In some embodiments, at least 90% of the LPEI fragments in the composition are connected to the PEG fragment by a single covalent linking moiety Z, preferably, the covalent linking moiety Z creates a linear end-to-end linkage between the LPEI fragment and the PEG fragment. In some embodiments, at least 90% of the LPEI fragments in the composition are comprised in the conjugate, preferably, as determined by UV spectroscopy or mass spectroscopy. In some embodiments, at least 95% of the LPEI fragments in the composition are connected to the PEG fragment by a single covalent linking moiety Z, preferably, the covalent linking moiety Z creates a linear end-to-end linkage between the LPEI fragment and the PEG fragment. In some embodiments, at least 95% of the LPEI fragments in the composition are comprised in the conjugate, preferably, as determined by UV spectroscopy or mass spectroscopy.In some embodiments, at least 99% of the LPEI fragments in the composition are connected to the PEG fragment by a single covalent linking moiety Z, preferably the covalent linking moiety Z creates a linear end-to-end linkage between the LPEI fragment and the PEG fragment. In some embodiments, at least 99% of the LPEI fragments in the composition are comprised in the conjugate, preferably as determined by UV spectroscopy or mass spectrometry. In some embodiments, the composition consists essentially of the conjugate. In some embodiments, the LPEI fragments do not include substitutions beyond their first and second ends.
[0074] In some embodiments, Formula I* has the structure: R 1 -(NH-CH2-CH2) n -NHC(O)-(CH2-CH2-O) m -X 2 In some embodiments, formula I* does not include the structure R 1 -(NR 2 -CH2-CH2) n -NHC(O)-X 1 -(O-CH2-CH2) m -X 2 In some embodiments, the composition does not include the structure R 1 -(NH-CH2-CH2) n -NHC(O)-X 1 -(O-CH2-CH2) m -X 2 In some embodiments, the composition does not include a conjugate of structure R 1 -(NR 2 -CH2-CH2) n -NHC(O)-(CH2-CH2-O) m -X 2 -L conjugates are not included.
[0075] In some embodiments, R 1 is -H.
[0076] In some embodiments, R in the composition 2 At least 80% of the R in the composition are —H. 2 At least 85%, preferably 90%, preferably 95%, more preferably 99% of the R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -the R in the moiety 2 At least 85%, preferably 90% of R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -the R in the moiety 2 At least 90% of R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -the R in the moiety 2 At least 90% of R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -the R in the moiety 2 At least 91%, preferably at least 92%, more preferably at least 93% of R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -the R in the moiety 2 At least 94%, preferably at least 95%, more preferably 96% of R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -the R in the moiety 2 At least 95%, preferably at least 97%, even more preferably at least 98%, and even more preferably 99% of the total is H.
[0077] In some embodiments, ring A is an 8-membered cycloalkenyl, a 5-membered heterocycloalkyl, or a 7-8-membered heterocycloalkenyl, wherein each cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl has one or more R A1 is optionally replaced by
[0078] In some embodiments, ring A is cyclooctene, succinimide, or a 7-8 membered heterocycloalkenyl, where the heterocycloalkyl or heterocycloalkenyl contains no heteroatoms other than N, O, and S, and each cyclooctene, heterocycloalkyl, or heterocycloalkenyl contains one or more R A1 is optionally replaced by
[0079] In some embodiments, ring A is cyclooctene, succinimide, or a 7-8 membered heterocycloalkenyl, where the heterocycloalkyl or heterocycloalkenyl contains one or more heteroatoms, preferably one or two heteroatoms selected from N, O, and S, and each cyclooctene, heterocycloalkyl, or heterocycloalkenyl contains one or more R A1 is optionally replaced by
[0080] In some embodiments, ring A is cyclooctene, succinimide, or an 8-membered heterocycloalkene, where the heterocycloalkene contains exactly one heteroatom selected from N, O, and S, and each cyclooctene or heterocycloalkene contains one or more R A1 is optionally replaced by
[0081] In some embodiments, R A1 is -H, oxo or fluorine, or two R A1 combine to form one or more fused phenyl rings, preferably one or two fused phenyl rings, and each phenyl ring is optionally substituted with one or more --OSO3H or SO3H.
[0082] In some embodiments, ring A is cyclooctene, succinimide, or an 8-membered heterocycloalkene, where the heterocycloalkene contains exactly one heteroatom selected from N, O, and S, and each cyclooctene or heterocycloalkene optionally contains one or more R A1 is substituted with R A1 is oxo or fluorine, or two R A1 combine to form one or more fused phenyl rings, preferably one or two fused phenyl rings.
[0083] In some embodiments, ring A is cyclooctene, succinimide, or an 8-membered heterocycloalkene, where the heterocycloalkene contains exactly one heteroatom selected from N, and each cyclooctene or heterocycloalkene contains one or two R A1 is optionally replaced by
[0084] In some embodiments, R A1 is -H, oxo or fluorine, or two R A1 combine to form one or more fused phenyl rings, preferably one or two fused phenyl rings, and each phenyl ring is A2 is optionally replaced by
[0085] In some embodiments, ring A is cyclooctene, succinimide, or an 8-membered heterocycloalkene, wherein the heterocycloalkene contains exactly one heteroatom selected from N, and each cyclooctene or heterocycloalkene contains one or two R A1 optionally substituted with R A1 is -H, oxo or fluorine, or two R A1 combine to form one or more fused phenyl rings, preferably one or two fused phenyl rings, and each phenyl ring is optionally substituted with one or more -OSO3H or SO3H.
[0086] In some preferred embodiments, ring A is cyclooctene, succinimide, or an 8-membered heterocycloalkene, the heterocycloalkene containing exactly one heteroatom selected from N, and each cyclooctene or heterocycloalkene containing one or two R A1 optionally substituted with R A1 is -H or two R A1 combine to form one or more fused phenyl rings, preferably one or two fused phenyl rings, and each phenyl ring is optionally substituted with one or more -OSO3H or SO3H.
[0087] Preparation of linear conjugates The conjugates of the present invention can be prepared by several methods well known to those skilled in the art of polymer synthesis. For example, the compounds of the present invention can be synthesized using the methods described below, along with synthetic methods known in the field of polymer chemistry, or variations thereof recognized by those skilled in the art. Methods include, but are not limited to, the methods described below. The conjugates of the present invention can be synthesized according to the steps outlined in general schemes 1, 2, 3, 4, 5, 6, 7, and 8, or can be prepared using an alternating sequence of assembling intermediates without departing from the present invention. The conjugates of the present invention can also be synthesized using slight variations of the steps outlined below. For example, while scheme 3 shows the use of a tetrafluorophenyl ester as the electrophilic functional group for coupling with hEGF, those skilled in the art will recognize other suitable electrophilic functional groups that can be used for the same purpose.
[0088] In some preferred embodiments, the LPEI fragment and the PEG fragment are coupled via a [3+2] cycloaddition between an azide and an alkene or alkyne to form a 1,2,3 triazole or a 4,5-dihydro-1H-[1,2,3]triazole. In some preferred embodiments, the LPEI fragment contains an azide functionality and the PEG fragment contains an alkene or alkyne functionality.
[0089] LPEI fragment The conjugates of the present invention can comprise an LPEI fragment and a PEG fragment. Linear polyethyleneimine (LPEI) has the chemical formula -[NH-CH-CH]-. LPEI can be synthesized according to several methods known in the art, including, inter alia, polymerization of 2-oxazoline followed by hydrolysis of the pendant amide bond (see, e.g., Brissault et al., Bioconjugate Chem., 2003, 14, 581-587). As noted above, polymerization of poly(2-oxazoline) from 2-oxazoline (i.e., a suitable precursor for LPEI) can be initiated with any suitable initiator. In some embodiments, the initiator leaves an initiator residue at the alpha-terminus of the poly(2-oxazoline). In preferred embodiments, the initiator residue (i.e., Formula I* or R of Formula I) is a 2-oxazoline. 1 ) is a hydrogen atom or C 1~ C6 alkyl, preferably hydrogen or C1-C4 alkyl, more preferably hydrogen or methyl group; most preferably hydrogen atom. In a preferred embodiment, the initial residue R 1 is a hydrogen atom or C 1~ C6 alkyl, preferably hydrogen or C1-C4 alkyl, more preferably hydrogen or methyl group; most preferably hydrogen atom. In a preferred embodiment, the initial residue (i.e., R 1 ) is —H or CH3, most preferably —H. In a preferred embodiment, said initial residue R of formula I* 1 is —H. In a preferred embodiment, the initial residue R of formula I 1 is -H. In a preferred embodiment, said initial residue R of formula I* 1 is —CH3. In a preferred embodiment, the initial residue R of formula I 1 is —CH3. However, one skilled in the art will understand that the initiating residue can be the residue remaining from any suitable initiator capable of initiating the polymerization of 2-oxazoline to poly(2-oxazoline).
[0090] In some embodiments, an LPEI fragment can be coupled to a PEG fragment via a [3+2] cycloaddition between an azide and an alkene or alkyne to form a 1,2,3 triazole or a 4,5-dihydro-1H-[1,2,3]triazole, where the LPEI fragment contains an azide (-N3) functional group at the omega-terminus of the chain. In some preferred embodiments, the LPEI fragment is not further substituted except for a single substitution at the alpha-terminus. For example, in some preferred embodiments, the LPEI fragment contains the repeating formula -[NH-CH2-CH2]- and is substituted at the omega-terminus with an azide group that can be coupled to an alkyne or alkene substituent on the PEG fragment. In some preferred embodiments, the alpha-terminus of the LPEI fragment is substituted with a hydrogen atom or a C 1~ It may be substituted with a C6 alkyl, preferably hydrogen or a C1-C4 alkyl, more preferably hydrogen or a methyl group; most preferably a hydrogen atom.
[0091] For example, in some preferred embodiments, the LPEI fragment contains a hydrogen atom or a C at the alpha terminus. 1~ The LPEI fragment may be substituted with a C6 alkyl, preferably a hydrogen atom or a C1-C4 alkyl, more preferably a hydrogen atom or a methyl group, and at the omega terminus with an azide group; in some preferred embodiments, there are no additional substitutions on the LPEI fragment. For example, the conjugates of the present invention may have the following formula: [ka] (In the formula, R 1 is any suitable starting residue, preferably hydrogen or C 1~ C6 alkyl, preferably hydrogen or C1-C4 alkyl, more preferably hydrogen or methyl, most preferably hydrogen) It can be prepared from the LPEI fragment of
[0092] In some embodiments, the LPEI fragment can be terminated with a thiol group, such that in some embodiments, the omega-terminus of the LPEI fragment comprises, and preferably is, a thiol group, which can be coupled to a reactive alkene group on a PEG fragment via a thiol-ene reaction. Thus, in some embodiments, the conjugates of the present invention have the following formula: [ka] (In the formula, R 1 may be any suitable starting residue, preferably hydrogen or methyl, preferably hydrogen) It can be prepared from the LPEI fragment of
[0093] In some embodiments, the LPEI fragment can be terminated with an alkene group, and thus in some embodiments, the omega end of the LPEI fragment comprises, and preferably is, an alkene group, which can be coupled to a reactive thiol group on a PEG fragment via a thiol-ene reaction. Thus, in some embodiments, the conjugates of the present invention have the following formula: [ka] (In the formula, R 1 may be any suitable starting residue, preferably hydrogen or methyl, preferably hydrogen) It can be prepared from the LPEI fragment of
[0094] LPEI fragments can include a range of lengths (i.e., repeat units, as represented above by the variable "n"). For example, LPEI fragments can include 1 to 1000 repeat units (i.e., -NH-CH-CH-). In some embodiments, LPEI fragments can exist as dispersed polymer moieties and do not include a discrete number of -NH-CH-CH- repeat units. For example, LPEI fragments can exist as dispersed polymer moieties with molecular weights of about 5 KDa to 50 KDa, preferably with a dispersity of about 5 or less, preferably about 4 or less, preferably about 3 or less, preferably about 2 or less, and preferably about 1.5 or less. In some embodiments, LPEI fragments can exist as dispersed polymer moieties with molecular weights of about 10 KDa to 40 KDa, preferably with a dispersity of about 4 or less, preferably about 3 or less, preferably about 2 or less, and preferably about 1.5 or less. In some embodiments, LPEI fragments can be present as dispersed polymer moieties having a molecular weight of about 12 KDa to 30 KDa and a dispersity of about 3 or less, preferably about 2 or less, and preferably about 1.5 or less. In some embodiments, LPEI fragments can be present as dispersed polymer moieties having a molecular weight of about 15 KDa to 27 KDa and a dispersity of about 2 or less, preferably about 1.5 or less. In some embodiments, LPEI fragments can be present as dispersed polymer moieties having a molecular weight of about 17 KDa to 25 KDa and a dispersity of about 1.2 or less.
[0095] For example, the LPEI fragment can be present as a dispersed polymer portion comprising about 115-1150 repeating units, preferably having a dispersity of about 5 or less, preferably about 4 or less, preferably about 3 or less, preferably about 2 or less, and preferably about 1.5 or less. In some embodiments, the LPEI fragment can be present as a dispersed polymer portion comprising about 230-930 repeating units, with a dispersity of about 4 or less, preferably about 3 or less, preferably about 2 or less, and preferably about 1.5 or less. In some embodiments, the LPEI fragment can be present as a dispersed polymer portion comprising about 280-700 repeating units, with a dispersity of about 3 or less, preferably about 2 or less, and preferably about 1.5 or less. In some embodiments, the LPEI fragment can be present as a dispersed polymer portion comprising about 350-630 repeating units, with a dispersity of about 2 or less, preferably about 1.5 or less. In some embodiments, the LPEI fragment can be present as a dispersed polymer portion comprising about 400-580 repeating units, with a dispersity of about 1.2 or less.
[0096] In some embodiments, R 1 -(NR 2 -CH2-CH2) n - moiety is a dispersed polymer moiety having 115 to 1150 repeating units n and a dispersity of about 5 or less, wherein preferably, the R 1 -(NR 2 -CH2-CH2) n The R - moiety is a dispersed polymer moiety having 280 to 700 repeating units n and a dispersity of about 3 or less, and more preferably 1 -(NR 2 -CH2-CH2) n The R - moiety is a dispersed polymer moiety having 350 to 630 repeat units n and a dispersity of about 2 or less, and again more preferably 1 -(NR 2 -CH2-CH2) n The - moiety is a dispersed polymer moiety having 400 to 580 repeating units n and a dispersity of about 1.2 or less.
[0097] In a preferred embodiment, the polyethyleneimine fragment is a disperse polymer moiety having about 115 to about 1150 repeating units and about 230 to about 930 repeating units with a dispersity of about 5 or less, preferably about 4 or less, more preferably about 280 to about 700 repeating units with a dispersity of about 3 or less; again more preferably about 350 to about 630 repeating units with a dispersity of about 2 or less; even more preferably about 400 to about 580 repeating units with a dispersity of about 1.2 or less.
[0098] In a preferred embodiment, the polyethyleneimine fragment is a dispersed polymer moiety having about 115 to about 1150 repeating units and a dispersity of about 5 or less, preferably about 4 or less, preferably about 3 or less, preferably about 2 or less, and preferably about 1.5 or less. In a preferred embodiment, the polyethyleneimine fragment is a dispersed polymer moiety having about 230 to about 930 repeating units and a dispersity of about 4 or less, preferably about 3 or less, preferably about 2 or less, and preferably about 1.5 or less. In a preferred embodiment, the polyethyleneimine fragment is a dispersed polymer moiety having about 280 to about 700 repeating units and a dispersity of about 3 or less, preferably about 2 or less, and preferably about 1.5 or less. In a preferred embodiment, the polyethyleneimine fragment is a dispersed polymer moiety having about 350 to about 630 repeating units and a dispersity of about 2 or less, preferably about 1.5 or less. In a preferred embodiment, the polyethyleneimine fragment is a dispersed polymer moiety having about 400 to about 580 repeating units and a dispersity of about 1.2 or less.
[0099] As discussed above, those skilled in the art will understand that, in some embodiments, LPEI fragments can include organic residues (i.e., pendant amide groups) connected by nitrogen atoms embedded within the LPEI chain. Those skilled in the art will understand that such organic residues (i.e., amide groups) can be formed during the ring-opening polymerization of 2-oxazolines to form poly(2-oxazolines). Without wishing to be bound by theory, LPEIs can be formed from poly(2-oxazolines) by cleavage of amide groups (e.g., using an acid such as HCl). However, in some cases, not all amide bonds may be cleaved under these conditions. Thus, in some embodiments, about 5% or less of the nitrogen atoms in LPEI fragments can be connected to organic residues to form amides. In some embodiments, about 4%, about 3%, about 2%, about 1%, about 0.5%, about 0.4%, about 0.3%, about 0.2%, or about 0.1% of the nitrogen atoms in LPEI fragments can be connected to organic residues to form amides. Those skilled in the art will understand that the molecular weight of an LPEI fragment includes the percentage of the LPEI fragment that is attached to an organic residue as an amide. Furthermore, those skilled in the art will understand that while the chemical structures depicted herein show repeating -NH-CH-CH- fragments, trace amounts of residual organic residues, such as pendant amide groups (e.g., as defined above), may still be present in the resulting triconjugates or polyplexes of the present disclosure. The term "triconjugate," as sometimes used herein, is intended to refer to the conjugates of the present invention. The prefix "tri-" is due to the three components included in the conjugates of the present invention: the LPEI fragment, the PEG fragment, and the targeting fragment.
[0100] PEG fragment Polyethylene glycol (PEG) has the chemical formula -[O-CH-CH]-. In some preferred embodiments, PEG fragments can be coupled to LPEI fragments via a [3+2] cycloaddition between an azide and an alkene or alkyne to form a 1,2,3-triazole or a 4,5-dihydro-1H-[1,2,3]triazole, where the PEG fragment contains an alkene or alkyne functional group. For example, in some preferred embodiments, the PEG fragment contains a repeating formula -[O-CH-CH]-, an alkene or alkyne group (e.g., a linking moiety "X" discussed below) that can be coupled to an azide group on the corresponding LPEI fragment. 1 ") at the first end (i.e., terminal end).
[0101] In some preferred embodiments, the alkene or alkyne group is an activated alkene or alkyne group that can spontaneously react with an azide (e.g., without the addition of a catalyst, such as a copper catalyst). For example, an activated alkyne group can be incorporated into a 7- or 8-membered ring, resulting in a strained species that spontaneously reacts with the azide group of an LPEI fragment. The activated alkene can include a maleimide moiety, where the alkene is activated by conjugation to an adjacent carbonyl group. In some preferred embodiments, the second end (i.e., terminal end) of the PEG fragment is linked to a targeting fragment (e.g., hEGF, HER2, folate, or DUPA) (e.g., a linking moiety "X" discussed below). 2 "); in some preferred embodiments, there are no additional substitutions on the PEG fragment.
[0102] PEG fragments can include a range of lengths (i.e., repeating units represented by the variable "m"). In other embodiments, PEG fragments can include a discrete number of repeating -O-CH-CH- units and are not defined in terms of average chain length. In preferred embodiments, the -(O-CH-CH) m - is a dispersed polymer moiety. In a preferred embodiment, the -(O-CH-CH) mThe - moiety comprises, and preferably consists of, a discrete number m of repeating units. In a preferred embodiment, the -(O-CH-CH) m The moiety comprises, and preferably consists of, a discrete number m of consecutive repeating units.
[0103] In some preferred embodiments, the PEG fragment is a dispersed polymer moiety comprising from about 1 to about 200 repeating units, preferably from about 1 to about 200 repeating units. In some preferred embodiments, the PEG fragment can comprise from 1 to 100 repeating units (i.e., -O-CH2-CH2-). Preferably, the PEG fragment of the present invention comprises from about 1 to about 100 repeating units, from about 1 to about 90 repeating units, from about 1 to about 80 repeating units, from about 1 to about 70 repeating units, from about 1 to about 60 repeating units, from about 1 to about 50 repeating units, from about 1 to about 50 repeating units, from about 1 to about 40 repeating units, from about 1 to about 30 repeating units, or from about 1 to about 20 repeating units. In some other preferred embodiments, the PEG fragment comprises a discrete number of repeating units, m, preferably 12 repeating units or 24 repeating units. In some embodiments, the polyethylene glycol fragment is a disperse polymer moiety having about 2 to about 80 repeating units and a dispersity of about 2.0 or less, preferably about 1.8 or less, and even about 1.5 or less; preferably about 2 to about 70 repeating units with a dispersity of about 1.8 or less, preferably about 1.5 or less; more preferably about 2 to about 50 repeating units with a dispersity of about 1.5 or less. In some embodiments, the -(O-CH2-CH2) m The - moiety is a dispersed polymer moiety having from about 2 to about 80 repeating units and from about 2 to about 70 repeating units with a dispersity of about 2.0 or less, preferably from about 2 to about 70 repeating units with a dispersity of about 1.8 or less; more preferably from about 2 to about 50 repeating units with a dispersity of about 1.5 or less.
[0104] In a preferred embodiment, the polyethylene glycol fragment, PEG fragment, comprises, preferably consists of, a discrete number of repeating units m, preferably 12 or 24 repeating units. In a preferred embodiment, the m (the -(O-CH-CH) mThe moiety) comprises, preferably consists of, a discrete number of repeating units m, preferably 12 or 24 repeating units.
[0105] In a preferred embodiment, the PEG fragment comprises, preferably consists of, a discrete number of repeating units m between 2 and 100, preferably a discrete number of repeating units m between 4 and 60. In a preferred embodiment, the PEG fragment comprises, preferably consists of, a discrete number of repeating units m between 4 and 60, preferably a discrete number of repeating units m between 10 and 60. In preferred embodiments, the PEG fragment comprises, preferably consists of, a discrete number of repeating units m of 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59 or 60. In preferred embodiments, the PEG fragment comprises, and preferably consists of, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, or 60 discrete numbers of repeating units m. In preferred embodiments, the PEG fragment comprises, and preferably consists of, 4 discrete numbers of repeating units m. In preferred embodiments, the PEG fragment comprises, and preferably consists of, 12 discrete numbers of repeating units m. In preferred embodiments, the PEG fragment comprises, and preferably consists of, 24 discrete numbers of repeating units m. In preferred embodiments, the PEG fragment comprises, and preferably consists of, 36 discrete numbers of repeating units m.
[0106] In a preferred embodiment, the PEG fragment comprises, preferably consists of, a discrete number of consecutive repeating units m between 2 and 100, preferably a discrete number of consecutive repeating units m between 4 and 60. In a preferred embodiment, the PEG fragment comprises, preferably consists of, a discrete number of consecutive repeating units m between 4 and 60, preferably a discrete number of consecutive repeating units m between 10 and 60. In preferred embodiments, the PEG fragment comprises, preferably consists of, a discrete number of consecutive repeating units m: 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59 or 60. In preferred embodiments, the PEG fragment comprises, and preferably consists of, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, or 60 discrete numbers of consecutive repeating units m. In preferred embodiments, the PEG fragment comprises, and preferably consists of, 4 discrete numbers of consecutive repeating units m. In preferred embodiments, the PEG fragment comprises, and preferably consists of, 12 discrete numbers of consecutive repeating units m. In preferred embodiments, the PEG fragment comprises, and preferably consists of, 24 discrete numbers of consecutive repeating units m. In preferred embodiments, the PEG fragment comprises, and preferably consists of, 36 discrete numbers of consecutive repeating units m.
[0107] In a preferred embodiment, the —(O—CH—CH) of formula I* or formula I m The - moiety comprises, preferably consists of, a discrete number of repeating units m between 2 and 100, preferably a discrete number of repeating units m between 4 and 60. In a preferred embodiment, the -(O-CH2-CH2) m The - moiety comprises, preferably consists of, a discrete number of repeating units m between 4 and 60, preferably a discrete number of repeating units m between 10 and 60. In a preferred embodiment, the -(O-CH2-CH2) mThe - moiety comprises, and preferably consists of, a discrete number of repeating units m of 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59 or 60. In a preferred embodiment, the -(O-CH2-CH2) m The - moiety comprises, and preferably consists of, a discrete number of repeating units m of 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, or 60. In a preferred embodiment, the -(O-CH-CH) m The - moiety comprises, and preferably consists of, a discrete number of repeating units m of 4. In a preferred embodiment, the -(O-CH-CH) m The - moiety comprises, and preferably consists of, 12 discrete repeating units m. In a preferred embodiment, the -(O-CH-CH) m The - moiety comprises, and preferably consists of, a discrete number of repeating units m of 24. In a preferred embodiment, the -(O-CH-CH) m The - moiety comprises, and preferably consists of, 36 discrete numbers of repeating units m.
[0108] In a preferred embodiment, the —(O—CH—CH) of formula I* or formula I m The - moiety comprises, preferably consists of, a discrete number of consecutive repeating units m between 2 and 100, preferably a discrete number of consecutive repeating units m between 4 and 60. In a preferred embodiment, the -(O-CH2-CH2) m The - moiety comprises, preferably consists of, a discrete number of consecutive repeating units m between 4 and 60, preferably a discrete number of consecutive repeating units m between 10 and 60. In a preferred embodiment, the -(O-CH2-CH2) mThe - moiety comprises, and preferably consists of, a discrete number of consecutive repeating units m of 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59 or 60. In a preferred embodiment, the -(O-CH2-CH2) m In a preferred embodiment, the -(O-CH2-CH2) moiety comprises, and preferably consists of, a discrete number of consecutive repeating units m of 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, or 60. m In a preferred embodiment, the -(O-CH2-CH2) moiety comprises, and preferably consists of, a discrete number of consecutive repeating units m of 4. m The - moiety comprises, and preferably consists of, 12 discrete numbers of consecutive repeating units m. In a preferred embodiment, the -(O-CH-CH) m The - moiety comprises, and preferably consists of, 24 discrete numbers of consecutive repeating units m. In a preferred embodiment, the -(O-CH-CH) m The - moiety comprises, and preferably consists of, 36 discrete numbers of consecutive repeating units m.
[0109] In another aspect, the present invention provides a composition comprising a conjugate of formula I: [ka] [In the formula, [ka] is a single or double bond; n is any integer from 1 to 1500; m is a discrete number of repeating units m between 2 and 100, preferably a discrete number of repeating units m between 4 and 60; R 1 is the starting residue, where preferably R1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -R in 2 at least 80%, preferably at least 90% of is H; Ring A may have one or more R A1 5-10 membered cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl optionally substituted with R A1 are independently selected from C1-C6 alkyl, C1-C6 alkoxy, oxo, or halogen; or two R A1 together with the atoms to which they are attached to form one or more fused C6-C 10 can form an aryl, C-C heteroaryl, or C-C cycloalkyl ring, where each fused aryl, heteroaryl, or cycloalkyl is joined to one or more R A2 optionally substituted with R A2 is independently selected from C1-C6 alkyl, C1-C6 alkoxy, halogen, —SO3H, or OSO3H; X 1 is a divalent covalent linking moiety; X 2 is a divalent covalent linking moiety; and L is a targeting fragment, wherein preferably said targeting fragment is capable of binding to a cell, and more preferably said targeting fragment is capable of binding to a cell surface receptor. or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or enantiomer thereof. 1 is -H. In a preferred embodiment, 1 is -CH3.
[0110] In another aspect, the present invention provides a conjugate of formula I: [ka] [In the formula, [ka] is a single or double bond; n is any integer from 1 to 1500; m is a discrete number of repeating units m between 2 and 100, preferably a discrete number of repeating units m between 4 and 60; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -R in 2 at least 80%, preferably at least 90% of is H; Ring A may have one or more R A1 5-10 membered cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl optionally substituted with R A1 are independently selected from C1-C6 alkyl, C1-C6 alkoxy, oxo, or halogen; or two R A1 together with the atoms to which they are attached to form one or more fused C6-C 10 can form an aryl, C-C heteroaryl, or C-C cycloalkyl ring, where each fused aryl, heteroaryl, or cycloalkyl is joined to one or more R A2 optionally substituted with R A2 is independently selected from C1-C6 alkyl, C1-C6 alkoxy, halogen, —SO3H, or OSO3H; X 1 is a divalent covalent linking moiety; X 2 is a divalent covalent linking moiety; and L is a targeting fragment, wherein preferably said targeting fragment is capable of binding to a cell, and more preferably said targeting fragment is capable of binding to a cell surface receptor. or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or enantiomer thereof. 1 is -H. In a preferred embodiment, 1 is -CH3.
[0111] In another aspect, the present invention provides a composition comprising a conjugate of formula I: [ka] [In the formula, [ka] is a single or double bond; n is any integer from 1 to 1500; m is the repeating unit of 36 discrete numbers; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -R in 2 at least 80%, preferably at least 90% of is H; Ring A may have one or more R A1 5-10 membered cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl optionally substituted with R A1 are independently selected from C1-C6 alkyl, C1-C6 alkoxy, oxo, or halogen; or two R A1 together with the atoms to which they are attached to form one or more fused C6-C 10can form an aryl, C-C heteroaryl, or C-C cycloalkyl ring, and each fused aryl, heteroaryl, or cycloalkyl can be joined by one or more R A2 optionally substituted with R A2 is independently selected from C1-C6 alkyl, C1-C6 alkoxy, halogen, —SO3H, or OSO3H; X 1 is a divalent covalent linking moiety; X 2 is a divalent covalent linking moiety; and L is a targeting fragment, wherein preferably said targeting fragment is capable of binding to a cell, and more preferably said targeting fragment is capable of binding to a cell surface receptor. or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or enantiomer thereof. 1 is -H. In a preferred embodiment, 1 is -CH3.
[0112] In another aspect, the present invention provides a conjugate of formula I: [ka] [In the formula, [ka] is a single or double bond; n is any integer from 1 to 1500; m is the repeating unit of 36 discrete numbers; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -R in 2 at least 80%, preferably at least 90% of is H; Ring A may have one or more R A1 5-10 membered cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl optionally substituted with R A1 are independently selected from C1-C6 alkyl, C1-C6 alkoxy, oxo, or halogen; or two R A1 together with the atoms to which they are attached to form one or more fused C6-C 10 can form an aryl, C-C heteroaryl, or C-C cycloalkyl ring, and each fused aryl, heteroaryl, or cycloalkyl can be joined by one or more R A2 optionally substituted with R A2 is independently selected from C1-C6 alkyl, C1-C6 alkoxy, halogen, —SO3H, or OSO3H; X 1 is a divalent covalent linking moiety; X 2 is a divalent covalent linking moiety; and L is a targeting fragment, wherein preferably said targeting fragment is capable of binding to a cell, and more preferably said targeting fragment is capable of binding to a cell surface receptor. or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or enantiomer thereof. 1 is -H. In a preferred embodiment, 1 is -CH3.
[0113] In another aspect, the present invention provides a composition comprising a conjugate of formula I: [ka] [In the formula, [ka] is a single or double bond; n is any integer from 1 to 1500; m is a discrete number of consecutive repeat units m from 2 to 100, preferably a discrete number of consecutive repeat units m from 4 to 60; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -R in 2 at least 80%, preferably at least 90% of is H; Ring A may have one or more R A1 5-10 membered cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl optionally substituted with R A1 are independently selected from C1-C6 alkyl, C1-C6 alkoxy, oxo, or halogen; or two R A1 together with the atoms to which they are attached to form one or more fused C6-C 10 can form an aryl, C-C heteroaryl, or C-C cycloalkyl ring, where each fused aryl, heteroaryl, or cycloalkyl is joined to one or more R A2 optionally substituted with R A2 is independently selected from C1-C6 alkyl, C1-C6 alkoxy, halogen, —SO3H, or OSO3H; X 1 is a divalent covalent linking moiety; X 2 is a divalent covalent linking moiety; and L is a targeting fragment, wherein preferably said targeting fragment is capable of binding to a cell, and more preferably said targeting fragment is capable of binding to a cell surface receptor. or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or enantiomer thereof. 1 is -H. In a preferred embodiment, 1 is -CH3.
[0114] In another aspect, the present invention provides a conjugate of formula I: [ka] [In the formula, [ka] is a single or double bond; n is any integer from 1 to 1500; m is a discrete number of consecutive repeat units m from 2 to 100, preferably a discrete number of consecutive repeat units m from 4 to 60; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -R in 2 at least 80%, preferably at least 90% of is H; Ring A may have one or more R A1 5-10 membered cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl optionally substituted with R A1 are independently selected from C1-C6 alkyl, C1-C6 alkoxy, oxo, or halogen; or two R A1 together with the atoms to which they are attached to form one or more fused C6-C 10 can form an aryl, C-C heteroaryl, or C-C cycloalkyl ring, where each fused aryl, heteroaryl, or cycloalkyl is joined to one or more R A2 optionally substituted with R A2 is independently selected from C1-C6 alkyl, C1-C6 alkoxy, halogen, —SO3H, or OSO3H; X 1 is a divalent covalent linking moiety; X2 is a divalent covalent linking moiety; and L is a targeting fragment, wherein preferably said targeting fragment is capable of binding to a cell, and more preferably said targeting fragment is capable of binding to a cell surface receptor. or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or enantiomer thereof. 1 is -H. In a preferred embodiment, 1 is -CH3.
[0115] In another aspect, the present invention provides a composition comprising a conjugate of formula I: [ka] [In the formula, [ka] is a single or double bond; n is any integer from 1 to 1500; m is a continuous repeating unit m of 36 discrete numbers; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -R in 2 at least 80%, preferably at least 90% of is H; Ring A may have one or more R A1 5-10 membered cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl optionally substituted with R A1 are independently selected from C1-C6 alkyl, C1-C6 alkoxy, oxo, or halogen; or two R A1 together with the atoms to which they are attached to form one or more fused C6-C10 can form an aryl, C-C heteroaryl, or C-C cycloalkyl ring, and each fused aryl, heteroaryl, or cycloalkyl can be joined by one or more R A2 optionally substituted with R A2 is independently selected from C1-C6 alkyl, C1-C6 alkoxy, halogen, —SO3H, or OSO3H; X 1 is a divalent covalent linking moiety; X 2 is a divalent covalent linking moiety; and L is a targeting fragment, wherein preferably said targeting fragment is capable of binding to a cell, and more preferably said targeting fragment is capable of binding to a cell surface receptor. or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or enantiomer thereof. 1 is -H. In a preferred embodiment, 1 is -CH3.
[0116] In another aspect, the present invention provides a conjugate of formula I: [ka] [In the formula, [ka] is a single or double bond; n is any integer from 1 to 1500; m is a continuous repeating unit of 36 discrete numbers; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -R in 2at least 80%, preferably at least 90% of is H; Ring A may have one or more R A1 5-10 membered cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl optionally substituted with R A1 are independently selected from C1-C6 alkyl, C1-C6 alkoxy, oxo, or halogen; or two R A1 together with the atoms to which they are attached to form one or more fused C6-C 10 can form an aryl, C-C heteroaryl, or C-C cycloalkyl ring, and each fused aryl, heteroaryl, or cycloalkyl can be joined by one or more R A2 optionally substituted with R A2 is independently selected from C1-C6 alkyl, C1-C6 alkoxy, halogen, —SO3H, or OSO3H; X 1 is a divalent covalent linking moiety; X 2 is a divalent covalent linking moiety; and L is a targeting fragment, wherein preferably said targeting fragment is capable of binding to a cell, and more preferably said targeting fragment is capable of binding to a cell surface receptor. or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or enantiomer thereof. 1 is -H. In a preferred embodiment, 1 is -CH3.
[0117] In some preferred embodiments, the conjugates of the invention comprise LPEI fragments present as dispersed polymer moieties, where n is from about 280 to about 700 with a dispersity of about 3 or less, preferably from about 350 to about 630 with a dispersity of about 2 or less, and more preferably from about 400 to 580 with a dispersity of about 1.2 or less, and the conjugates of the invention further comprise (i) PEG fragments present as dispersed polymer moieties, where m is from about 2 to about 80 and a dispersity of about 2 or less, preferably from about 2 to about 70 with a dispersity of about 1.8 or less; more preferably from about 2 to about 50 repeat units with a dispersity of about 1.5; or (ii) PEG fragments present as a discrete number of repeat units, m, where preferably the discrete number of repeat units, m, is 12 or 24 repeat units.
[0118] In some embodiments, the conjugates of the present invention comprise LPEI fragments present as dispersed polymer moieties of about 17 and 25 KDa, with a dispersity of about 1.2 or less, and PEG fragments comprising, preferably consisting of, 12 repeating units. In some preferred embodiments, the conjugates of the present invention comprise LPEI fragments present as dispersed polymer moieties of about 17-25 KDa molecular weight, with a dispersity of about 1.2 or less, and PEG fragments preferably consisting of 24 repeating units.
[0119] target fragment The conjugates of the present invention comprise a targeting moiety that enables the conjugates of the present invention and the polyplexes of the present invention to be directed to a particular target cell type, collection of cells, organ, or tissue. Typically and preferably, the targeting moiety is capable of binding to a target cell, preferably its cell receptor or cell surface receptor.
[0120] As used herein, the term "cell surface receptor" refers to a protein, glycoprotein, or lipoprotein that is present on the surface of a cell and that is typically and preferably a characteristic marker for cell recognition. Typically and preferably, said cell surface receptor is capable of binding to ligands including hormones, neurotransmitters, cytokines, growth factors, cell adhesion molecules, or nutrients in the form of peptides, small molecules, saccharides and oligosaccharides, lipids, amino acids, and other binding moieties such as antibodies, aptamers, affibodies, antibody fragments, and the like.
[0121] The conjugates and polyplexes of the present invention, which include targeting moieties, are intended to mimic such ligand-receptor interactions. Thus, in a preferred embodiment, the targeting moiety is capable of binding to a cell surface receptor. In a preferred embodiment, the cell surface receptor is selected from growth factor receptors, extracellular matrix proteins, cytokine receptors, hormone receptors, glycosylphosphatidylinositol (GPI)-anchored membrane proteins, carbohydrate-binding integral membrane proteins, lectins, ion channels, G protein-coupled receptors, and enzyme-linked receptors such as tyrosine kinase-coupled receptors.
[0122] In a preferred embodiment, the targeting moiety is capable of binding to a cell surface receptor. In a preferred embodiment, the cell surface receptor is selected from a growth factor receptor, an extracellular matrix protein, a cytokine receptor, a hormone receptor, a glycosylphosphatidylinositol (GPI)-anchored membrane protein, a carbohydrate-binding integral membrane protein, a lectin, an ion channel, a G protein-coupled receptor, and an enzyme-linked receptor such as a tyrosine kinase-coupled receptor. In a preferred embodiment, the cell surface receptor is a growth factor receptor. In a preferred embodiment, the cell surface receptor is an extracellular matrix protein. In a preferred embodiment, the cell surface receptor is a cytokine receptor. In a preferred embodiment, the cell surface receptor is a hormone receptor. In a preferred embodiment, the cell surface receptor is a glycosylphosphatidylinositol (GPI)-anchored membrane protein. In a preferred embodiment, the cell surface receptor is a carbohydrate-binding integral membrane protein. In a preferred embodiment, the cell surface receptor is a lectin. In a preferred embodiment, the cell surface receptor is an ion channel. In a preferred embodiment, said cell surface receptor is an enzyme-linked receptor, wherein preferably said enzyme-linked receptor is a tyrosine kinase-coupled receptor.
[0123] In a preferred embodiment, the cell surface receptor is selected from epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), prostate surface membrane antigen (PSMA), insulin-like growth factor 1 receptor (IGF1R), vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR). In a preferred embodiment, the cell surface receptor is epidermal growth factor receptor (EGFR). In a preferred embodiment, the cell surface receptor is human epidermal growth factor receptor 2 (HER2). In a preferred embodiment, the cell surface receptor is prostate surface membrane antigen (PSMA). In a preferred embodiment, the cell surface receptor is insulin-like growth factor 1 receptor (IGF1R). In a preferred embodiment, the cell surface receptor is vascular endothelial growth factor receptor (VEGFR). In a preferred embodiment, the cell surface receptor is platelet-derived growth factor receptor (PDGFR). In a preferred embodiment, the cell surface receptor is fibroblast growth factor receptor (FGFR).
[0124] The targeting fragment according to the present invention is intended to position and deliver, particularly selectively, the polyplexes and payloads, e.g., nucleic acids, of the present invention to a desired target, particularly a desired target cell. Furthermore, the conjugates of the present invention comprising said targeting fragment not only enable the selective delivery of the conjugates and polyplexes to a target, e.g., a target cell, but also enable internalization and promote selective cellular uptake of the polyanionic payload by the target, particularly by the target cell. Thus, the targeting fragment according to the present invention represents a portion of the conjugates and polyplexes of the present invention that is capable of specific binding to a selected target, preferably a selected target cell, and more preferably a cellular receptor.
[0125] In preferred embodiments, the targeting fragment is capable of binding to a target cell. In preferred embodiments, the targeting fragment is capable of binding to a selected target cell type. In preferred embodiments, the targeting fragment is capable of binding to a target cell receptor. In preferred embodiments, the targeting fragment is capable of binding to a target cell surface receptor.
[0126] In preferred embodiments, the targeting segment functions to bind to a target cell. In preferred embodiments, the targeting segment functions to bind to a selected target cell type. In preferred embodiments, the targeting segment functions to bind to a target cell receptor, and in preferred embodiments, the targeting segment functions to bind to a target cell surface receptor.
[0127] In preferred embodiments, the targeting fragment is capable of specifically binding to a target cell. In preferred embodiments, the targeting fragment is capable of specifically binding to a selected target cell type. In preferred embodiments, the targeting fragment is capable of specifically binding to a target cell receptor. In preferred embodiments, the targeting fragment is capable of specifically binding to a target cell surface receptor.
[0128] In one embodiment, specifically binding to a target cell, target cell receptor, or target cell surface receptor means that the targeting fragment and the conjugate of the invention and / or the polyplex of the invention bind to said target cell, said target cell receptor, said target cell surface receptor, respectively, at least 2-fold, preferably at least 3-fold, more preferably at least 4-fold, and again more preferably at least 5-fold stronger than they bind to other non-targeted cells, cell receptors, or cell surface receptors, typically and preferably as measured by a dissociation constant (KD). Preferably, the targeting fragment binds to said target cell, said target cell receptor, or said target cell surface receptor, respectively, at least 2-fold, preferably at least 3-fold, more preferably at least 4-fold, and again more preferably at least 5-fold stronger than they bind to other non-targeted cells, cell receptors, or cell surface receptors, typically and preferably as measured by a dissociation constant (KD). -5 Less than M, preferably 10 -6 Less than M, more preferably 10 -7 less than M, and even more preferably 10 -8 Binds to selected cell surface receptors with a KD less than M.
[0129] In one embodiment, the specific binding to a target cell, target cell receptor, or target cell surface receptor means that the targeting fragment and the conjugate of the present invention and / or the polyplex of the present invention, respectively, bind to the target cell, said target cell receptor, or said target cell surface receptor at least 2-fold, preferably at least 3-fold, more preferably at least 5-fold, and even more preferably at least 10-fold, and even more preferably at least 100-fold stronger than a corresponding conjugate and / or polyplex identical to the conjugate of the present invention and / or the polyplex of the present invention, but comprising a non-specific fragment such as a hydroxy group or an OMe moiety, preferably an -OMe moiety, instead of the targeting fragment, as exemplified in Example 23. Binding to a target cell, target cell receptor, or target cell surface receptor is typically and preferably measured by a dissociation constant (KD). Preferably, the targeting fragment binds to a target cell, said target cell receptor, or said target cell surface receptor at least 2-fold, preferably at least 3-fold, more preferably at least 5-fold, and even more preferably at least 10-fold, and even more preferably at least 100-fold stronger than a corresponding conjugate and / or polyplex identical to the conjugate of the present invention and / or the polyplex of the present invention, but comprising a non-specific fragment such as a hydroxy group or an OMe moiety, preferably an -OMe moiety, instead of the targeting fragment, as exemplified in Example 23. -5 Less than M, preferably 10 -6 Less than M, more preferably 10 -7 less than M, and even more preferably 10 -8 It binds to a selected target cell surface receptor with a KD of less than M. In a preferred embodiment, said binding or said specific binding, and thus the binding level of the conjugates of the invention and the polyplexes of the invention, respectively, can be determined by binding or displacement assays, or by FRET or other measures demonstrating the interaction between the targeting fragment and the cell receptor, preferably the cell surface receptor.
[0130] The term "binding", as used herein with respect to the binding of a targeting moiety to a cell, cell receptor or cell surface receptor, preferably refers to interactions via non-covalent bonds, such as electrostatic interactions, van der Waals interactions, hydrogen bonds, hydrophobic interactions, ionic bonds, charge interactions, affinity interactions, and / or dipole-dipole interactions.
[0131] In another embodiment, said specific binding to a target cell, target cell receptor, or target cell surface receptor results in a biological effect caused by said specific binding of a targeting fragment and a conjugate and / or polyplex of the invention, respectively, and / or caused by a delivered conjugate and / or polyplex of the invention and a polyanionic payload, which biological effect is at least 2-fold, preferably at least 3-fold, more preferably at least 5-fold, even more preferably at least 10-fold, and even more preferably at least 25-fold, at least 50-fold, or at least 100-fold greater than said biological effect of a non-targeted cell, non-targeted cell receptor, or non-targeted cell surface receptor.
[0132] In another embodiment, the specific binding to the target cell, target cell receptor, or target cell surface receptor results in a biological effect caused by the specific binding of the targeting fragment to the conjugate and / or polyplex of the invention, respectively, and / or caused by the delivered conjugate and / or polyplex of the invention with a polyanionic payload, which biological effect is at least 2-fold, preferably at least 3-fold, more preferably at least 5-fold, even more preferably at least 10-fold, and even more preferably at least 25-fold, at least 50-fold, or at least 100-fold greater than a corresponding conjugate and / or polyplex of the invention that is identical to the conjugate and / or polyplex of the invention but comprises a non-specific fragment such as a hydroxy group or an OMe moiety, preferably an -OMe moiety, instead of the targeting fragment, as exemplified in Example 23.
[0133] Binding and specific binding can also be determined by measuring activation of protein signaling, and thus can be measured by measuring protein phosphorylation or protein expression, mRNA expression in cells or tissues (using Western blot analysis, real-time PCR, RNAseq, IHC, etc.). The level of delivery of the polyplexes of the present invention to a particular tissue can be measured by comparing the amount of protein produced in cells with overexpression with cells with normal and low expression, by measuring protein secretion using Western blot analysis, luminescence / fluorescence assays, flow cytometry assays, or ELISA, ECLIA, etc. By comparing the amount of expression or secretion of downstream proteins (derived from delivered nucleic acids such as PolyIC) in cells / tissues with overexpression of the target receptor compared to normal cells / tissues or cells / tissues with low expression, by measuring protein secretion using Western blot analysis, luminescence / fluorescence assays, flow cytometry assays, or ELISA, ECLIA, etc. Delivery levels can also be measured by cytotoxicity using cell viability assays or cell death assays, including MTT, methylene blue assay, cell titer glow assay, and propidium iodide assay. By comparing the amount of protein produced in the tissue to the weight of the tissue, by comparing the therapeutic and / or prophylactic amount in the tissue to the weight of the tissue, by comparing the amount of protein produced in the tissue to the total amount of protein in the tissue, or by comparing the therapeutic and / or prophylactic amount in the tissue to the total therapeutic and / or prophylactic amount in the tissue. It will be understood that delivery of the polyplexes of the invention to the target cells or target tissues need not be determined in the subject being treated, but may be determined in surrogates such as animal or cell models.
[0134] Thus, in preferred embodiments, the biological effect is selected from (i) activation of protein signaling, (ii) protein expression, (iii) mRNA expression in cells or tissues, (iv) expression or secretion of downstream proteins from the delivered nucleic acid, such as delivered poly(IC), in cells / tissues in which the target cell surface receptor is overexpressed compared to normal cells / tissues or cells / tissues with low expression, and (v) cytotoxicity.
[0135] In one embodiment, the target cells include, but are not limited to, hepatocytes, epithelial cells, hematopoietic cells, epithelial cells, endothelial cells, lung cells, bone cells, stem cells, mesenchymal cells, neural cells, cardiac cells, adipocytes, and vascular smooth muscle cells. Thus, in one embodiment, the target cells are cells in the liver. In one embodiment, the target cells are epithelial cells. In one embodiment, the target cells are hepatocytes. In one embodiment, the target cells are hematopoietic cells. In one embodiment, the target cells are muscle cells. In one embodiment, the target cells are endothelial cells. In one embodiment, the target cells are tumor cells or cells in the tumor microenvironment. In one embodiment, the target cells are blood cells. In one embodiment, the target cells are cells in lymph nodes. In one embodiment, the target cells are cells in the lungs. In one embodiment, the target cells are cells in the skin. In one embodiment, the target cells are spleen cells. In one embodiment, the target cells are antigen-presenting cells, such as professional antigen-presenting cells in the spleen. In one embodiment, the target cells are dendritic cells in the spleen. In one embodiment, the target cells are T cells. In one embodiment, the target cell is a B cell. In one embodiment, the target cell is a NK cell. In one embodiment, the target cell is a monocyte.
[0136] In some embodiments, the targeting moiety selectively or preferentially interacts with a particular cell type. The targeting moiety not only serves to selectively target the conjugates and polyplexes of the present invention to a particular cell, but also typically promotes selective uptake of the conjugates and corresponding polyplexes of the present invention within a particular cell type. In some embodiments, the targeting moiety selectively or preferentially interacts with a particular cell surface receptor. When the targeting moiety of a conjugate and / or polyplex selectively or preferentially interacts with a cell surface receptor, the conjugate and / or polyplex can be selectively or preferentially taken up by cells containing the cell surface receptor.
[0137] In a preferred embodiment, the targeting moiety is a peptide, a protein, a small molecule ligand, a saccharide, an oligosaccharide, a lipid, or an amino acid, wherein the peptide, the protein, the small molecule ligand, the saccharide, the oligosaccharide, the lipid, or the amino acid is selected from a hormone, a neurotransmitter, a cytokine, a growth factor, a cell adhesion molecule, or a nutrient, and the targeting moiety is an antibody, an antibody fragment, an aptamer, or an affibody.
[0138] The term "small molecule ligand," as used herein, particularly with respect to the targeting fragments of the present invention, relates to a chemical moiety having a molecular weight of at least 75 g / mol, preferably at least 100 g / mol, and more preferably at least 200 g / mol, and preferably having a molecular weight of less than about 2000 g / mol. In some embodiments, the small molecule has a molecular weight of less than about 1500 g / mol, more preferably less than about 1000 g / mol. In further preferred embodiments, the small molecule has a molecular weight of less than about 800 g / mol, and even more preferably less than about 500 g / mol. The term "small molecule ligand," as used herein, particularly with respect to the targeting fragments of the present invention, more preferably relates to such a ligand that binds, preferably specifically binds, to a target cell, a target cell receptor, or preferably a target cell surface receptor. In preferred embodiments, the small molecule ligand has a molecular weight of at least 75 g / mol, preferably at least 100 g / mol, and more preferably at least 200 g / mol, and preferably has a molecular weight of less than about 2000 g / mol, and preferably less than about 1500 g / mol. In preferred embodiments, the small molecule ligand has a molecular weight of at least 75 g / mol, preferably at least 100 g / mol, more preferably at least 200 g / mol, preferably less than about 2000 g / mol, preferably less than about 1500 g / mol, and the small molecule ligand is capable of binding, preferably specifically binding, to a target cell surface receptor.
[0139] In some embodiments, the targeting fragment is a native, natural, or modified ligand or a paralog thereof, or a non-natural ligand such as an antibody, a single-chain variable fragment (scFv), or an antibody mimetic such as an affibody. In preferred embodiments, the targeting fragment is a native, natural, or modified cell surface antigen ligand or a paralog thereof, or a non-natural cell surface antigen ligand, e.g., an antibody, a single-chain variable fragment (scFv), or an antibody mimetic, e.g., an affibody. In preferred embodiments, the targeting fragment is a native, natural, or modified cell surface receptor ligand or a paralog thereof, or a non-natural cell surface receptor ligand, e.g., an antibody, a single-chain variable fragment (scFv), or an antibody mimetic, e.g., an affibody. In preferred embodiments, the targeting fragment is a small molecule ligand, a peptide, a protein, an aptamer, a native, natural, or modified ligand, and / or a paralog thereof. In preferred embodiments, the targeting moiety is a small molecule ligand, peptide, protein, aptamer, native, natural or modified cell surface antigen ligand and / or paralog thereof, wherein said small molecule ligand has a molecular weight of at least 75 g / mol, preferably at least 100 g / mol, more preferably at least 200 g / mol, and preferably has a molecular weight of less than about 2000 g / mol, preferably less than about 1500 g / mol. In preferred embodiments, the targeting moiety is a small molecule ligand, peptide, protein, aptamer, native, natural or modified cell surface receptor ligand and / or paralog thereof, wherein said small molecule ligand has a molecular weight of at least 75 g / mol, preferably at least 100 g / mol, more preferably at least 200 g / mol, and preferably has a molecular weight of less than about 2000 g / mol, preferably less than about 1500 g / mol. In preferred embodiments, the targeting moiety is a small molecule ligand, a peptide, a protein, an aptamer, a native, naturally occurring or engineered ligand and / or a paralog thereof, an antibody, a single chain variable fragment (scFv), or an antibody mimetic such as an affibody.
[0140] In a preferred embodiment, the targeting fragment is a small molecule ligand, a peptide, a protein, an aptamer, a native, natural, or modified cell surface receptor ligand, and / or a paralog thereof. In a preferred embodiment, the targeting fragment is a small molecule ligand, a peptide, a protein, an aptamer, a native, natural, or modified ligand, and / or a paralog thereof, wherein the small molecule ligand, the peptide, the protein, the aptamer, the native, natural, or modified ligand, and / or the paralog thereof is capable of binding, preferably selectively, to a cell surface receptor. In a preferred embodiment, the targeting fragment is a small molecule ligand. In a preferred embodiment, the targeting fragment is a small molecule ligand, wherein the small molecule ligand is capable of binding, preferably selectively, to a cell surface receptor. In a preferred embodiment, the targeting fragment is a peptide. In a preferred embodiment, the targeting fragment is a peptide, wherein the peptide is capable of binding, preferably selectively, to a cell surface receptor. In a preferred embodiment, the targeting fragment is a protein. In a preferred embodiment, the targeting fragment is a protein, wherein the protein is capable of binding, preferably selectively, to a cell surface receptor. In a preferred embodiment, the targeting fragment is an aptamer. In a preferred embodiment, the targeting fragment is an aptamer, which is capable of binding, preferably selectively binding, to a cell surface receptor. In a preferred embodiment, the targeting fragment is a native, natural, or modified ligand and / or a paralog thereof, preferably a native, natural, or modified cell surface receptor ligand and / or a paralog thereof. In a preferred embodiment, the targeting fragment is a native, natural, or modified ligand and / or a paralog thereof, wherein the native, natural, or modified ligand and / or a paralog thereof is capable of binding, preferably selectively binding, to a cell surface receptor. In a preferred embodiment, the targeting fragment is an antibody, a single-chain variable fragment (scFv), or an antibody mimetic, such as an affibody.In a preferred embodiment, the targeting fragment is an antibody, a single chain variable fragment (scFv), or an antibody mimetic, such as an affibody, which is capable of binding, preferably selectively binding, to a cell surface receptor.
[0141] In a preferred embodiment, the targeting moiety is selected from a small molecule ligand, a peptide, a protein, an aptamer, an antibody, an antibody fragment, preferably a single chain variable fragment (scFv), an antibody mimetic, preferably an affibody, a nanobody, a diabody, a designed ankyrin repeat protein (DARPin), a growth factor or a functional fragment thereof, preferably hEGF, a hormone or a functional fragment thereof, preferably insulin, a cytokine or a functional fragment thereof, an integrin, an interleukin or a functional fragment thereof, an enzyme, a nucleic acid, a fatty acid, a carbohydrate, a monosaccharide, an oligosaccharide or a polysaccharide, a peptidoglycan, a glycopeptide, asialoorosomucoid, mannose-6-phosphate, mannose, Sialyl-Lewis x , N-acetyllactosamine, galactose, a lysosomotropic agent and / or a nuclear localization agent, preferably T antigen, tumor low pH inserting peptide (PHLIP), p32 targeting peptide, preferably LyP-1 tumor homing peptide, insulin-like growth factor 1, vascular endothelial growth factor, platelet-derived growth factor and / or fibroblast growth factor.
[0142] In some embodiments, the targeting moiety is a non-natural ligand such as an antibody or antibody fragment (e.g., a single-chain variable fragment (scFv), an antibody mimetic such as an affibody, nanobody, diabody, designed ankyrin repeat protein (DARPin), or other antibody variant). In some embodiments, the targeting moiety is a growth factor or a fragment thereof, preferably a functional fragment (e.g., hEGF); a hormone or a fragment thereof, preferably a functional fragment (e.g., insulin), asialoorosomucoid, mannose-6-phosphate, mannose, sialyl Lewis x, N-acetyllactosamine, galactose, lysosomotropic agents and / or nuclear localization agents (e.g., T antigen), tumor low pH inserting peptides (PHLIP), p32 targeting peptides, such as LyP-1 tumor homing peptide, insulin-like growth factor 1, vascular endothelial growth factor, platelet-derived growth factor, and / or fibroblast growth factor. Further non-limiting examples of targeting moieties include enzymes, nucleic acids, fatty acids, carbohydrates, mono-, oligo-, or polysaccharides, peptidoglycans, and glycopeptides.
[0143] In a preferred embodiment, the targeting moiety is selected from a small molecule ligand, a peptide, a protein, an aptamer, an antibody, an antibody fragment, preferably a Fab, Fab', F(ab')2 or scFv fragment, an antibody mimetic, preferably an affibody, a nanobody, a diabody, a designed ankyrin repeat protein (DARPin), a growth factor or a functional fragment thereof, preferably hEGF, a hormone or a functional fragment thereof, preferably insulin, a cytokine or a functional fragment thereof, an interleukin or a functional fragment thereof, an enzyme, a nucleic acid, a fatty acid, a carbohydrate, a monosaccharide, an oligosaccharide or a polysaccharide, a peptidoglycan, a glycopeptide, asialoorosomucoid, mannose-6-phosphate, mannose, Sialyl-Lewis x , N-acetyllactosamine, galactose, lysosomotropic agents and / or nuclear localization agents, preferably T antigen, tumor low pH insert peptide (PHLIP), p32 targeting peptide, preferably LyP-1 tumor homing peptide, insulin-like growth factor 1, vascular endothelial growth factor, platelet-derived growth factor and / or fibroblast growth factor.
[0144] In some embodiments, the targeting fragment L is hEGF; an anti-HER2 peptide, preferably an anti-HER2 antibody or affibody; DUPA; a folate receptor targeting fragment, folic acid; a somatostatin receptor targeting fragment, preferably somatostatin and / or octreotide; an integrin targeting fragment, preferably an arginine-glycine-aspartic acid (RGD)-containing fragment; a low pH insertion peptide; an asialoglycoprotein receptor targeting fragment, preferably asialoorosomucoid; an insulin receptor targeting fragment, preferably insulin; a mannose-6-phosphate receptor targeting fragment, preferably mannose-6-phosphate; a mannose receptor targeting fragment, preferably mannose; Sialyl Lewis x The antibody is selected from an antigen-targeting fragment, preferably E-selectin; a sigma-2 receptor agonist, preferably N,N-dimethyltryptamine (DMT), a sphingolipid-derived amine and / or a steroid, more preferably progesterone; a p32-targeting ligand, preferably an anti-p32 antibody or a p32-binding LyP-1 tumor-homing peptide; a Trop-2-targeting fragment, preferably an anti-Trop-2 antibody and / or antibody fragment; insulin-like growth factor 1; vascular endothelial growth factor; platelet-derived growth factor; and fibroblast growth factor.
[0145] In some embodiments, the targeting fragment L is a targeting fragment derived from hEGF; an anti-HER2 peptide, preferably an anti-HER2 antibody or affibody; DUPA; folate; a somatostatin receptor targeting fragment, preferably somatostatin and / or octreotide; an integrin targeting fragment, preferably an arginine-glycine-aspartic acid (RGD)-containing fragment; a low pH insertion peptide; an asialoglycoprotein receptor targeting fragment, preferably asialoorosomucoid; an insulin receptor targeting fragment, preferably insulin; a mannose-6-phosphate receptor targeting fragment, preferably mannose-6-phosphate; a mannose receptor targeting fragment, preferably mannose; Sialyl Lewis xThe antibody is selected from an antigen-targeting fragment, preferably E-selectin; a sigma-2 receptor agonist, preferably N,N-dimethyltryptamine (DMT), a sphingolipid-derived amine and / or a steroid, more preferably progesterone; a p32-targeting ligand, preferably an anti-p32 antibody or a p32-binding LyP-1 tumor-homing peptide; a Trop-2-targeting fragment, preferably an anti-Trop-2 antibody and / or antibody fragment; insulin-like growth factor 1; vascular endothelial growth factor; platelet-derived growth factor; and fibroblast growth factor.
[0146] In preferred embodiments, the targeting fragment is an EGFR targeting fragment; a PSMA targeting fragment; an anti-HER2 peptide, preferably an anti-HER2 antibody or an affibody; folate; a somatostatin receptor targeting fragment, preferably somatostatin and / or octreotide; an integrin targeting fragment, preferably an arginine-glycine-aspartic acid (RGD)-containing fragment; a low pH insertion peptide; an asialoglycoprotein receptor targeting fragment, preferably asialoorosomucoid; an insulin receptor targeting fragment, preferably insulin; a mannose-6-phosphate receptor targeting fragment, preferably mannose-6-phosphate; a mannose receptor targeting fragment, preferably mannose; Sialyl Lewis x The antibody is selected from an antigen-targeting fragment, preferably E-selectin; a sigma-2 receptor agonist, preferably N,N-dimethyltryptamine (DMT), a sphingolipid-derived amine and / or a steroid, more preferably progesterone; a p32-targeting ligand, preferably an anti-p32 antibody or a p32-binding LyP-1 tumor-homing peptide; a Trop-2-targeting fragment, preferably an anti-Trop-2 antibody and / or antibody fragment; insulin-like growth factor 1; vascular endothelial growth factor; platelet-derived growth factor; and fibroblast growth factor.
[0147] In a preferred embodiment, the targeting moiety is an epidermal growth factor, such as human epidermal growth factor (hEGF), where typically and preferably the coupling to the remainder of the conjugate is via an amino group on the hEGF, which can be selectively taken up by cells that have increased expression (e.g., overexpression) of the human epidermal growth factor receptor (EGFR).
[0148] In a preferred embodiment, the targeting segment is capable of binding to the epidermal growth factor receptor (EGFR), also referred to herein as an EGFR targeting segment.
[0149] EGFR is a transmembrane glycoprotein that is a member of the protein kinase superfamily and a receptor for members of the epidermal growth factor family. EGFR is a cell surface protein that binds to epidermal growth factor, thereby inducing receptor dimerization and tyrosine autophosphorylation, leading to cell proliferation. In a preferred embodiment, the EGFR-targeting fragment can bind to an epitope on the extracellular domain of EGFR.
[0150] In a preferred embodiment, the targeting fragment is capable of binding to cells expressing EGFR. In a preferred embodiment, the targeting fragment is capable of binding to cells overexpressing EGFR. In one embodiment, the cells overexpressing EGFR refer to an elevated level of EGFR expressed in the cells in a particular tissue compared to the level of EGFR measured in normal, healthy cells of the same type of tissue under similar conditions. In one embodiment, the cells overexpressing EGFR refer to an increase in the level of EGFR in the cells compared to the level in the same cells or closely related, non-malignant cells under normal physiological conditions. In one embodiment, the cells overexpressing EGFR refer to at least 10-fold, more preferably at least 20-fold, expression of EGFR compared to the expression of EGFR in normal cells or normal tissues.
[0151] In a preferred embodiment, the targeting fragment can bind to cells that express or overexpress EGFR. For example, EGFR is overexpressed in neoplastic tissues and cancer types, such as gliomas and carcinomas or cancers of epithelial origin, including head and neck, thyroid, breast, ovarian, colon, gastro-colorectal, gastro-small intestine, cervix, bladder, lung, nasopharyngeal and esophageal tissues, such as squamous cells (e.g., Gan et al., J Cell Mol Med. 2009 Sep; 13(9b): 3993-4001; Aratani et al., Anticancer Research June 2017, 37(6) 3129-3135), in particular glioma, non-small cell lung carcinoma, breast cancer, glioblastoma, squamous cell carcinoma, such as head and neck squamous cell carcinoma, small intestine, colorectal cancer, adenocarcinoma, ovarian cancer, bladder cancer or prostate cancer, and metastases thereof.
[0152] EGFR expression and overexpression are preferably detected using monoclonal antibodies targeting EGFR, for example, by immunohistochemical methods (e.g., as described in Kriegs et al., Nature, 2019, 9:13564; Prenzel et al., Endocr Relat Cancer 8, 11-31, 2001). A cutoff of 5% or more EGFR-positive cells can be used to define EGFR expression in different types of tissues or cells. Thus, cells or tissues with less than 5% positive cells can be considered negative.
[0153] In a preferred embodiment, the targeting fragment is capable of specifically binding to EGFR. Typically, specific binding is at least about 1×10 -3 M ~ approx. 1×10 -12 Binding affinity or dissociation constant K of the target fragment within M D In a preferred embodiment, the targeting fragment is capable of specifically binding to EGFR, and typically and preferably, the affinity or specific binding is determined by a dissociation constant (K D ) and the affinity or specific binding is measured by -3 Less than M, preferably 10 -4 less than M, more preferably 10 -5less than M, more preferably 10 -6 Less than M, more preferably 10 -7 M or less, and even more preferably 10 -8 M, and again more preferably less than 10 -9 K less than M D In a preferred embodiment, the targeting fragment is capable of specifically binding to EGFR, and typically and preferably, the affinity or specific binding is determined by a dissociation constant (K D ) and the specific binding is measured by -3 Under M, 10 -4 Under M, 10 -5 Under M, 10 -6 Under M, 10 -7 Under M, 10 -8 Less than M and 10 -9 K less than M D For detection of binding or complex or measurement of affinity, molecules can be analyzed using a competitive binding assay, typically and preferably a Biacore 3000 instrument (Biacore Inc., Piscataway NJ; e.g., Wei-Ting Kuo et al., PLoS One. 2015, 10(2): e0116610 or U.S. Patent Application Publication No. 2017224620). Preferably, binding results in the formation of a complex between the EGFR target fragment and EGFR, and the binding or complex can be detected.
[0154] In a preferred embodiment, the targeting fragment is an EGFR antibody, an EGFR affibody, an EGFR aptamer, an EGFR targeting peptide, or an EGFR-targeted tyrosine kinase inhibitor. In a preferred embodiment, the EGFR-targeting fragment is an EGFR antibody, an EGFR affibody, an EGFR aptamer, an EGFR-targeting peptide, or an EGFR-targeted tyrosine kinase inhibitor.
[0155] In a preferred embodiment, the targeting fragment is an EGFR targeting peptide. EGFR targeting peptide typically and preferably refers to a peptide ligand of EGFR. Such peptide ligands are known to those skilled in the art and are described, for example, in U.S. Patent Application Publication No. 2017224620 and Gent et al., 2018, Pharmaceuticals 2018, 10, 2 (the disclosures of which are incorporated herein by reference in their entirety). EGFR targeting peptides have low immunogenic potential and exhibit good penetration into solid tumor tissues.
[0156] In a preferred embodiment, the EGFR target peptide has a molecular weight of about 1000 g / mol to about 2000 g / mol, preferably about 1100 g / mol to about 1900 g / mol, more preferably about 1200 g / mol to about 1800 g / mol, and even more preferably about 1300 g / mol to about 1700 g / mol.
[0157] In a preferred embodiment, the EGFR-targeting peptide comprises, or preferably consists of, the sequence YHWYGYTPQNVI (GE11) (SEQ ID NO: 9). In a preferred embodiment, the targeting fragment comprises, or preferably consists of, the sequence YHWYGYTPQNVI (GE11) (SEQ ID NO: 9). GE-11 has excellent affinity for EGFR and also exhibits binding specificity for EGFR (kd = 22 nM) (Ruoslahti et al., Adv. Mater. 2012, 24, 3747-3756; Li et al., J. Res. Commun. 2005, 19, 1978-1985). GE11 displaces from EGFR after the addition of the physiological ligand EGF, demonstrating both its selective binding to EGFR and its receptor affinity. GE11 has been reported to have high potential for accelerating nanoparticle endocytosis due to an alternative EGFR-dependent actin-driven pathway. (Mickeler et al., Nano Lett. 2012, 12, 3417-3423; Song et al., FASEB J. 2009, 23, 1396-1404) It has been shown that EGFR levels on the surface of cancer cells remain constant after treatment with GE11 polyplexes, indicating an EGFR recycling process with long-term receptivity of cells to circulating GE11 polyplexes.
[0158] In a preferred embodiment, the EGFR targeting fragment comprises, or preferably consists of, GE11 (SEQ ID NO: 9), particularly for use in treating solid tumors characterized by EGFR-overexpressing cells. Conjugates and polyplexes of the invention comprising, or preferably consisting of, GE11 as the targeting fragment are believed to be stable polyplexes, ensuring that the polyanion and nucleic acid payload are not released before the polyplex reaches its target cell.
[0159] In a preferred embodiment, the targeting fragment is an EGFR antibody. EGFR antibody refers to an antibody that binds to EGFR. In a preferred embodiment, the EGFR antibody is human. In a preferred embodiment, the EGFR antibody is a humanized EGFR antibody. In a preferred embodiment, the EGFR antibody is a monoclonal human. In a preferred embodiment, the EGFR antibody is a humanized EGFR antibody. In a preferred embodiment, the EGFR antibody is a monoclonal fully human EGFR antibody. In another preferred embodiment, the EGFR antibody is an scFv or Fab fragment.
[0160] EGFR antibodies are known to those skilled in the art and are described, for example, in WO 2008 / 105773 and WO 2017 / 185662 (the disclosures of which are incorporated herein by reference in their entireties), and include antibodies such as bevacizumab, panitumumab, cetuximab, tomzotuximab, futuximab, zatuximab, modotuximab, imgatuzumab, zalutumumab, matuzumab, necitumumab, nimotuzumab, CEVIAvax EGF, clone EGFR, L8A4, E6.2, TH190DS, Pep2, Pep3, LR-DM1, P1X, YC088, ratML66, FM32 9, TGM10-1, F4, 2F8, 15H8, TAB-301MZ-S(P), mAb528, 2224, E7.6.3, C225, CBL155, MR1 , MR1, L211C, N5-4, TH83DS, L2-12B, 15H8, 12Do3, 7A7, 42C11(MOB-1078z), PABL-080, HPAB-2204LY-S(P), VHH205, ABT-806, Tab-271MZ, Hu225, LA22, Fab fragment DL11, Fab fragment DX 1-6, VHH104, OA-cb6, 07D06, Fab fragment HPAB-0419-FY-F(E), Fab fragment TAB-285MZ-F(E), Fab fragment TAB-2 93MZ-F(E), Fab fragment HPAB-0136-YJ-F(E), FGF-R2, EG-19-11, Fab fragment pSEX81-63, DX1-4, scFv fragment DX 1-6, EG-26-11, EG-26-11, DX1-4, TAB-326MZ, scFv fragment 528, scFv fragment LA1, scFv fragment 07D06, single domain antibody VHH139, scFv fragment EG-19-11, single domain antibody VHH134, single domain antibody 9G8, ABT-414, AMG-595, and IMGN-289. Those skilled in the art will appreciate that any antibody that recognizes and / or specifically binds to EGFR may be used in accordance with the present invention.
[0161] In a preferred embodiment, the targeting fragment is an EGFR inhibitor. EGFR inhibitors refer to targeting fragments that block cell surface localization and signal transduction of EGFR, such as oligosaccharyltransferase inhibitors, such as nerve growth inhibitor-1; or EGFR kinase inhibitors, such as afatinib, erlotinib, osimertinib, and gefitinib. EGFR inhibitors are known to those skilled in the art and are described, for example, in International Publication No. 2018078076 and U.S. Patent Application Publication No. 2017224620, the disclosures of which are incorporated herein by reference in their entireties.
[0162] In a preferred embodiment, the targeting fragment is an EGFR aptamer. Preferred EGFR targeting aptamers include, but are not limited to, those disclosed in Na Li et al. (PLoS One. 2011; 6(6): e20299), Deng-LiangWang et al. (Biochemical and Biophysical Res Com, 453(4), 2014, pp 681-685), Min Woo Kim et al. (Theranostics 2019; 9(3): 837-852), Akihiro Eguchi et al. (JACS Au 2021, 1, 5, 578-585) or Yingpan Song et al. (RSC Adv., 2020, 10, 28355-28364), the disclosures of which are incorporated herein by reference in their entirety.
[0163] The term EGFR aptamer also includes EGFR aptamer derivatives and / or functional fragments of EGFR aptamers. In some embodiments, an EGFR aptamer derivative has less than 30, 25, 20, 15, 10, 5, 4, 3, 2, or 1 nucleic acid substituted relative to the corresponding EGFR aptamer. In some embodiments, the sequence of the EGFR aptamer derivative is at least 80%, preferably 85%, more preferably 90%, again more preferably 95%, and most preferably 99% identical to the corresponding EGFR aptamer.
[0164] In a preferred embodiment, the targeting fragment is an EGFR affibody. Preferred EGFR affibodies include, but are not limited to, ZEGFR:1907, ZEGFR:2377, or ZEGFR:03115 (available from Affibody Medical AB) or dimeric forms of these affibodies. In a preferred embodiment, the EGFR affibody has the sequence of SEQ ID NO:8.
[0165] In a preferred embodiment, the targeting fragment is the EGFR ligand epidermal growth factor (EGF). Thus, in a preferred targeting fragment, the targeting fragment is epidermal growth factor (EGF). In a preferred embodiment, the targeting fragment is human EGF (hEGF), mouse EGF (mEGF), rat EGF or guinea pig EGF. In a highly preferred embodiment, the targeting fragment is human EGF (hEGF). In a highly preferred embodiment, the targeting fragment comprises, and preferably consists of, the sequence of SEQ ID NO: 7.
[0166] In some embodiments, EGF is modified, for example, by deleting or replacing one or more amino acids or by truncating EGF. Modified and / or truncated EGF molecules are disclosed, for example, in International Publication No. 2019023295. EGF has many residues that are conserved across rat, mouse, guinea pig, and human species (Savage et al., J. Biol. Chem., 247:7612-7621, 1973; Carpenter and Cohen, Ann. Rev. Biochem., 48:193-316, 1979; Simpson et al., Eur J Biochem, 153:629-37, 1985). In particular, six cysteine residues at positions 6, 14, 20, 31, 33, and 42 are conserved because they form three disulfide bridges to provide a conserved tertiary protein structure. Also conserved across all four species are residues at positions 7, 9, 11, 12, 13, 15, 18, 21, 24, 29, 32, 34, 36, 37, 39, 41, 46, and 47. Many of these residues can be predicted to facilitate or provide important binding interactions with the corresponding EGFR. Both full-length human EGF (53 residues) and a truncated form resulting from trypsin cleavage (48 residues) have been described to retain strong binding affinity and activation of EGFR (Calnan et al., 47(5):622-7, 2000; Gregory, Regul Pept, 22:217-26, 1988). Mutagenesis studies of various residues have been reported to correlate the effect of specific residue replacements on EGF binding to EGFR or EGFR activation (Campion et al., Biochemistry, 29, 9988-9993, 1990; Engler et al., J. Biol. Chem., 267:2274-2281, 1992; Tadaki and Niyogi, J. Biol. Chem., 268:10114-10119, 1993). The X-ray crystal structure of EGF bound to EGFR has been solved, revealing important binding interactions and identifying residues not directly involved in binding (Ogiso et al., Cell, Vol. 110, 775-787, 2002).
[0167] In another aspect, the present invention provides a composition comprising a conjugate of formula I*: R 1 -(NR 2 -CH2-CH2) n -ZX 1 -(O-CH2-CH2) m -X 2 -L(formula I*); [In the formula, n is any integer from 1 to 1500; m is any integer from 1 to 200, preferably m is any integer from 1 to 100; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -R in 2 at least 80%, preferably 90% of which is H; X 1 and X 2 are independently a divalent covalent linking moiety; Z is a divalent covalent linking moiety, wherein Z is not a single bond and Z is not -NHC(O)-; L is a target fragment, wherein said target fragment comprises, or preferably consists of, the sequence YHWYGYTPQNVI(GE11) (SEQ ID NO: 9). or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or enantiomer thereof, preferably consisting of said conjugate.
[0168] In another aspect, the present invention provides a conjugate of formula I*: R 1 -(NR 2 -CH2-CH2) n -ZX 1 -(O-CH2-CH2) m -X 2 -L(formula I*); [In the formula, n is any integer from 1 to 1500; m is any integer from 1 to 200, preferably m is any integer from 1 to 100; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -R in 2 at least 80%, preferably 90% of which is H; X 1 and X 2 are independently a divalent covalent linking moiety; Z is a divalent covalent linking moiety, wherein Z is not a single bond and Z is not -NHC(O)-; L is a target fragment, wherein said target fragment comprises, or preferably consists of, the sequence YHWYGYTPQNVI(GE11) (SEQ ID NO: 9). or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or enantiomer thereof.
[0169] In another aspect, the present invention provides a composition comprising a conjugate of formula I: [ka] [In the formula, [ka] is a single or double bond; n is any integer from 1 to 1500; m is any integer from 1 to 200; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2)n -R in 2 at least 80%, preferably at least 90% of is H; Ring A may have one or more R A1 5-10 membered cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl optionally substituted with R A1 are independently selected from C1-C6 alkyl, C1-C6 alkoxy, oxo, or halogen; or two R A1 together with the atoms to which they are attached to form one or more fused C6-C 10 can form an aryl, C-C heteroaryl, or C-C cycloalkyl ring, and each fused aryl, heteroaryl, or cycloalkyl can be joined by one or more R A2 optionally substituted with R A2 is independently selected from C1-C6 alkyl, C1-C6 alkoxy, halogen, —SO3H, or OSO3H; X 1 is a divalent covalent linking moiety; X 2 is a divalent covalent linking moiety; and L is a target fragment, wherein said target fragment comprises, or preferably consists of, the sequence YHWYGYTPQNVI(GE11) (SEQ ID NO: 9). or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or enantiomer thereof.
[0170] In another aspect, the present invention provides a conjugate of formula I: [ka] [In the formula, [ka] is a single or double bond; n is any integer from 1 to 1500; m is any integer from 1 to 200; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -R in 2 at least 80%, preferably at least 90% of is H; Ring A may have one or more R A1 5-10 membered cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl optionally substituted with R A1 are independently selected from C1-C6 alkyl, C1-C6 alkoxy, oxo, or halogen; or two R A1 together with the atoms to which they are attached to form one or more fused C6-C 10 can form an aryl, C-C heteroaryl, or C-C cycloalkyl ring, and each fused aryl, heteroaryl, or cycloalkyl can be joined by one or more R A2 optionally substituted with R A2 is independently selected from C1-C6 alkyl, C1-C6 alkoxy, halogen, —SO3H, or OSO3H; X 1 is a divalent covalent linking moiety; X 2 is a divalent covalent linking moiety; and L is a target fragment, wherein said target fragment comprises, or preferably consists of, the sequence YHWYGYTPQNVI(GE11) (SEQ ID NO: 9). or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or enantiomer thereof.
[0171] In another aspect, the present invention provides a composition comprising a conjugate of formula I: [ka] [In the formula, [ka] is a single or double bond; n is any integer from 1 to 1500; m is a discrete number of repeating units m between 2 and 100, preferably a discrete number of repeating units m between 4 and 60; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -R in 2 at least 80%, preferably at least 90% of is H; Ring A may have one or more R A1 5-10 membered cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl optionally substituted with R A1 are independently selected from C1-C6 alkyl, C1-C6 alkoxy, oxo, or halogen; or two R A1 together with the atoms to which they are attached to form one or more fused C6-C 10 can form an aryl, C-C heteroaryl, or C-C cycloalkyl ring, where each fused aryl, heteroaryl, or cycloalkyl is joined to one or more R A2 optionally substituted with R A2 is independently selected from C1-C6 alkyl, C1-C6 alkoxy, halogen, —SO3H, or OSO3H; X 1 is a divalent covalent linking moiety; X 2 is a divalent covalent linking moiety; and L is a targeting fragment, wherein said targeting fragment is an EGFR targeting fragment, preferably said EGFR targeting fragment is capable of specifically binding to cells expressing, preferably overexpressing, EGFR. or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or enantiomer thereof.
[0172] In another aspect, the present invention provides a composition comprising a conjugate of formula I: [ka] [In the formula, [ka] is a single or double bond; n is any integer from 1 to 1500; m is a discrete number of consecutive repeat units m from 2 to 100, preferably a discrete number of consecutive repeat units m from 4 to 60; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -R in 2 at least 80%, preferably at least 90% of is H; Ring A may have one or more R A1 5-10 membered cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl optionally substituted with R A1 are independently selected from C1-C6 alkyl, C1-C6 alkoxy, oxo, or halogen; or two R A1 together with the atoms to which they are attached to form one or more fused C6-C 10can form an aryl, C-C heteroaryl, or C-C cycloalkyl ring, where each fused aryl, heteroaryl, or cycloalkyl is joined to one or more R A2 optionally substituted with R A2 is independently selected from C1-C6 alkyl, C1-C6 alkoxy, halogen, —SO3H, or OSO3H; X 1 is a divalent covalent linking moiety; X 2 is a divalent covalent linking moiety; and L is a targeting fragment, wherein said targeting fragment is an EGFR targeting fragment, preferably said EGFR targeting fragment is capable of specifically binding to cells expressing, preferably overexpressing, EGFR. or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or enantiomer thereof.
[0173] In another aspect, the present invention provides a conjugate of formula I: [ka] [In the formula, [ka] is a single or double bond; n is any integer from 1 to 1500; m is a discrete number of repeating units m between 2 and 100, preferably a discrete number of repeating units m between 4 and 60; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -R in 2 at least 80%, preferably at least 90% of is H; Ring A may have one or more RA1 5-10 membered cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl optionally substituted with R A1 are independently selected from C1-C6 alkyl, C1-C6 alkoxy, oxo, or halogen; or two R A1 together with the atoms to which they are attached to form one or more fused C6-C 10 can form an aryl, C-C heteroaryl, or C-C cycloalkyl ring, where each fused aryl, heteroaryl, or cycloalkyl is joined to one or more R A2 optionally substituted with R A2 is independently selected from C1-C6 alkyl, C1-C6 alkoxy, halogen, —SO3H, or OSO3H; X 1 is a divalent covalent linking moiety; X 2 is a divalent covalent linking moiety; and L is a targeting fragment, wherein preferably said targeting fragment is capable of binding to a cell, and more preferably said targeting fragment is capable of binding to a cell surface receptor. or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or enantiomer thereof.
[0174] In another aspect, the present invention provides a conjugate of formula I: [ka] [In the formula, [ka] is a single or double bond; n is any integer from 1 to 1500; m is a discrete number of consecutive repeat units m from 2 to 100, preferably a discrete number of consecutive repeat units m from 4 to 60; R 1 is the starting residue, where preferably R1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -R in 2 at least 80%, preferably at least 90% of is H; Ring A may have one or more R A1 5-10 membered cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl optionally substituted with R A1 are independently selected from C1-C6 alkyl, C1-C6 alkoxy, oxo, or halogen; or two R A1 together with the atoms to which they are attached to form one or more fused C6-C 10 can form an aryl, C-C heteroaryl, or C-C cycloalkyl ring, where each fused aryl, heteroaryl, or cycloalkyl is joined to one or more R A2 optionally substituted with R A2 is independently selected from C1-C6 alkyl, C1-C6 alkoxy, halogen, —SO3H, or OSO3H; X 1 is a divalent covalent linking moiety; X 2 is a divalent covalent linking moiety; and L is a targeting fragment, wherein preferably said targeting fragment is capable of binding to a cell, and more preferably said targeting fragment is capable of binding to a cell surface receptor. or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or enantiomer thereof.
[0175] In a preferred embodiment, the targeting fragment is capable of binding to prostate surface membrane antigen (PSMA), also referred to herein as a PSMA targeting fragment.
[0176] PSMA is a multifunctional transmembrane protein that functions as a glutamate carboxypeptidase and also demonstrates rapid ligand-induced internalization and recycling (Liu H, et al., 1998, Cancer Res 58:4055-4060). PSMA is primarily expressed in four body tissues, including the prostate epithelium, the proximal tubules of the kidney, the jejunal brush border of the small intestine, and the ganglia of the nervous system (Mhawech-Fauceglia et al., Histopathology 2007, 50:472-483). In a preferred embodiment, the targeting fragment can bind to an epitope on the extracellular domain of PSMA.
[0177] In a preferred embodiment, the targeting fragment, preferably the PSMA targeting fragment, can bind to cells that express PSMA. In a preferred embodiment, the targeting fragment, preferably the PSMA targeting fragment, can bind to cells that overexpress PSMA. For example, PSMA is overexpressed in neoplastic tissue and malignant prostate, particularly in prostate adenocarcinoma compared to normal tissue, and the level of PSMA expression is further upregulated as the disease progresses to the metastatic stage (Silver et al., 1997, Clin. Cancer Res., 3:81). PSMA is also expressed and overexpressed in other tumor types (Mhawech-Fauceglia et al., Histopathology 2007, 50:472-483; Israeli RS et al., Cancer Res 1994, 54:1807-1811; Chang SS et al., Cancer Res 1999, 59:3192-198).
[0178] In one embodiment, overexpressed PSMA refers to an elevated level of PSMA expressed in the cells of a particular tissue compared to the level of PSMA measured in normal, healthy cells of the same tissue type under similar conditions. In one embodiment, overexpressed PSMA refers to an increase in the level of PSMA in a cell compared to the level in the same cell or a closely related, non-malignant cell under normal physiological conditions. In one embodiment, the cells that overexpress PSMA are characterized by at least 10-fold higher expression of PSMA compared to normal cells or normal tissue. In one embodiment, the cells that overexpress PSMA are characterized by expression of PSMA with a cutoff of 5% or more PSMA-positive cells, as described, for example, in Mhawech-Fauceglia et al., 2007, which can be used to define PSMA expression in different types of tissues or cells. Therefore, as described in Hupe et al., 2018 2018 (Hupe MC et al, Frontiers in Oncology 2018, 8(623):1-7), cells or tissues with less than 5% positive cells were considered negative, or PSMA expression was classified according to its intensity and scored as 0 (no expression), 1 (low expression), 2 (moderate expression), and 3 (high expression).
[0179] In a preferred embodiment, the targeting moiety is capable of binding to cells that express or overexpress PSMA. Cells that express PSMA typically include tumor cells, such as prostate, bladder, pancreatic, lung, kidney, and colon tumor cells, melanoma, and sarcoma. In a preferred embodiment, the targeting moiety is capable of binding to cells that express or overexpress PSMA, and the cells are tumor cells, preferably selected from prostate, bladder, pancreatic, lung, kidney, and colon tumor cells, melanoma, and sarcoma. In a preferred embodiment, the targeting moiety is capable of binding to cells that express or overexpress PSMA, and the cells are tumor cells, and the tumor cells are prostate tumor cells.
[0180] In preferred embodiments, the targeting fragment is capable of specifically binding to PSMA, and typically and preferably, the affinity or specific binding is determined by a dissociation constant (K D ) and the affinity or specific binding is measured by -3 Less than M, preferably 10 -4 less than M, more preferably 10 -5 less than M, more preferably 10 -6 Less than M, more preferably 10 -7 M or less, and even more preferably 10 -8 M, and again more preferably less than 10 -9 M, and again more preferably less than 10 -10 K less than M D In preferred embodiments, the targeting fragment is capable of specifically binding to PSMA, and typically and preferably, the affinity or specific binding is determined by a dissociation constant (K D ) and the affinity or specific binding is measured by -3 Under M, 10 -4 Under M, 10 -5 Under M, 10 -6 Under M, 10 -7 Under M, 10 -8 Less than M and 10 -9 K less than M D Preferably, the binding results in the formation of a complex between the targeting fragment and PSMA, wherein the binding or complex can be detected, typically and preferably, using a Biacore 3000 instrument (Biacore Inc., Piscataway NJ) or a cell-based binding assay or Flow Induced Dispersion Analysis (FIDA), typically and preferably as described in Kularatne et al., Mol Pharm. 2009;6(3):790-800.
[0181] In preferred embodiments, the targeting fragment is a PSMA antibody, a PSMA aptamer, or a small molecule PSMA targeting fragment. In preferred embodiments, the PSMA targeting fragment is a PSMA antibody, a PSMA aptamer, or a small molecule PSMA targeting fragment. The term "small molecule PSMA targeting fragment," as used herein, refers to a chemical moiety having a molecular weight of less than about 2000 g / mol, typically and preferably capable of binding to PSMA. In some embodiments, the small molecule PSMA targeting fragment has a molecular weight of less than about 1800 g / mol. In some embodiments, the small molecule PSMA targeting fragment has a molecular weight of less than about 1500 g / mol, more preferably less than about 1000 g / mol. In further preferred embodiments, the small molecule has a molecular weight of less than about 800 g / mol, even more preferably less than about 500 g / mol.
[0182] In some embodiments, the PSMA-targeting fragment is a PSMA antibody, an antibody capable of binding to PSMA, hi some embodiments, the antibody is a monoclonal antibody, a polyclonal antibody, and / or an antibody fragment, preferably a functional fragment thereof, a chimeric antibody, a recombinant antibody, and / or a bispecific or multispecific antibody. Such PSMA antibodies include, but are not limited to, scFv antibodies A5, G0, G1, G2, and G4 and mAbs 3 / E7, 3 / F11, 3 / A12, K7, K12, and D20 (Elsasser-Beile et al., 2006, Prostate, 66:1359); mAbs E99, J591, J533, and J415 (Liu et al., 1997, Cancer Res., 57:3629; Liu et al., 1998, Cancer Res., 58:4055; Fracasso et al., 2002, Prostate, 53:9; McDevitt et al., 2000, Cancer Res., 60:6095; McDevitt et al., 2001, Science, 294:1537; Smith-Jones et al. al.,2000,Cancer Res.,60:5237;Vallabhajosula et al.,2004,Prostate,58:145;Bander et al.,2003,J.Urol.,170:1717;Patri et al. mAb 7E11--C5.3 (Horoszewicz et al., 1987, Anticancer Res., 7:927); Antibody 7E11 (Horoszewicz et al., 1987, Anticancer Res., 7:927; and U.S. Patent No. 5,162,504); and Chang et al., 1999, Cancer Res., 59:3192; Murphy et al. al., 1998, J. Urol., 160:2396; Grauer et al., 1998, Cancer Res., 58:4787; and Wang et al., 2001, Int. J. Cancer, 92:871.Those skilled in the art will appreciate that any antibody that recognizes and / or specifically binds to PSMA may be used in accordance with the present invention. All of the foregoing documents and disclosures are incorporated herein by reference in their entireties.
[0183] In some embodiments, the targeting fragment capable of binding to PSMA is an aptamer. PSMA targeting aptamers include, but are not limited to, the A10 aptamer or the A9 aptamer (Lupold et al., 2002, Cancer Res., 62:4029; and Chu et al., 2006, Nuc. Acid Res., 34:e73), their derivatives, and / or functional fragments thereof. In some embodiments, in the aptamer derivative, less than 30, 25, 20, 15, 10, 5, 4, 3, 2, or 1 nucleic acid is substituted for the aptamer. In some embodiments, the sequence of the aptamer derivative is at least 80%, preferably 85%, more preferably 90%, again more preferably 95%, and most preferably 99% identical.
[0184] In a preferred embodiment, the targeting moiety is a small molecule PSMA targeting moiety. In a preferred embodiment, the PSMA targeting moiety is a small molecule PSMA targeting moiety, preferably a small molecule PSMA targeted peptidase inhibitor. In a preferred embodiment, the small molecule PSMA peptidase inhibitors include 2-PMPA, GPI5232, VA-033, phenylalkylphosphonamidates (Jackson et al., 2001, Curr. Med. Chem., 8:949; Bennett et al., 1998, J. Am. Chem. Soc., 120:12139; Jackson et al., 2001, J Med. Chem., 44:4170; Tsukamoto et al., 2002, Bioorg. Med. Chem. Lett., 12:2189; Tang et al., 2003, Biochem. Biophys. Res. Commun., 307:8; Oliver et al., 2003, Bioorg. Med. Chem., 11:4455; and Maung et al., 2003, Bioorg. Med. Chem., 11:4455). al., 2004, Bioorg. Med. Chem., 12:4969), and / or analogs and derivatives thereof. All of the foregoing documents (scientific and other publications, patents, and patent applications) are incorporated herein by reference in their entirety. In some embodiments, the small molecule PSMA targeting fragment is a protein, peptide, amino acid, or derivative thereof. In preferred embodiments, the small molecule PSMA targeting fragment comprises thiol and indole thiol derivatives, such as 2-MPPA and 3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid derivatives (Majer et al., 2003, J. Med. Chem., 4611989; and U.S. Patent Application Publication No. 2005 / 0080128). In some embodiments, the small molecule PSMA targeting fragment comprises a hydroxamate derivative (Stoermer et al., 2003, Bioorg. Med. Chem. Lett., 1312097).In a preferred embodiment, the small molecule PSMA peptidase inhibitor is an androgen receptor targeted agent (ARTA), such as those described in U.S. Pat. Nos. 7,026,500; 7,022,870; 6,998,500; 6,995,284; 6,838,484; 6,569,896; 6,492,554; and U.S. Pat. Publication No. 2006 / 0287547; No. 2006 / 0276540; No. 2006 / 0258628; No. 2006 / 0241180; No. 2006 / 0183 No. 931; No. 2006 / 0035966; No. 2006 / 0009529; No. 2006 / 0004042; No. 2005 / 0033074; No. 2004 / 0 No. 260108; No. 2004 / 0260092; No. 2004 / 0167103; No. 2004 / 0147550; No. 2004 / 0147489; No. 20 04 / 0087810; 2004 / 0067979; 2004 / 0052727; 2004 / 0029913; 2004 / 0014975; Nos. 2003 / 0232792; 2003 / 0232013; 2003 / 0225040; 2003 / 0162761; 2004 / 0087810; 2003 / 0022868; 2002 / 0173495; 2002 / 0099096; and 2002 / 0099036. In some embodiments, the small molecule PSMA targeting fragment comprises a polyamine, such as putrescine, spermine, and spermidine (U.S. Patent Application Publication Nos. 2005 / 0233948 and 2003 / 0035804). All of the foregoing documents and disclosures are incorporated herein by reference in their entireties.
[0185] In preferred embodiments, the small molecule PSMA peptidase inhibitors include PBDA- and urea-based inhibitors, such as ZJ 43, ZJ, ZJ 17, and ZJ 38 (Nan et al., 2000, J. Med. Chem., 43:772; and Kozikowski et al., 2004, J. Med. Chem., 47, 7, 1729-1738), and / or analogs and derivatives thereof. Other agents that bind to PSMA can also be used, such as PSMA-targeting fragments, including those found in Clin. Cancer Res., 2008 14:3036-43, or PSMA-targeting fragments prepared by sequentially adding components to a preformed urea, such as the lysine-urea-glutamate compound described by Banerjee et al. (J. Med. Chem., vol. 51, pp. 4504-4517, 2008). In a preferred embodiment, the one or more targeting moieties capable of binding to prostate-specific membrane antigen (PSMA) are small molecule PSMA targeting moieties, more preferably small molecule urea-based inhibitors.
[0186] In a preferred embodiment, the small molecule PSMA-targeting fragment is a urea-based inhibitor (also referred to herein as a urea-based peptidase inhibitor), more preferably a urea-based inhibitor as described in Kularatne et al., Mol Pharmaceutics 2009, 6, 780; Kularatne et al., Mol. Pharmaceutics 2009, 6, 790; Kopka et al., J Nucl Med 2017, 58:17S-26S, Kozikowski et al., J Med Chem. 2001, 44:298-301, Kozikowski et al., J Med Chem. 2004, 47:1729-1738, International Publication No. 2017 / 044936, International Publication No. WO2011 / 084518, International Publication No. 2011 / 084521, International Publication No. 2011 / 084513, International Publication No. 2012 / 166923, International Publication No. 2008 / 105773, International Publication No. 2008 / 121949, International Publication No. 2012 / 135592, International Publication No. 2010 / 005740, International Publication No. 2015 / 168379, International Publication No. 03 / 045436, International Publication No. 03 / 045436, International Publication No. 2016 / 183447, International Publication No. and small molecule urea-based inhibitors such as those disclosed in International Publication Nos. 2015 / 258102, WO 2011 / 084513, WO 2017 / 089942, U.S. Patent Application Publication Nos. 2010 / 278927, WO 2012 / 016188, WO 2008 / 124634, WO 2009 / 131435, U.S. Patent Application Publication Nos. 2007 / 225213, WO 2017 / 086467, WO 2009 / 026177, WO 2012005572, WO 2014 / 072357, and WO 2011 / 108930. All of the foregoing documents and disclosures are incorporated herein by reference in their entirety.
[0187] In a preferred embodiment, the targeting moiety is a dipeptide urea-based PSMA peptidase inhibitor, preferably a small molecule dipeptide urea-based PSMA peptidase inhibitor. In a preferred embodiment, the PSMA targeting moiety is a dipeptide urea-based PSMA peptidase inhibitor, preferably a small molecule dipeptide urea-based PSMA peptidase inhibitor.
[0188] The term "urea-based PSMA peptidase inhibitor" refers to a PSMA peptidase inhibitor containing a urea group. The term "dipeptide urea-based PSMA peptidase inhibitor" refers to a PSMA peptidase inhibitor containing a urea group and two peptides or amino acids independently attached to the -NH2 group of the urea group, while the term "small molecule dipeptide urea-based PSMA peptidase inhibitor" further refers to a dipeptide urea-based PSMA peptidase inhibitor having a molecular weight of less than about 2000 g / mol and typically and preferably capable of binding to PSMA. In some embodiments, the small molecule dipeptide urea-based PSMA peptidase inhibitor has a molecular weight of less than about 1800 g / mol, less than about 1500 g / mol, and preferably less than about 1000 g / mol. In further preferred embodiments, the small molecule dipeptide urea-based PSMA peptidase inhibitor has a molecular weight of less than about 800 g / mol, and more preferably less than about 500 g / mol. The PSMA peptidase inhibitor can reduce the activity of the PSMA transmembrane zinc(II) metalloenzyme, which catalyzes the cleavage of terminal glutamate. More preferably, the small molecule urea-based PSMA peptidase inhibitor has a molecular weight of less than about 500 g / mol. Even more preferably, the small molecule urea-based PSMA peptidase inhibitor is preferably a glutamate-urea PSMA peptidase inhibitor, such as those mentioned in Kopka et al., J Nuc Med, 58(9), suppl. 2, 2017; Wirtz et al., EJNMMI Research (2018) 8:84 and the references cited therein (all of which are incorporated herein by reference in their entirety).
[0189] In a preferred embodiment, the targeting moiety, preferably the urea based PSMA peptidase inhibitor, is a glutamate-urea moiety of Formula 1, preferably of Formula 1*: [ka] wherein R is preferably substituted or unsubstituted alkyl, substituted or unsubstituted aryl, and any combination thereof; more preferably R is C substituted one or more times, preferably once, with OH, SH, NH or COOH. 1~6 alkyl, preferably C2-C4 alkyl, wherein one of the NH2, OH or SH or COOH groups is X 2 In another preferred embodiment, R is a C alkyl group optionally substituted once with OH, SH, NH, or COOH, wherein R is a C alkyl group optionally substituted once with OH, SH, NH, or COOH. 1~6 alkyl, preferably C2-C4 alkyl, wherein the NH2, OH, SH or COOH groups are each 2 In a highly preferred embodiment, R is a C alkyl substituted once with COOH, wherein each COOH group is X 2 It serves as a linking moiety and a point of covalent attachment to the PEG fragment.
[0190] In a preferred embodiment, the targeting fragment is a glutamate-urea moiety of Formula 1: [ka] wherein R is a C substituted one or more times, preferably one time, with OH, SH, NH or COOH. 1~6 alkyl, preferably C2-C4 alkyl, wherein one of the NH2, OH or SH or COOH groups is X 2In another preferred embodiment, R is a C alkyl group substituted once with OH, SH, NH, or COOH. 1~6 alkyl, preferably C2-C4 alkyl, wherein the NH2, OH, SH or COOH groups are each 2 In a highly preferred embodiment, R is a C alkyl substituted once with COOH, wherein each COOH group is X 2 It serves as a linking moiety and a point of covalent attachment to the PEG fragment.
[0191] In another preferred embodiment, the targeting fragment is a glutamate-urea moiety of formula 1*: [ka] wherein R is a C substituted one or more times, preferably one time, with OH, SH, NH or COOH. 1~6 alkyl, preferably C2-C4 alkyl, wherein one of the NH2, OH or SH or COOH groups is X 2 In another preferred embodiment, R is a C alkyl group substituted once with OH, SH, NH, or COOH. 1~6 alkyl, preferably C2-C4 alkyl, wherein the NH2, OH, SH or COOH groups are each 2 In a highly preferred embodiment, R is a C alkyl substituted once with COOH, wherein each COOH group is X 2 It serves as a linking moiety and a point of covalent attachment to the PEG fragment.
[0192] In a further preferred embodiment, the targeting fragment comprises, or preferably consists of, a DUPA residue (HOOC-(CH2)2-CH(COOH)-NH-CO-NH-CH(COOH)-(CH2)2-CO-). In a further highly preferred embodiment, the targeting fragment consists of a DUPA residue (HOOC(CH2)2-CH(COOH)-NH-CO-NH-CH(COOH)-(CH2)2-CO-) in which both chiral C atoms have the (S)-configuration, as shown in formula 1*.
[0193] In a further aspect, the present invention provides a composition comprising a conjugate of formula I*: R 1 -(NR 2 -CH2-CH2) n -ZX 1 -(O-CH2-CH2) m -X 2 -L (Formula I*); wherein n is any integer from 1 to 1500; m is any integer from 1 to 200, preferably m is any integer from 1 to 100; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -R in 2 at least 80%, preferably 90%, of X are H; 1 and X 2 are independently a divalent covalent linking moiety; Z is a divalent covalent linking moiety, where Z is not -NHC(O)-, preferably, Z is a divalent covalent linking moiety, where Z is not a single bond and Z is not -NHC(O)-; L is a targeting fragment capable of binding to cells overexpressing prostate surface membrane antigen (PSMA), where preferably said L is a DUPA residue (HOOC(CH2)2-CH(COOH)-NH-CO-NH-CH(COOH)-(CH2)2-CO-) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or enantiomer thereof, and preferably consisting of said conjugate.
[0194] In a further aspect, the present invention provides a composition comprising a conjugate of formula I*: R 1 -(NR 2 -CH2-CH2) n -ZX 1 -(O-CH2-CH2) m -X 2 -L (Formula I*); wherein n is any integer from 1 to 1500; m is any integer from 1 to 200, preferably m is any integer from 1 to 100; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -R in 2 at least 80%, preferably 90%, of X are H; 1 and X 2 are independently a divalent covalent linking moiety; Z is a divalent covalent linking moiety, where Z is not -NHC(O)-, preferably Z is a divalent covalent linking moiety, where Z is not a single bond and Z is not -NHC(O)-; L is a targeting fragment capable of binding to prostate surface membrane antigen (PSMA), where preferably said L is a DUPA residue (HOOC(CH2)2-CH(COOH)-NH-CO-NH-CH(COOH)-(CH2)2-CO-) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or enantiomer thereof, and preferably consisting of said conjugate.
[0195] In a further aspect, the present invention provides a composition comprising a conjugate of formula I*: R 1 -(NR 2 -CH2-CH2) n -ZX 1 -(O-CH2-CH2) m -X 2-L (Formula I*); wherein n is any integer from 1 to 1500; m is any integer from 1 to 200, preferably m is any integer from 1 to 100; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -R in 2 at least 80%, preferably 90%, of X are H; 1 and X 2 are independently a divalent covalent linking moiety; Z is a divalent covalent linking moiety, where Z is not -NHC(O)-, preferably, Z is a divalent covalent linking moiety, where Z is not a single bond and Z is not -NHC(O)-; L is a targeting fragment, where said targeting fragment L is a DUPA residue (HOOC(CH)-CH(COOH)-NH-CO-NH-CH(COOH)-(CH)-CO-) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or enantiomer thereof, and preferably consisting of said conjugate.
[0196] In another aspect, the present invention provides a conjugate of formula I*: R 1 -(NR 2 -CH2-CH2) n -ZX 1 -(O-CH2-CH2) m -X 2 -L(formula I*); [wherein n is an integer of 1 to 1500; m is an integer of 1 to 200, preferably an integer of 1 to 100; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -R in 2 at least 80%, preferably 90%, of X are H;1 and X 2 are independently a divalent covalent linking moiety; Z is a divalent covalent linking moiety, where Z is not -NHC(O)-, preferably Z is a divalent covalent linking moiety, where Z is not a single bond and Z is not -NHC(O)-; L is a targeting fragment capable of binding to cells overexpressing prostate surface membrane antigen (PSMA), where preferably said L is a DUPA residue (HOOC(CH2)2-CH(COOH)-NH-CO-NH-CH(COOH)-(CH2)2-CO-). or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or enantiomer thereof.
[0197] In another aspect, the present invention provides a conjugate of formula I*: R 1 -(NR 2 -CH2-CH2) n -ZX 1 -(O-CH2-CH2) m -X 2 -L(formula I*); [wherein n is an integer of 1 to 1500; m is an integer of 1 to 200, preferably an integer of 1 to 100; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -R in 2 at least 80%, preferably 90%, of X are H; 1 and X 2are independently a divalent covalent linking moiety; Z is a divalent covalent linking moiety, where Z is not -NHC(O)-, preferably Z is a divalent covalent linking moiety, where Z is not a single bond and Z is not -NHC(O)-; L is a targeting fragment capable of binding to prostate surface membrane antigen (PSMA), where preferably L is a DUPA residue (HOOC(CH2)2-CH(COOH)-NH-CO-NH-CH(COOH)-(CH2)2-CO-). or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or enantiomer thereof.
[0198] In another aspect, the present invention provides a conjugate of formula I*: R 1 -(NR 2 -CH2-CH2) n -ZX 1 -(O-CH2-CH2) m -X 2 -L(formula I*); [wherein n is an integer of 1 to 1500; m is an integer of 1 to 200, preferably an integer of 1 to 100; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -R in 2 at least 80%, preferably 90%, of X are H; 1 and X 2 are independently a divalent covalent linking moiety; Z is a divalent covalent linking moiety, where Z is not -NHC(O)-, preferably Z is a divalent covalent linking moiety, where Z is not a single bond and Z is not -NHC(O)-; L is a targeting fragment, where said targeting fragment L is a DUPA residue (HOOC(CH)-CH(COOH)-NH-CO-NH-CH(COOH)-(CH)-CO-). or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or enantiomer thereof.
[0199] In some embodiments, the conjugate is a conjugate of Formula I: [ka] [In the formula, [ka] is a single or double bond; n is any integer from 1 to 1500; m is any integer from 1 to 200; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n - the R in the part 2 at least 80%, preferably at least 90% of is H; Ring A may have one or more R A1 5-10 membered cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl optionally substituted with; R A1 are independently selected from C1-C6 alkyl, C1-C6 alkoxy, oxo, or halogen; or two R A1 together with the atoms to which they are attached to form one or more fused C6-C 10 can form an aryl, C-C heteroaryl, or C-C cycloalkyl ring, where each fused aryl, heteroaryl, or cycloalkyl is joined to one or more R A2 optionally substituted with; R A2is independently selected from C1-C6 alkyl, C1-C6 alkoxy, halogen, —SO3H, or OSO3H; X 1 is the formula -(Y 1 ) p where p is an integer from 1 to 20, and Y 1 Each occurrence of represents independently a chemical bond, -CR 11 R 12 -, -C(O)-, -O-, -S-, -NR 13 -, an amino acid residue, a divalent phenyl moiety, a divalent carbocyclic moiety, a divalent heterocyclic moiety, and a divalent heteroaryl moiety, wherein each divalent phenyl or heteroaryl is selected from one or more R 13 and each divalent heterocycle is optionally substituted with one or more R 14 optionally substituted with R 11 , R 12 and R 13 is independently at each occurrence H, —SOH, —NH, —COH, or C-C alkyl, each alkyl being optionally substituted with —COH or NH; and 14 are independently selected at each occurrence as H, C1-C6 alkyl, or oxo, C6-C 10 aryl, or 5-8 membered heteroaryl); X 2 is the formula -(Y 2 ) q where q is an integer from 1 to 50 and Y 2 Each occurrence of represents independently a chemical bond, -CR 21 R 22 -, NR 23 -, -O-, -S-, -C(O)-, an amino acid residue, a divalent phenyl moiety, a divalent carbocyclic moiety, a divalent heterocyclic moiety, and a divalent heteroaryl moiety, wherein each divalent phenyl and divalent heteroaryl is selected from one or more R 23 and each divalent heterocyclic moiety is optionally substituted with one or more R 24 optionally substituted with R 21 , R 22 and R 23are each independently at each occurrence -H, -SO3H, -NH2, -CO2H, or C1-C6 alkyl, where each C1-C6 alkyl is selected from one or more of -OH, oxo, -CO2H, -NH2, C6-C6 10 optionally substituted with aryl or 5-8 membered heteroaryl; and R 24 is a linking moiety for (each occurrence is independently -H, -COH, C-C alkyl, or oxo); and L is a targeting fragment, wherein preferably said targeting fragment L is a DUPA residue (HOOC(CH2)2-CH(COOH)-NH-CO-NH-CH(COOH)-(CH2)2-CO-). or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or enantiomer thereof.
[0200] In another aspect, the present invention provides a composition comprising a conjugate of formula I: [ka] [In the formula, [ka] is a single or double bond; n is any integer from 1 to 1500; m is a discrete number of repeating units m between 2 and 100, preferably a discrete number of repeating units m between 4 and 60; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -R in 2 at least 80%, preferably at least 90% of is H; Ring A may have one or more R A15-10 membered cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl optionally substituted with R A1 are independently selected from C1-C6 alkyl, C1-C6 alkoxy, oxo, or halogen; or two R A1 together with the atoms to which they are attached to form one or more fused C6-C 10 can form an aryl, C-C heteroaryl, or C-C cycloalkyl ring, where each fused aryl, heteroaryl, or cycloalkyl is joined to one or more R A2 optionally substituted with R A2 is independently selected from C1-C6 alkyl, C1-C6 alkoxy, halogen, —SO3H, or OSO3H; X 1 is a divalent covalent linking moiety; X 2 is a divalent covalent linking moiety; and L is a targeting fragment, wherein said targeting fragment is a PSMA targeting fragment, preferably said PSMA targeting fragment is capable of specifically binding to cells that express, preferably overexpress, PSMA. or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or enantiomer thereof. 1 is -H. In a preferred embodiment, 1 is -CH3. In a further preferred embodiment, the targeting fragment comprises, or preferably consists of, a DUPA residue (HOOC-(CH2)2-CH(COOH)-NH-CO-NH-CH(COOH)-(CH2)2-CO-). In a further highly preferred embodiment, the targeting fragment consists of a DUPA residue (HOOC(CH2)2-CH(COOH)-NH-CO-NH-CH(COOH)-(CH2)2-CO-) in which both chiral C atoms have the (S)-configuration, as shown in formula 1*.
[0201] In another aspect, the present invention provides a conjugate of formula I: [ka] [In the formula, [ka] is a single or double bond; n is any integer from 1 to 1500; m is a discrete number of repeating units m between 2 and 100, preferably a discrete number of repeating units m between 4 and 60; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -R in 2 at least 80%, preferably at least 90% of is H; Ring A may have one or more R A1 5-10 membered cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl optionally substituted with R A1 are independently selected from C1-C6 alkyl, C1-C6 alkoxy, oxo, or halogen; or two R A1 together with the atoms to which they are attached to form one or more fused C6-C 10 can form an aryl, C-C heteroaryl, or C-C cycloalkyl ring, where each fused aryl, heteroaryl, or cycloalkyl is joined to one or more R A2 optionally substituted with R A2 is independently selected from C1-C6 alkyl, C1-C6 alkoxy, halogen, —SO3H, or OSO3H; X 1 is a divalent covalent linking moiety; X 2 is a divalent covalent linking moiety; and L is a targeting fragment, wherein said targeting fragment is a PSMA targeting fragment, preferably said PSMA targeting fragment is capable of specifically binding to cells that express, preferably overexpress, PSMA. or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or enantiomer thereof. 1 is -H. In a preferred embodiment, 1 is -CH3. In a further preferred embodiment, the targeting fragment comprises, or preferably consists of, a DUPA residue (HOOC-(CH2)2-CH(COOH)-NH-CO-NH-CH(COOH)-(CH2)2-CO-). In a further highly preferred embodiment, the targeting fragment consists of a DUPA residue (HOOC(CH2)2-CH(COOH)-NH-CO-NH-CH(COOH)-(CH2)2-CO-) in which both chiral C atoms have the (S)-configuration, as shown in formula 1*.
[0202] In another aspect, the present invention provides a composition comprising a conjugate of formula I: [ka] [In the formula, [ka] is a single or double bond; n is any integer from 1 to 1500; m is the repeating unit of 36 discrete numbers; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -R in 2 at least 80%, preferably at least 90% of is H; Ring A may have one or more R A15-10 membered cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl optionally substituted with R A1 are independently selected from C1-C6 alkyl, C1-C6 alkoxy, oxo, or halogen; or two R A1 together with the atoms to which they are attached to form one or more fused C6-C 10 can form an aryl, C-C heteroaryl, or C-C cycloalkyl ring, where each fused aryl, heteroaryl, or cycloalkyl is joined to one or more R A2 optionally substituted with R A2 is independently selected from C1-C6 alkyl, C1-C6 alkoxy, halogen, —SO3H, or OSO3H; X 1 is a divalent covalent linking moiety; X 2 is a divalent covalent linking moiety; and L is a targeting fragment, wherein said targeting fragment is a PSMA targeting fragment, preferably said PSMA targeting fragment is capable of specifically binding to cells that express, preferably overexpress, PSMA. or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or enantiomer thereof. 1 is -H. In a preferred embodiment, 1 is -CH3. In a further preferred embodiment, the targeting fragment comprises, or preferably consists of, a DUPA residue (HOOC-(CH2)2-CH(COOH)-NH-CO-NH-CH(COOH)-(CH2)2-CO-). In a further highly preferred embodiment, the targeting fragment consists of a DUPA residue (HOOC(CH2)2-CH(COOH)-NH-CO-NH-CH(COOH)-(CH2)2-CO-) in which both chiral C atoms have the (S)-configuration, as shown in formula 1*.
[0203] In another aspect, the present invention provides a conjugate of formula I: [ka] [In the formula, [ka] is a single or double bond; n is any integer from 1 to 1500; m is the repeating unit of 36 discrete numbers; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -R in 2 at least 80%, preferably at least 90% of is H; Ring A may have one or more R A1 5-10 membered cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl optionally substituted with R A1 are independently selected from C1-C6 alkyl, C1-C6 alkoxy, oxo, or halogen; or two R A1 together with the atoms to which they are attached to form one or more fused C6-C 10 can form an aryl, C-C heteroaryl, or C-C cycloalkyl ring, where each fused aryl, heteroaryl, or cycloalkyl is joined to one or more R A2 optionally substituted with R A2 is independently selected from C1-C6 alkyl, C1-C6 alkoxy, halogen, —SO3H, or OSO3H; X 1 is a divalent covalent linking moiety; X 2 is a divalent covalent linking moiety; and L is a targeting fragment, wherein said targeting fragment is a PSMA targeting fragment, preferably said PSMA targeting fragment is capable of specifically binding to cells that express, preferably overexpress, PSMA. or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or enantiomer thereof. 1 is -H. In a preferred embodiment, 1 is -CH3. In a further preferred embodiment, the targeting fragment comprises, or preferably consists of, a DUPA residue (HOOC-(CH2)2-CH(COOH)-NH-CO-NH-CH(COOH)-(CH2)2-CO-). In a further highly preferred embodiment, the targeting fragment consists of a DUPA residue (HOOC(CH2)2-CH(COOH)-NH-CO-NH-CH(COOH)-(CH2)2-CO-) in which both chiral C atoms have the (S)-configuration, as shown in formula 1*.
[0204] In another aspect, the present invention provides a composition comprising a conjugate of formula I: [ka] [In the formula, [ka] is a single or double bond; n is any integer from 1 to 1500; m is a discrete number of consecutive repeat units m from 2 to 100, preferably a discrete number of consecutive repeat units m from 4 to 60; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -R in 2 at least 80%, preferably at least 90% of is H; Ring A may have one or more R A1 5-10 membered cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl optionally substituted with R A1 are independently selected from C1-C6 alkyl, C1-C6 alkoxy, oxo, or halogen; or two R A1 together with the atoms to which they are attached to form one or more fused C6-C 10 can form an aryl, C-C heteroaryl, or C-C cycloalkyl ring, where each fused aryl, heteroaryl, or cycloalkyl is joined to one or more R A2 optionally substituted with R A2 is independently selected from C1-C6 alkyl, C1-C6 alkoxy, halogen, —SO3H, or OSO3H; X 1 is a divalent covalent linking moiety; X 2 is a divalent covalent linking moiety; and L is a targeting fragment, wherein said targeting fragment is a PSMA targeting fragment, preferably said PSMA targeting fragment is capable of specifically binding to cells that express, preferably overexpress, PSMA. or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or enantiomer thereof. 1 is -H. In a preferred embodiment, 1 is -CH3. In a further preferred embodiment, the targeting fragment comprises, or preferably consists of, a DUPA residue (HOOC-(CH2)2-CH(COOH)-NH-CO-NH-CH(COOH)-(CH2)2-CO-). In a further highly preferred embodiment, the targeting fragment consists of a DUPA residue (HOOC(CH2)2-CH(COOH)-NH-CO-NH-CH(COOH)-(CH2)2-CO-) in which both chiral C atoms have the (S)-configuration, as shown in formula 1*.
[0205] In another aspect, the present invention provides a conjugate of formula I: [ka] [In the formula, [ka] is a single or double bond; n is any integer from 1 to 1500; m is a discrete number of consecutive repeat units m from 2 to 100, preferably a discrete number of consecutive repeat units m from 4 to 60; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -R in 2 at least 80%, preferably at least 90% of is H; Ring A may have one or more R A1 5-10 membered cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl optionally substituted with R A1 are independently selected from C1-C6 alkyl, C1-C6 alkoxy, oxo, or halogen; or two R A1 together with the atoms to which they are attached to form one or more fused C6-C 10 can form an aryl, C-C heteroaryl, or C-C cycloalkyl ring, where each fused aryl, heteroaryl, or cycloalkyl is joined to one or more R A2 optionally substituted with R A2 is independently selected from C1-C6 alkyl, C1-C6 alkoxy, halogen, —SO3H, or OSO3H; X 1 is a divalent covalent linking moiety; X 2 is a divalent covalent linking moiety; and L is a targeting fragment, wherein said targeting fragment is a PSMA targeting fragment, preferably said PSMA targeting fragment is capable of specifically binding to cells that express, preferably overexpress, PSMA. or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or enantiomer thereof. 1 is -H. In a preferred embodiment, 1 is -CH3. In a further preferred embodiment, the targeting fragment comprises, or preferably consists of, a DUPA residue (HOOC-(CH2)2-CH(COOH)-NH-CO-NH-CH(COOH)-(CH2)2-CO-). In a further highly preferred embodiment, the targeting fragment consists of a DUPA residue (HOOC(CH2)2-CH(COOH)-NH-CO-NH-CH(COOH)-(CH2)2-CO-) in which both chiral C atoms have the (S)-configuration, as shown in formula 1*.
[0206] In another aspect, the present invention provides a composition comprising a conjugate of formula I: [ka] [In the formula, [ka] is a single or double bond; n is any integer from 1 to 1500; m is a continuous repeating unit of 36 discrete numbers; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -R in 2 at least 80%, preferably at least 90% of is H; Ring A may have one or more RA1 5-10 membered cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl optionally substituted with R A1 are independently selected from C1-C6 alkyl, C1-C6 alkoxy, oxo, or halogen; or two R A1 together with the atoms to which they are attached to form one or more fused C6-C 10 can form an aryl, C-C heteroaryl, or C-C cycloalkyl ring, where each fused aryl, heteroaryl, or cycloalkyl is joined to one or more R A2 optionally substituted with R A2 is independently selected from C1-C6 alkyl, C1-C6 alkoxy, halogen, —SO3H, or OSO3H; X 1 is a divalent covalent linking moiety; X 2 is a divalent covalent linking moiety; and L is a targeting fragment, wherein said targeting fragment is a PSMA targeting fragment, preferably said PSMA targeting fragment is capable of specifically binding to cells that express, preferably overexpress, PSMA. or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or enantiomer thereof. 1 is -H. In a preferred embodiment, 1 is -CH3. In a further preferred embodiment, the targeting fragment comprises, or preferably consists of, a DUPA residue (HOOC-(CH2)2-CH(COOH)-NH-CO-NH-CH(COOH)-(CH2)2-CO-). In a further highly preferred embodiment, the targeting fragment consists of a DUPA residue (HOOC(CH2)2-CH(COOH)-NH-CO-NH-CH(COOH)-(CH2)2-CO-) in which both chiral C atoms have the (S)-configuration, as shown in formula 1*.
[0207] In another aspect, the present invention provides a conjugate of formula I: [ka] [In the formula, [ka] is a single or double bond; n is any integer from 1 to 1500; m is a continuous repeating unit of 36 discrete numbers; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -R in 2 at least 80%, preferably at least 90% of is H; Ring A may have one or more R A1 5-10 membered cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl optionally substituted with R A1 are independently selected from C1-C6 alkyl, C1-C6 alkoxy, oxo, or halogen; or two R A1 together with the atoms to which they are attached to form one or more fused C6-C 10 can form an aryl, C-C heteroaryl, or C-C cycloalkyl ring, where each fused aryl, heteroaryl, or cycloalkyl is joined to one or more R A2 optionally substituted with R A2 is independently selected from C1-C6 alkyl, C1-C6 alkoxy, halogen, —SO3H, or OSO3H; X 1 is a divalent covalent linking moiety; X 2 is a divalent covalent linking moiety; and L is a targeting fragment, wherein said targeting fragment is a PSMA targeting fragment, preferably said PSMA targeting fragment is capable of specifically binding to cells that express, preferably overexpress, PSMA. or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or enantiomer thereof. 1 is -H. In a preferred embodiment, 1 is -CH3. In a further preferred embodiment, the targeting fragment comprises, or preferably consists of, a DUPA residue (HOOC-(CH2)2-CH(COOH)-NH-CO-NH-CH(COOH)-(CH2)2-CO-). In a further highly preferred embodiment, the targeting fragment consists of a DUPA residue (HOOC(CH2)2-CH(COOH)-NH-CO-NH-CH(COOH)-(CH2)2-CO-) in which both chiral C atoms have the (S)-configuration, as shown in formula 1*.
[0208] In another aspect, the present invention provides a composition comprising a conjugate of formula I: [ka] [In the formula, [ka] is a single or double bond; n is any integer from 1 to 1500; m is a discrete number of consecutive repeat units m from 2 to 100, preferably a discrete number of consecutive repeat units m from 4 to 60; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -R in 2 at least 80%, preferably at least 90% of is H; Ring A may have one or more R A1 5-10 membered cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl optionally substituted with R A1 are independently selected from C1-C6 alkyl, C1-C6 alkoxy, oxo, or halogen; or two R A1 together with the atoms to which they are attached to form one or more fused C6-C 10 can form an aryl, C-C heteroaryl, or C-C cycloalkyl ring, where each fused aryl, heteroaryl, or cycloalkyl is joined to one or more R A2 optionally substituted with R A2 is independently selected from C1-C6 alkyl, C1-C6 alkoxy, halogen, —SO3H, or OSO3H; X 1 is the formula -(Y 1 ) p where p is an integer from 1 to 20, and Y 1 Each occurrence of represents independently a chemical bond, -CR 11 R 12 -, -C(O)-, -O-, -S-, -NR 13 -, an amino acid residue, a divalent phenyl moiety, a divalent heterocyclic moiety, and a divalent heteroaryl moiety, wherein each divalent phenyl or heteroaryl is selected from one or more R 13 and each divalent heterocycle is optionally substituted with one or more R 14 optionally substituted with R 11 , R 12 and R 13 is independently at each occurrence H or C1-C6 alkyl; and 14 is a linking moiety for (each occurrence is independently H, C1-C6 alkyl, or oxo); X 2 is the formula -(Y 2 ) q - (wherein q is an integer from 1 to 50, and Y 2 Each occurrence of represents independently a chemical bond, -CR 21 R 22 -, NR23 -, -O-, -S-, -C(O)-, an amino acid residue, a divalent phenyl moiety, a divalent heterocyclic moiety, and a divalent heteroaryl moiety, wherein each divalent phenyl and divalent heteroaryl is selected from one or more R 23 and each divalent heterocyclic moiety is optionally substituted with one or more R 24 optionally substituted with R 21 , R 22 and R 23 are each independently at each occurrence -H, -CO2H, or C1-C6 alkyl, where each C1-C6 alkyl is selected from one or more of -OH, oxo, C6-C 10 optionally substituted with aryl or 5-8 membered heteroaryl; and R 24 is a linking moiety for (each occurrence is independently -H, -COH, C-C alkyl, or oxo); and L is a targeting fragment, wherein said targeting fragment is a PSMA targeting fragment, preferably said PSMA targeting fragment is capable of specifically binding to cells that express, preferably overexpress, PSMA. or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or enantiomer thereof. 1 is -H. In a preferred embodiment, 1 is -CH3. In a further preferred embodiment, the targeting fragment comprises, or preferably consists of, a DUPA residue (HOOC-(CH2)2-CH(COOH)-NH-CO-NH-CH(COOH)-(CH2)2-CO-). In a further highly preferred embodiment, the targeting fragment consists of a DUPA residue (HOOC(CH2)2-CH(COOH)-NH-CO-NH-CH(COOH)-(CH2)2-CO-) in which both chiral C atoms have the (S)-configuration, as shown in formula 1*.
[0209] In another aspect, the present invention provides a composition comprising a conjugate of formula I: [ka] [In the formula, [ka] is a single or double bond; n is any integer from 1 to 1500; m is a continuous repeating unit of 36 discrete numbers; R 1 is the starting residue, where preferably R 1 is -H or CH3; R 2 are independently —H or an organic residue, and the —(NR 2 -CH2-CH2) n -R in 2 at least 80%, preferably at least 90% of is H; Ring A may have one or more R A1 5-10 membered cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl optionally substituted with R A1 are independently selected from C1-C6 alkyl, C1-C6 alkoxy, oxo, or halogen; or two R A1 together with the atoms to which they are attached to form one or more fused C6-C 10 can form an aryl, C-C heteroaryl, or C-C cycloalkyl ring, where each fused aryl, heteroaryl, or cycloalkyl is joined to one or more R A2 optionally substituted with R A2 is independently selected from C1-C6 alkyl, C1-C6 alkoxy, halogen, —SO3H, or OSO3H; X 1 is a divalent covalent linking moiety; X 2 is a divalent covalent linking moiety; and L is a targeting fragment, wherein said targeting fragment is a PSMA targeting fragment, preferably said PSMA targeting fragment is capable of specifically binding to cells that express, preferably overexpress, PSMA. or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or enantiomer thereof. 1 is -H. In a preferred embodiment, 1 is -CH3. In a further preferred embodiment, the targeting fragment comprises, or preferably consists of, a DUPA residue (HOOC-(CH2)2-CH(COOH)-NH-CO-NH-CH(COOH)-(CH2)2-CO-). In a further highly preferred embodiment, the targeting fragment consists of a DUPA residue (HOOC(CH2)2-CH(COOH)-NH-CO-NH-CH(COOH)-(CH2)2-CO-) in which both chiral C atoms have the (S)-configuration, as shown in formula 1*.
[0210] In a preferred embodiment, the DUPA residue is a linking moiety X 2 is linked to the PEG targeting fragment by
[0211] Such linking moieties are known to those skilled in the art and are disclosed in U.S. Patent Application Publication Nos. 2020 / 0188523, 2011 / 0288152, and 2010 / 324008, the disclosures of which are incorporated herein by reference in their entireties.
[0212] In a preferred embodiment, the linking moiety X 2 is a peptide linker or C1-C 10 In a preferred embodiment, the linking moiety X 2 is a peptide linker.
[0213] In a preferred embodiment, the linking moiety X 2is a peptide linker, wherein said peptide linker comprises, preferably consists of, the sequence of SEQ ID NO: 3 (-(NH-(CH2)7-CO)-Phe-Phe-(NH-CH2-CH(NH2)-CO)-Asp-Cys-) or the sequence of SEQ ID NO: 1 (-(NH-(CH2)7-CO)-Phe-Gly-Trp-Trp-Gly-Cys-). In a preferred embodiment, said linking moiety X 2 is a peptide linker, wherein said peptide linker comprises, preferably consists of, the sequence of SEQ ID NO: 1 (-(NH-(CH2)7-CO)-Phe-Gly-Trp-Trp-Gly-Cys-). In a further preferred embodiment, said linking moiety X 2 comprises, and preferably consists of, SEQ ID NO: 1 or 3, and the target fragment is HOOC(CH2)2-CH(COOH)-NH-CO-NH-CH(COOH)-(CH2)2-CO- (DUPA residue). In a highly preferred embodiment, the linking moiety X 2 comprises, and preferably consists of, SEQ ID NO: 1, wherein the targeting fragment L is HOOC(CH2)2-CH(COOH)-NH-CO-NH-CH(COOH)-(CH2)2-CO- (DUPA residue). In a preferred embodiment, said targeting fragment L is HOOC-(CH2)2-CH(COOH)-NH-CO-NH-CH(COOH)-(CH2)2-CO-, which is capable of binding to cells overexpressing PSMA, and said linking moiety X 2 comprises, and preferably consists of, SEQ ID NO:1.
[0214] In another preferred embodiment, the targeting fragment is 2-[3-(1,3-dicarboxypropyl)ureido]pentanedioic acid (DUPA), where typically and preferably the coupling to the remainder of the conjugate is via the terminal carboxyl group of the DUPA. Thus, in a further preferred embodiment, the targeting fragment L is a DUPA residue (HOOC(CH)-CH(COOH)-NH-CO-NH-CH(COOH)-(CH)-CO-). DUPA can be selectively taken up by cells with increased (e.g., overexpressing) prostate-specific membrane antigen (PSMA).
[0215] In preferred embodiments, the targeting fragment is capable of binding to the asialoglycoprotein receptor (ASGPr), also referred to herein as an ASGPr targeting fragment. Thus, in some embodiments, the targeting fragment is an ASGPr targeting fragment. The asialoglycoprotein receptor (ASGPr) is a carbohydrate-binding protein (i.e., a lectin) that binds to asialoglycoproteins and glycoproteins, preferably galactose-terminal glycoproteins, preferably branched galactose-terminal glycoproteins. Preferably, the ASGPr targeting fragment is capable of binding to an epitope on the extracellular domain of the ASGPr.
[0216] Preferably, the ASGPr targeting fragment is capable of binding to cells expressing ASGPr. In a preferred embodiment, the targeting fragment is capable of binding to cells overexpressing ASGPr, preferably hepatocytes. In a preferred embodiment, the targeting fragment is capable of binding to cells expressing ASGPr. In a preferred embodiment, the targeting fragment is capable of binding to cells overexpressing ASGPr. In one embodiment, the cells overexpressing ASGPr refer to an elevated level of ASGPr expressed in the cells in a particular tissue compared to the level of ASGPr measured in normal healthy cells of the same type of tissue under similar conditions. In one embodiment, the cells overexpressing ASGPr refer to an increase in the level of ASGPr in the cells compared to the level of the same cells or closely related non-malignant cells under normal physiological conditions. In one embodiment, the cells overexpressing ASGPr refer to an increase in ASGPr expression at least 5-fold, preferably at least 10-fold, and more preferably at least 20-fold, compared to the expression of ASGPr in normal cells or normal tissues. For example, ASGPr is overexpressed in liver cells, preferably hepatocytes and liver cancer cells. In a preferred embodiment, the ASGPr targeting fragment is capable of binding to liver cells, preferably hepatocytes or cancerous liver cells and metastases thereof.
[0217] Preferably, the ASGPr-targeting fragment is capable of specifically binding to the ASGPr. Typically, specific binding is about 1×10 -3 M ~ approx. 1×10 -12 M refers to the binding affinity or dissociation constant (KD) of the targeting fragment of M. To detect binding or measure affinity of a complex, molecules can be analyzed using competitive binding assays, such as with a Biacore 3000 instrument (see, e.g., Kuo et al., PLoS One, 2015;10(2):e01166610). Preferably, the ASGPr-targeting fragment can specifically bind to ASGPr with a binding affinity equal to or greater than the binding affinity of galactose.
[0218] In preferred embodiments, the ASGPr targeting fragment comprises a small molecule or small molecule ligand, a peptide, a protein, more preferably an ASGPr antibody, an ASGPr affibody, an ASGPr aptamer, an ASGPr targeting peptide, lactose, galactose, N-acetylgalactosamine (GalNAc), galactosamine, N-formylgalactosamine, N-acetyl-galactosamine, N-propionylgalactosamine, Nn-butanoylgalactosamine, and N-iso-butanoylgalactosamine, and combinations thereof (Iobst, ST and Drickamer, KJBC 1996, 271, 6686). In some embodiments, the ASGPr targeting fragment is monomeric (i.e., has a single galactosamine). In some embodiments, the ASGPr targeting fragment is multimeric (i.e., has multiple galactosamines).
[0219] In a preferred embodiment, the ASGPr targeting fragment is a galactose cluster. A galactose cluster is understood as a molecule having two to four terminal galactose derivatives. As used herein, the term galactose derivative includes both galactose and derivatives of galactose that have affinity for the asialoglycoprotein receptor that is equal to or greater than that of galactose. Preferably, the galactose derivative is selected from galactose, galactosamine, N-formylgalactosamine, N-acetylgalactosamine, N-propionylgalactosamine, Nn-butanoylgalactosamine, and N-isobutanoylgalactosamine. Preferably, the galactose derivative is N-acetylgalactosamine (GalNAc).
[0220] In a preferred embodiment, the galactose cluster contains three galactose derivatives, each linked to a central branch point, and preferably each terminal galactose derivative is linked to the remainder of the galactose cluster via its C-1 carbon. In a preferred embodiment, the galactose derivatives are linked to the branch point via a linker or spacer, preferably a flexible hydrophilic spacer, more preferably a PEG spacer, and even more preferably a PEG3 spacer.
[0221] In preferred embodiments, the galactose cluster has three terminal galactosamines or galactosamine derivatives, each of which has affinity for the ASGPr (i.e., a triantennary galactose derivative cluster). In some embodiments, the galactose cluster comprises triantennary galactose, trivalent galactose, and galactose trimer. Preferably, the galactose cluster has three terminal N-acetyl-galactosamines.
[0222] In another preferred embodiment, the targeting moiety is folic acid, where typically and preferably the coupling to the remainder of the conjugate is via the terminal carboxyl group of the folic acid. In some preferred embodiments, the targeting moiety can be folate. Without wishing to be bound by theory, folate can be selectively taken up by cells that have increased expression (e.g., overexpression) of folate receptors.
[0223] In further preferred embodiments, the targeting moiety is a HER2 targeting ligand, which in some embodiments can be selectively taken up by cells that have increased expression (eg, overexpression) of HER2.
[0224] In some embodiments, the targeting fragment may be a somatostatin receptor targeting fragment. Without wishing to be bound by theory, the somatostatin receptor targeting fragment may be selectively taken up by cells that have increased expression (e.g., overexpression) of a somatostatin receptor, such as somatostatin receptor 2 (SSTR2).
[0225] In some embodiments, the targeting moiety can be an integrin targeting moiety, such as an arginine-glycine-aspartic acid (RGD)-containing ligand (e.g., a cyclic RGD ligand). Without wishing to be bound by theory, the integrin targeting moiety can target an integrin (e.g., α v β6 integrin or α v It can be selectively taken up by cells that have increased expression (eg, overexpression) of an RGD integrin, such as β8 integrin.
[0226] In some embodiments, the targeting fragment can be a low pH insertion peptide (pHLIP). Without wishing to be bound by theory, the low pH insertion peptide can be selectively taken up by cells present in a low pH microenvironment. In some embodiments, the targeting fragment can be an asialoglycoprotein receptor targeting fragment, such as asialoorosomucoid. Without wishing to be bound by theory, the asialoglycoprotein receptor targeting fragment can be selectively taken up by cells with increased expression (e.g., overexpression) of the asialoglycoprotein receptor. In some embodiments, the targeting fragment can be an insulin receptor targeting fragment, e.g., insulin. Without wishing to be bound by theory, the insulin receptor targeting fragment can be selectively taken up by cells with increased expression (e.g., overexpression) of the insulin receptor. In some embodiments, the targeting fragment can be a mannose-6-phosphate receptor targeting fragment, such as mannose-6-phosphate. Without wishing to be bound by theory, the mannose-6-phosphate receptor targeting fragment may be selectively taken up by cells that have increased expression (e.g., overexpression) of mannose-6-phosphate receptors (e.g., monocytes). In some embodiments, the targeting fragment may be a mannose receptor targeting fragment, such as mannose. Without wishing to be bound by theory, the mannose receptor targeting fragment may be selectively taken up by cells that have increased expression (e.g., overexpression) of mannose receptors. In some embodiments, the targeting fragment may be a sialyl Lewis receptor, such as E-selectin. x Without wishing to be bound by theory, Sialyl Lewis x The antigen-targeting fragment is Sialyl Lewis xThe targeting fragment may be selectively taken up by cells with increased expression (e.g., overexpression) of glycosides, such as antigens. In some embodiments, the targeting fragment may be an N-acetyllactosamine targeting fragment. Without wishing to be bound by theory, the N-acetyllactosamine targeting fragment may be selectively taken up by cells with increased expression (e.g., overexpression) of N-acetyllactosamine. In some embodiments, the targeting fragment may be a galactose targeting fragment. Without wishing to be bound by theory, the galactose targeting fragment may be selectively taken up by cells with increased expression (e.g., overexpression) of galactose. In some embodiments, the targeting fragment may be a sigma-2 receptor agonist, such as N,N-dimethyltryptamine (DMT), a sphingolipid-derived amine, and / or a steroid (e.g., progesterone). Without wishing to be bound by theory, the sigma-2 receptor agonist may be selectively taken up by cells with increased expression (e.g., overexpression) of the sigma-2 receptor. In some embodiments, the targeting fragment can be a p32 targeting ligand, such as an anti-p32 antibody or a p32-binding LyP-1 tumor-homing peptide. Without wishing to be bound by theory, the p32 targeting ligand can be selectively taken up by cells with increased expression (e.g., overexpression) of the mitochondrial protein p32. In some embodiments, the targeting fragment can be a Trop-2 targeting fragment, such as an anti-Trop-2 antibody and / or antibody fragment. Without wishing to be bound by theory, the Trop-2 targeting fragment can be selectively taken up by cells with increased expression (e.g., overexpression) of Trop-2. In some embodiments, the targeting fragment is an insulin-like growth factor 1 receptor targeting fragment, such as insulin-like growth factor 1. Without wishing to be bound by theory, the insulin-like growth factor 1 receptor targeting fragment can be selectively taken up by cells with increased expression (e.g., overexpression) of insulin-like growth factor 1 receptor. In some embodiments, the targeting fragment can be a VEGF receptor targeting fragment, such as VEGF.Without wishing to be bound by theory, the VEGF receptor targeting fragment may be selectively taken up by cells that have increased expression (e.g., overexpression) of a VEGF receptor. In some embodiments, the targeting fragment may be a platelet-derived growth factor receptor targeting fragment, such as a platelet-derived growth factor. Without wishing to be bound by theory, the platelet-derived growth factor receptor targeting fragment may be selectively taken up by cells that have increased expression (e.g., overexpression) of a platelet-derived growth factor receptor. In some embodiments, the targeting fragment may be a fibroblast growth factor receptor targeting fragment, such as a fibroblast growth factor. Without wishing to be bound by theory, the fibroblast growth factor receptor targeting fragment may be selectively taken up by cells that have increased expression (e.g., overexpression) of a fibroblast growth factor receptor.
[0227] Coupling of PEG fragments to target fragments In some embodiments, the second end of the PEG fragment is a linking group (i.e., X) that links the PEG fragment to a targeting fragment. 2 ) is functionalized with a linking moiety X 2 contains a reactive group for coupling to an appropriate, i.e., complementary, reactive group on the targeting fragment. 2 It will be appreciated that various complementary reactive groups may be involved in such coupling reactions between the reactive groups. In some embodiments, the targeting fragment L is unmodified and is a PEG fragment and a linking moiety X, respectively. 2 For example, Scheme 3 shows the nucleophilic addition of hEGF to an electrophilic tetrafluorophenyl ester attached to a PEG fragment. As shown in Scheme 3, the nucleophilic amine of hEGF displaces the tetrafluorophenol of the tetrafluorophenyl ester to form a PEG fragment and a linking moiety, X. 2 In some embodiments, the targeting fragment L is linked to the linking moiety X using a suitable chemical linkage, such as an amide bond or an ester bond. 2For example, Schemes 4 and 5 show X containing an amide linkage. 2 The DUPA and folate groups are shown attached to the PEG fragment by a linker, respectively. The amide groups are linked to the appropriate carboxylic acid groups of DUPA and folate and to the PEG-X 2 It is formed by a dehydration synthesis reaction between the appropriate amine on the fragment.
[0228] In some preferred embodiments, the first end (i.e., terminal end) of the PEG fragment is functionalized with an alkene or alkyne group, which in some embodiments can be used to react with an azide-functionalized LPEI; the second end (i.e., terminal end) of the PEG fragment is functionalized with a targeting moiety, which in some embodiments can be used to promote uptake of the conjugate and corresponding polyplex in a particular cell type. Thus, in some preferred embodiments, the resulting conjugates of the invention can have the general structure LPEI-PEG-targeting moiety arranged in a linear end-to-end manner.
[0229] The conjugates of the present invention can be prepared using a variety of different methods and steps. Schemes 1 and 2 below show different strategies for disposing the conjugates of the present invention. As shown in Scheme 1 below, the conjugates of the present invention can be prepared by first coupling a PEG fragment to a targeting fragment, followed by coupling the targeting fragment-modified PEG fragment to an LPEI fragment. As shown in Scheme 2 below, the conjugates of the present invention can be prepared by first coupling a PEG fragment to an LPEI fragment, followed by coupling the LPEI-modified PEG fragment to a targeting fragment.
[0230] Scheme 1. Exemplary coupling of bifunctional PEG to a targeting moiety and subsequently to an LPEI. [ka] As shown in Scheme 1, a bifunctional PEG (e.g., a PEG containing an alkene or alkyne and an electrophile) can first be reacted with a targeting fragment (e.g., hEGF, DUPA, or folate) to generate a PEG fragment covalently linked to the targeting fragment. The alkene or alkyne group of the targeting fragment-modified PEG can then be reacted with the azide group of the LPEI fragment via a [3+2] cycloaddition to generate a linear conjugate of the general structure LPEI-PEG targeting fragment.
[0231] Scheme 2. Exemplary coupling of bifunctional PEG to LPEI and subsequent targeting fragment [ka] As shown in Scheme 2, a bifunctional PEG (e.g., a PEG containing an alkene or alkyne and an electrophile) can first react with the azide group of an LPEI fragment via a [3+2] cycloaddition to generate a linear conjugate of LPEI and PEG covalently linked by a 1,2,3 triazole or A4,5-dihydro-1H-[1,2,3]triazole. The linear LPEI-PEG fragment can then be reacted with a targeting fragment (e.g., hEGF, DUPA, or folate) to generate a linear conjugate of the general structure LPEI-PEG targeting fragment.
[0232] Schemes 3-5 below illustrate general methods for coupling PEG fragments to various targeting fragments. Those skilled in the art will appreciate that PEG fragments can be coupled to various targeting fragments using any suitable chemistry (e.g., nucleophilic substitution, peptide coupling, etc.). For example, those skilled in the art will appreciate that it is not necessary to use a tetrafluorophenyl ester as the electrophile to couple the PEG fragment to hEGF as shown in Scheme 3, but that other electrophilic groups, such as maleate (as shown in Scheme 4), can also be used. Furthermore, those skilled in the art will appreciate that the reactive group on the bifunctionalized PEG fragment need not necessarily be an electrophilic group, but instead can be a nucleophilic group that reacts with, for example, an electrophilic moiety on a targeting fragment.
[0233] Scheme 3. Exemplary coupling of bifunctional PEG to hEGF. [ka] As shown in Scheme 3 above, in some embodiments, PEG can be modified to include electrophilic groups such as tetrafluorophenyl esters and / or activated alkyne groups such as DBCO. Treatment of the tetrafluorophenyl ester-modified PEG with hEGF in solution results in nucleophilic displacement via the nucleophilic amine of hEGF, yielding the hEGF-modified PEG. The DBCO group can be used in subsequent reactions for coupling to LPEI fragments. The variable m represents the number of repeating PEG units as described herein.
[0234] Scheme 4. Exemplary coupling of bifunctional PEG to DUPA. [ka] As shown in Scheme 4 above, PEG can be modified to contain an electrophilic maleimide (MAL) group and / or an activated alkyne group, such as DBCO. Maleimide-substituted PEG can be coupled to a nucleophilic partner, such as the illustrated DUPA-derived moiety (as shown in the scheme above, including the peptide spacer Aoc-Phe-Gly-Trp-Trp-Gly-Cys (SEQ ID NO: 1)) N-terminally derivatized with 2-[3-(1,3-dicarboxypropyl)ureido]pentanedioic acid (DUPA), which contains a nucleophilic group, i.e., a thiol, due to the amino acid residue derived from cysteine. Treatment of the MAL-modified PEG in solution with the thiol-modified DUPA-derived moiety results in nucleophilic 1,4 addition via the nucleophilic thiol of the DUPA-derived moiety, yielding the DUPA-modified PEG. The variable m represents the number of repeating PEG units, as described herein.
[0235] Scheme 5. Exemplary coupling of bifunctional PEG to folates. [ka] As shown in Scheme 5 above, PEG can be modified to contain an electrophilic maleimide (MAL) group. The maleimide-substituted PEG can be coupled to a nucleophilic partner, such as a folate residue, that has itself been modified to contain a nucleophilic group (e.g., a thiol). Treatment of the MAL-modified PEG in solution with a folate thiol results in nucleophilic 1,4 addition of folate via the nucleophilic thiol, yielding the folate-modified PEG. The variable m represents the number of repeating PEG units as described herein.
[0236] Coupling of PEG fragments to LPEI fragments The bifunctionalized PEG fragment can be coupled to the LPEI fragment before or after coupling to the targeting fragment. In a preferred embodiment, the bifunctionalized PEG fragment is coupled to the LPEI using cycloaddition chemistry, such as 1,3-dipolar cycloaddition or [3+2] cycloaddition between an azide and an alkene or alkyne to form a 1,2,3 triazole or a 4,5-dihydro-1H-[1,2,3]triazole. In another preferred embodiment, the bifunctionalized PEG fragment is coupled to the LPEI using thiol-ene chemistry between a thiol and an alkene to form a thioether.
[0237] Those skilled in the art will appreciate that any suitable alkene or alkyne group can be used to react with the azide group to couple the LPEI fragment to the PEG fragment. In some preferred embodiments, strain is introduced into the ring system by incorporating an alkene or alkyne group into the ring system. The strain on the ring system can be relieved upon reaction of the alkene or alkyne group, preferably without the use of an additional catalyst such as copper, to produce a 1,2,3-triazole or a 4,5-dihydro-1H-[1,2,3]triazole. Thus, in some preferred embodiments, suitable ring systems include a 7-, 8-, or 9-membered ring containing an alkyne group, or an 8-membered ring containing a trans alkene group. For example, suitable alkyne groups, such as cyclooctyne (OCT), monofluorinated cyclooctyne (MOFO), difluorocycloalkyne (DIFO), dibenzocyclooctynol (DIBO), dibenzoazacyclooctyne (DIBAC), bicyclononyne (BCN), biarylazacyclooctynone (BARAC), and tetramethylthiepinium (TMTI), can be used. Additionally, suitable alkene groups, such as transcyclooctene, transcycloheptene, and maleimide, can be used. For example, conjugates of the present invention can be prepared from a PEG fragment and a moiety containing an alkene or alkyne group according to one of the following formulas: [ka] (wherein the variable X 1 , X 2 , R 1A , L and m are defined above).
[0238] Without wishing to be bound by theory, azide and alkene or alkyne groups can react spontaneously (i.e., without the addition of a catalyst) to form 1,2,3-triazole or 4,5-dihydro-1H-[1,2,3]triazole. In some embodiments, the azide group reacts with an alkyne to form a 1,2,3-triazole. In some embodiments, the azide group reacts with an alkene to form a 4,5-dihydro-1H-[1,2,3]triazole.
[0239] Those skilled in the art will understand that both the LPEI fragment and the PEG fragment can be functionalized to include an azide group, and both the LPEI fragment and the PEG fragment can be functionalized to include an alkene or alkyne fragment (e.g., a strained alkene or alkyne). Thus, in some embodiments, the LPEI fragment includes an alkene or alkyne group (e.g., a strained alkene or alkyne) and the bifunctionalized PEG fragment includes an azide group. In some preferred embodiments, the bifunctionalized PEG fragment includes an alkene or alkyne group (e.g., a strained alkene or alkyne) and the LPEI fragment includes an azide group.
[0240] Those skilled in the art will also appreciate that the [3+2] cycloaddition between an azide and an alkene or alkyne group can afford adducts with different regiochemistries, as shown below in Schemes 6-8. Those skilled in the art will appreciate that all possible regiochemistries of the [3+2] cycloaddition are contemplated by the present invention.
[0241] In some preferred embodiments, the [3 + 2] azide-alkyne cycloaddition reaction occurs at a pH of 5 or less, preferably 4 or less. As shown below in the comparative example, when a PEG fragment modified with an activated alkyne was treated with a non-azide-containing LPEI fragment at pH 4, no reaction occurred. Without wishing to be bound by theory, these results suggest that the azide group of the LPEI fragment reacts chemoselectively with the alkyne or alkene (preferably a strained alkyne or alkene) group of the PEG fragment. However, at higher pH, the comparative example teaches that a by-product characterized by a hydroamination reaction between the nitrogen atom of the LPEI fragment and the alkene or alkyne was formed. Without wishing to be bound by theory, the present invention teaches that an LPEI fragment (e.g., containing a terminal azide) can be chemoselectively attached to a PEG fragment (e.g., containing an activated, preferably a strained, alkene or alkyne) at a pH of less than about 5, preferably about 4 or less.
[0242] Thus, in another aspect, the present invention provides a method of synthesizing a conjugate of Formula I, comprising reacting a thiol-containing LPEI fragment with an alkene-containing PEG fragment.
[0243] In another aspect, the present invention provides a method of synthesizing a conjugate as described and defined herein, preferably a method of synthesizing a conjugate of Formula I, wherein the method comprises reacting an omega end of a linear polyethyleneimine fragment with a first end of a polyethylene glycol fragment, wherein said reaction occurs at a pH of less than about 5, preferably 4 or less, and preferably said omega end of said linear polyethyleneimine fragment comprises an azide and said first end of said polyethylene glycol fragment comprises an alkene or alkyne, and said reaction is between said azide and said alkene or alkyne.
[0244] Scheme 6. Coupling of LPEI to dibenzocyclooctyne (DBCO)-modified PEG [ka] As shown in Scheme 6 above, in some embodiments, PEG can be modified to include a strained alkyne group, such as DBCO. Treatment of the DBCO-modified PEG in solution with an azide-modified LPEI results in a [3+2] cycloaddition of the azide to the alkyne of DBCO, yielding a 1,2,3 triazole. One skilled in the art will appreciate that the reaction shown above in Scheme 6 can produce triazole adducts with different regiochemistry, as shown above. The variables m and n represent the number of repeating PEG and LPEI units described herein.
[0245] Scheme 7. Coupling of LPEI to bicyclononyne (BCN)-modified PEG [ka] As shown in Scheme 7 above, in some embodiments, PEG can be modified to include a strained alkyne group, such as bicyclononyne (BCN). Treatment of the BCN-modified PEG in solution with an azide-modified LPEI results in a [3+2] cycloaddition of the azide to the BCN alkyne, yielding a 1,2,3 triazole. One skilled in the art will appreciate that the reaction shown above in Scheme 7 can produce triazole adducts with different regiochemistry, as shown above. The variables m and n represent the number of repeating PEG and LPEI units described herein.
[0246] Scheme 8. Coupling of LPEI to maleimide (MAL)-modified PEG [ka] As shown in Scheme 8 above, in some embodiments, PEG can be modified to include an alkene group, such as maleimide (MAL). Treatment of the MAL-modified PEG in solution with an azide-modified LPEI results in a [3+2] cycloaddition of the azide to the alkene of the MAL, yielding 4,5-dihydro-1H-[1,2,3]triazole. The variables m and n represent the number of repeating PEG and LPEI units as described herein.
[0247] Scheme 9. Coupling of LPEI to alkene-modified PEG [ka] As shown in Scheme 9 above, in some embodiments, PEG can be modified to contain a terminal alkene group, and LPEI can be modified to contain a terminal thiol group. Treatment of thiol-modified LPEI in solution with alkene-modified PEG can result in a thiol-ene reaction, yielding a thioether. The variables m and n represent the number of repeating PEG and LPEI units described herein.
[0248] X 1 and X 2 connecting part In some embodiments, the PEG fragment of the conjugates of the invention may be connected to the alkene or alkyne group and / or the targeting fragment by a covalent linking moiety.
[0249] X 1 connecting part In some embodiments, the PEG fragment of the conjugate of the invention is connected to a terminal activated (e.g., cyclic) alkene or alkyne group by a linking moiety. For example, X 1Linking moieties can be formed as a result of selecting a PEG fragment and an alkene or alkyne group, each containing reactive functional groups that can be combined by well-known chemical reactions. For example, a PEG fragment can be coupled to an activated (e.g., cyclic) alkene or alkyne group by standard means, such as peptide coupling (e.g., to form an amide), nucleophilic addition, or other means known to those skilled in the art.
[0250] In one embodiment, X 1 is the formula -(Y 1 ) p - [wherein p is an integer of 1 to 20, and Y 1 Each occurrence of represents independently a chemical bond, -CR 11 R 12 -, -C(O)-, -O-, -S-, -NR 13 -, an amino acid residue, a divalent phenyl moiety, a divalent carbocyle moiety, a divalent heterocyclic moiety, and a divalent heteroaryl moiety, wherein each divalent phenyl or heteroaryl is selected from one or more R 11 and each divalent heterocycle is optionally substituted with one or more R 14 optionally substituted with R 11 , R 12 and R 13 is independently at each occurrence -H, -SO3H, -NH2, or C1-C6 alkyl, where each alkyl is optionally substituted with -CO2H or NH2; and R 14 is independently, at each occurrence, -H, C1-C6 alkyl or oxo, C6-C 10 aryl or 5-8 membered heteroaryl).
[0251] In some embodiments, Y 1 is an amino acid residue, it can be oriented in any direction, i.e., —C(O)—CHR—NH— or —NH—CHR—C(O)—, where “R” represents the side chain of a naturally occurring amino acid.
[0252] In some embodiments, the divalent heteroaryl moiety is a divalent heteroaryl group containing one or more heteroatoms selected from O, N, S, and P, preferably one or two atoms selected from O and N. In some embodiments, the divalent heteroaryl moiety is a divalent furan, pyrrole, imidazole, pyrazole, triazole, pyridine, pyrimidine, pyridazine, pyrazine, thiophene, oxazole, or isoxazole, wherein the divalent heteroaryl is selected from one or more, preferably one or zero, R 14 is optionally replaced by
[0253] X 1 In the following embodiments for , unless otherwise specified, the wavy line indicates a bond of any orientation, i.e., to a PEG fragment or a divalent covalent linking moiety (e.g., "Z" or ring A).
[0254] In some embodiments, the divalent heterocyclic moiety is a divalent heterocyclic group containing one or more heteroatoms selected from O, N, S, and P, preferably one or two atoms selected from O and N. In some embodiments, the divalent heterocyclic moiety is a divalent heterocyclic group containing one or more heteroatoms, each of which is one or more R 14 In some preferred embodiments, the divalent heterocyclic moiety is succinimide. In some preferred embodiments, the two Y 1 are combined, and the formula [ka] can form a linking or partially linking moiety of
[0255] In a further preferred embodiment, two Y 1 are combined, and the formula [ka] where the wavy line next to the sulfur indicates the direction of the connection towards the target fragment.
[0256] In a further preferred embodiment, Y 1 is the expression: [ka] The linking moiety may comprise a linking moiety or a partial linking moiety.
[0257] In a further preferred embodiment, Y 1 is the expression: [ka] where the wavy line next to the sulfur indicates the direction of the connection towards the target fragment.
[0258] In some embodiments, X 1 is the formula -(Y 1 ) p where p is an integer from 1 to 8, and Y 1 Each occurrence of represents independently a chemical bond, -CHR 11 -, -C(O)-, -O-, -S-, -NH-, -C6H4-, [ka] is a linking moiety selected from
[0259] In some embodiments, X 1 is the formula -(Y 1 ) p where p is an integer from 1 to 8, and Y 1 Each occurrence independently represents a chemical bond, -CH2-, -C(O)-, -O-, -S-, -NH-, -C6H4-, [ka] is a linking moiety selected from
[0260] In some embodiments, X 1 is the formula -(Y 1 ) p where p is an integer from 1 to 8, and Y 1 Each occurrence independently represents a chemical bond, -CH2-, -C(O)-, -O-, -S-, -NH-, [ka] is a linking moiety selected from
[0261] In some embodiments, X 1 is the formula -(Y 1 ) p where p is an integer from 1 to 8, and Y 1 Each occurrence independently represents a chemical bond, -CH2-, -C(O)-, -O-, -NH-, [ka] where Y 1 is the linking moiety of the -NH- group (only -NH- when adjacent to a -C(O)- group to form a carbamate or amide).
[0262] In some embodiments, X 1 teeth, [ka] (wherein r is an integer of 1 to 8, preferably 1 to 4, more preferably 1 to 2; R 11 and R 12 are independently —H or C1-C6 alkyl, preferably —H or C1-C2 alkyl, more preferably —H).
[0263] In some embodiments, X 1 teeth, [ka] (wherein r and s are each independently an integer of 0 to 4, preferably 1 to 3, more preferably 1 to 2; the sum of r and s is 7 or less; R 11 and R 12 are independently -H or C1-C6 alkyl, preferably -H or C1-C2 alkyl, more preferably -H. Preferably, the wavy line closest to the integer "r" is the bond to a divalent covalent linking moiety (e.g., "Z" or ring A), and the wavy line closest to the integer "s" is the bond to the PEG fragment -[OCH2-CH2] m - is a bond to.
[0264] In some embodiments, X 1 teeth, [ka] (wherein s and t are each independently an integer of 0 to 4, preferably 1 to 3, more preferably 1 to 2; the sum of r and s is 7 or less; and R 11 , R 12 and R 13 are independently -H or C1-C6 alkyl, preferably -H or C1-C2 alkyl, more preferably -H. Preferably, the wavy line closest to the integer "r" is the bond to a divalent covalent linking moiety (e.g., "Z" or ring A), and the wavy line closest to the integer "s" is the bond to the PEG fragment -[OCH2-CH2] m - is a bond to.
[0265] In some embodiments, X 1 teeth, [ka] (wherein r is an integer of 0 to 3, preferably 1 to 3, more preferably 1 to 2; s and t are each independently an integer of 0 to 2, preferably 0 to 1; the sum of r, s, and t is 6 or less; and R 11 and R 12are independently -H or C1-C6 alkyl, preferably -H or C1-C2 alkyl, more preferably -H. Preferably, the wavy line closest to the integer "r" is the bond to a divalent covalent linking moiety (e.g., "Z" or ring A), and the wavy line closest to the integer "t" is the bond to the PEG fragment -[OCH2-CH2] m - is a bond to.
[0266] In some embodiments, X 1 teeth, [ka] (wherein r and s are each independently an integer of 0 to 4, preferably 1 to 3, more preferably 1 to 2; the sum of r and s is 6 or less; and R 11 , R 12 and R 13 are independently -H or C1-C6 alkyl, preferably -H or C1-C2 alkyl, more preferably -H. Preferably, the wavy line closest to the integer "r" is the bond to a divalent covalent linking moiety (e.g., "Z" or ring A), and the wavy line closest to the integer "s" is the bond to the PEG fragment -[OCH2-CH2] m - is a bond to.
[0267] In some embodiments, X 1 teeth, [ka] (wherein r and s are each independently an integer of 0 to 4, preferably 1 to 3, more preferably 1 to 2; the sum of r and s is 6 or less; and R 11 , R 12 and R 13 are independently -H or C1-C6 alkyl, preferably -H or C1-C2 alkyl, more preferably -H. Preferably, the wavy line closest to the integer "r" is the bond to a divalent covalent linking moiety (e.g., "Z" or ring A), and the wavy line closest to the integer "s" is the bond to the PEG fragment -[OCH2-CH2] m- is a bond to.
[0268] In some embodiments, X 1 teeth, [ka] (wherein r and t are each an integer of 0 to 3, and s is an integer of 0 to 3; preferably, r is 0, s is 2 or 3, and t is 2; the sum of r, s, and t is 5 or less; and R 11 , R 12 and R 13 are independently -H or C1-C6 alkyl, preferably -H or C1-C2 alkyl, more preferably -H. Preferably, the wavy line closest to the integer "r" is the bond to a divalent covalent linking moiety (e.g., "Z" or ring A), and the wavy line closest to the integer "t" is the bond to the PEG fragment -[OCH2-CH2] m - is a bond to.
[0269] In some embodiments, X 1 teeth, [ka] (wherein r and t are each an integer of 0 to 3; s is an integer of 0 to 3; the sum of r, s, and t is 5 or less; and R 11 and R 12 are independently -H or C1-C6 alkyl, preferably -H or C1-C2 alkyl, more preferably -H. Preferably, the wavy line closest to the integer "r" is the bond to a divalent covalent linking moiety (e.g., "Z" or ring A), and the wavy line closest to the integer "t" is the bond to the PEG fragment -[OCH2-CH2] m - is a bond to.
[0270] In some embodiments, X 1 teeth, [ka] (wherein r and s each independently represent an integer of 0 to 3, preferably 0 to 2; the sum of r and s is 5 or less; and R 11 , R 12 and R 13 are independently -H or C1-C6 alkyl, preferably -H or C1-C2 alkyl, more preferably -H. Preferably, the wavy line closest to the integer "r" is the bond to a divalent covalent linking moiety (e.g., "Z" or ring A), and the wavy line closest to the integer "s" is the bond to the PEG fragment -[OCH2-CH2] m - is a bond to.
[0271] In some embodiments, X 1 teeth, [ka] (wherein r is independently an integer of 0 to 4, preferably 0 to 2, more preferably 1 to 2; R 11 and R 12 are independently -H or C1-C6 alkyl, preferably -H or C1-C2 alkyl, more preferably -H. Preferably, the wavy line closest to the integer "r" is the bond to the divalent covalent linking moiety (e.g., "Z" or ring A), and the wavy line closest to the carbonyl group is the bond to the PEG fragment -[OCH2-CH2] m - is a bond to.
[0272] In some embodiments, X 1 teeth, [ka] (In the formula, r and s each independently represent an integer of 0 to 4, preferably 0 to 2, more preferably 1 to 2; the sum of r and s is 5 or less; R 11 and R 12are independently -H or C1-C6 alkyl, preferably -H or C1-C2 alkyl, more preferably -H. Preferably, the wavy line closest to the integer "r" is the bond to the divalent covalent linking moiety (e.g., "Z" or ring A), and the wavy line closest to the carbonyl group is the bond to the PEG fragment -[OCH2-CH2] m - is a bond to.
[0273] In some embodiments, X 1 teeth, [ka] (wherein r and s each independently represent an integer of 0 to 4, preferably 0 to 2; the sum of r and s is 5 or less; and R 11 , R 12 and R 13 are independently -H or C1-C6 alkyl, preferably -H or C1-C2 alkyl, more preferably -H. Preferably, the wavy line closest to the integer "r" is the bond to the divalent covalent linking moiety (e.g., "Z" or ring A), and the wavy line closest to the carbonyl group is the bond to the PEG fragment -[OCH2-CH2] m - is a bond to.
[0274] In some preferred embodiments, X 1 teeth, [ka] (In the formula, r is independently at each occurrence 0 to 6, preferably 0, 1, 2 or 5; s is independently, at each occurrence, 0 to 6, preferably 0, 2, or 4; t is independently, at each occurrence, 0 to 6, preferably 0, 1, 2, or 4; R 11 and R 12is independently selected at each occurrence from -H, -C1-C2 alkyl, -SO3H, and NH2; more preferably -H, -SO3H, -NH2; even more preferably -H; and R 13 is -H). Preferably, the wavy line closest to the integer "r" is the bond to a divalent covalent linking moiety (e.g., "Z" or ring A), and the wavy line closest to the integer "s" or "t" or the carbonyl group is the bond to the PEG fragment -[OCH2-CH2] m - is a bond to.
[0275] In some preferred embodiments, X 1 teeth, [ka] (In the formula, r is independently at each occurrence 0 to 6, preferably 0, 1, 2 or 5; s is independently, at each occurrence, 0 to 6, preferably 0, 2, or 4; t is independently, at each occurrence, 0 to 6, preferably 0, 1, 2, or 4; R 11 and R 12 is independently selected at each occurrence from —H, —C1-C2 alkyl, preferably —H; and R 13 is -H). Preferably, the wavy line closest to the integer "r" is the bond to a divalent covalent linking moiety (e.g., "Z" or ring A), and the wavy line closest to the integer "s" or "t" or the carbonyl group is the bond to the PEG fragment -[OCH2-CH2] m - is a bond to.
[0276] In some preferred embodiments, X 1 teeth, [ka] (In the formula, r is independently, at each occurrence, 0 to 6, preferably 0, 1, 2, or 5; more preferably 0; s is independently, at each occurrence, 0 to 6, preferably 0, 2, 3, or 4; more preferably 2 or 3; t is independently, at each occurrence, 0 to 6, preferably 0, 1, 2, or 4; more preferably 2; R 11 and R 12 is independently selected at each occurrence from —H, —C1-C2 alkyl, preferably —H; and R 13 is -H). Preferably, the wavy line closest to the integer "r" is the bond to a divalent covalent linking moiety (e.g., "Z" or ring A), and the wavy line closest to the integer "s" or "t" group is the bond to the PEG fragment -[OCH2-CH2] m - is a bond to.
[0277] In some preferred embodiments, X 1 teeth, [ka] (In the formula, X A is -NHC(O)- or C(O)NH-; and [ka] Preferably, the left wavy line is the bond to a divalent covalent linking moiety (e.g., "Z" or ring A) and the right wavy line is the bond to a PEG fragment -[OCH2-CH2] m - is a bond to.
[0278] In some preferred embodiments, X 1 teeth, [ka] Preferably, the left wavy line is the bond to a divalent covalent linking moiety (e.g., "Z" or ring A) and the right wavy line is the bond to a PEG fragment -[OCH2-CH2] m - is a bond to.
[0279] In some preferred embodiments, X 1 teeth, [ka] Preferably, the left wavy line is the bond to a divalent covalent linking moiety (e.g., "Z" or ring A) and the right wavy line is the bond to a PEG fragment -[OCH2-CH2] m - is a bond to.
[0280] In some embodiments, X 1 teeth, [ka] Preferably, the left wavy line is the bond to a divalent covalent linking moiety (e.g., "Z" or ring A) and the right wavy line is the bond to a PEG fragment -[OCH2-CH2] m - is a bond to.
[0281] In some preferred embodiments, X 1 teeth, [ka] Preferably, the left wavy line is the bond to a divalent covalent linking moiety (e.g., "Z" or ring A) and the right wavy line is the bond to a PEG fragment -[OCH2-CH2] m - is a bond to.
[0282] In some preferred embodiments, X 1 is -(CH2) 1~6 -; preferably, X 1 is -(CH2) 2~4 -; more preferably, X1 is -(CH2)2-.
[0283] X 2 connecting part In some embodiments, the PEG fragment of the conjugate of the invention is connected to a terminal targeting fragment by a linking moiety. For example, X 2 Linking moieties can be formed as a result of selecting PEG and targeting fragments, each containing reactive functional groups that can be combined by well-known chemical reactions. For example, PEG fragments can be coupled to targeting groups by standard means, such as peptide coupling (e.g., to form amides), nucleophilic addition, or other means known to those skilled in the art.
[0284] In one embodiment, X 2 is the formula -(Y 2 ) q - [wherein q is an integer of 1 to 50, and Y 2 Each occurrence of represents independently a chemical bond, -CR 21 R 22 -, NR 23 -, -O-, -S-, -C(O)-, an amino acid residue, a divalent phenyl moiety, a divalent carbocyclic moiety, a divalent heterocyclic moiety, and a divalent heteroaryl moiety, wherein each divalent phenyl and heteroaryl is selected from one or more R 23 and each divalent heterocyclic moiety is optionally substituted with one or more R 24 optionally substituted with; R 21 , R 22 and R 23 are each independently at each occurrence -H, -SO3H, -NH2, -CO2H, or C1-C6 alkyl, where each C1-C6 alkyl is selected from one or more of -OH, oxo, -CO2H, -NH2, C6-C6 10 optionally substituted with aryl or 5-8 membered heteroaryl; R 24 is independently, at each occurrence, -H, -CO2H, C1-C6 alkyl, or oxo.
[0285] In some embodiments, R 21 , R 22 and R 23 is independently at each occurrence -H, -COH, or C1-C6 alkyl. In some embodiments, R 21 , R 22 and R 23 are each independently —H or C1 to C4 alkyl, preferably C1 to C2 alkyl.
[0286] In some embodiments, R 21 , R 22 , R 23 and R 24 is -H.
[0287] In some embodiments, R 24 are independently -H, C1-C6 alkyl, or oxo.
[0288] In some embodiments, the divalent heteroaryl moiety is a divalent heteroaryl group containing one or more heteroatoms selected from O, N, S, and P, preferably one or two atoms selected from O and N. In some embodiments, the divalent heteroaryl moiety is a divalent furan, pyrrole, imidazole, pyrazole, triazole, pyridine, pyrimidine, pyridazine, pyrazine, thiophene, oxazole, or isoxazole, wherein the divalent heteroaryl is selected from one or more, preferably one or zero, R 21 is optionally replaced by
[0289] X 2 In the following embodiments for , unless otherwise specified, the wavy line represents a bond of any orientation, i.e., a PEG fragment (-[OCH2CH2] m -) or to the target fragment (i.e., "L").
[0290] In some embodiments, the divalent heterocyclic moiety is a divalent heterocyclic group containing one or more heteroatoms selected from O, N, S, and P, preferably one or two atoms selected from O and N. In some embodiments, the divalent heterocyclic moiety is a divalent heterocyclic group containing one or more heteroatoms, each of which is one or more R 24 In some preferred embodiments, the divalent heterocyclic moiety is succinimide. In some preferred embodiments, the two Y 2 are combined, and the formula [ka] can form a linking or partially linking moiety of
[0291] In a further preferred embodiment, two Y 2 are combined, and the formula [ka] where the wavy line next to the sulfur represents the bond to the targeting fragment (L) and the wavy line next to the nitrogen represents the bond to the PEG fragment (-[OCH-CH] m -) to represent a bond.
[0292] In a further preferred embodiment, two Y 2 are combined, and the formula [ka] where the wavy line next to the sulfur represents the PEG fragment (-[OCH-CH] m The wavy line next to the nitrogen represents the bond to the targeting fragment (L).
[0293] In a further preferred embodiment, Y 2 is the expression: [ka] The linking moiety may comprise a linking moiety or a partial linking moiety.
[0294] In a further preferred embodiment, Y 2 is the expression: [ka] where the wavy line next to the sulfur indicates the direction of the connection towards the target fragment.
[0295] In some embodiments, X 2 is the formula -(Y 2 ) q - (wherein q is an integer from 1 to 40, and Y 2 Each occurrence of represents a chemical bond, -CR 21 R 22 -, NH-, -O-, -S-, -C(O)-, amino acid residues, and [ka] are independently selected from R 21 and R 22 is independently at each occurrence -H, -CO2H, or C1-C6 alkyl, where each C1-C6 alkyl is selected from one or more of -OH, oxo, C6-C 10 is a linking moiety for a 5- to 8-membered heteroaryl (optionally substituted with aryl or 5- to 8-membered heteroaryl).
[0296] In some embodiments, X 2 is the formula -(Y 2 ) q - (wherein q is an integer from 1 to 40, and Y 2 Each occurrence of represents a chemical bond, -CHR 21 -, NH-, -O-, -S-, -C(O)-, amino acid residues, and [ka] are independently selected from R 21 is independently, at each occurrence, -H, -CO2H, or C1-C4 alkyl (preferably C1 alkyl), where each C1-C4 alkyl is selected from one or more C6-C 10 is a linking moiety for a 5- to 8-membered heteroaryl (optionally substituted with aryl or 5- to 8-membered heteroaryl).
[0297] In some embodiments, X 2 is the formula -(Y 2 ) q - (wherein q is an integer from 1 to 40, and Y 2 Each occurrence of represents a chemical bond, -CHR 21 -, NH-, -O-, -S-, -C(O)-, amino acid residues, and [ka] are independently selected from R 21 is independently, at each occurrence, -H, -CO2H, or C1-C4 alkyl (preferably C1 alkyl), where each C1-C4 alkyl is selected from one or more C6-C 10 is a linking moiety for a 5- to 8-membered heteroaryl (optionally substituted with aryl or 5- to 8-membered heteroaryl).
[0298] In some embodiments, X 2 is the formula -(Y 2 ) q - (wherein q is an integer from 1 to 40, and Y 2 Each occurrence of represents a chemical bond, -CHR 21 -, NH-, -O-, -S-, -C(O)-, amino acid residues, and [ka] are independently selected from R 21is independently, at each occurrence, —H, —COH, or C1-C3 alkyl (preferably C1 alkyl), where each C1-C3 alkyl is optionally substituted with one or more phenyl or indole, and is a linking moiety.
[0299] In some embodiments, X 2 is the formula -(Y 2 ) q - (wherein q is an integer from 1 to 40, and Y 2 Each occurrence of represents a chemical bond, -CHR 21 -, NH-, -O-, -S-, -C(O)-, amino acid residues, and [ka] are independently selected from R 21 is independently, at each occurrence, —H, —COH, or C1-C3 alkyl (preferably C1 alkyl), where each C1-C3 alkyl is optionally substituted with one or more phenyl or 3-indole, and is a linking moiety.
[0300] In some embodiments, X 2 is the formula -(Y 2 ) q - (wherein q is an integer from 1 to 40, and Y 2 Each occurrence of represents a chemical bond, -CHR 21 -, NH-, -O-, -S-, -C(O)-, amino acid residues, and [ka] are independently selected from; Y 2 is only -NH- when adjacent to a -C(O)- group to form a carbamate or amide; and R 21is independently, at each occurrence, —H, —COH, or C1-C3 alkyl (preferably C1 alkyl), where each C1-C3 alkyl is optionally substituted with one or more phenyl or 3-indole, and is a linking moiety.
[0301] In some embodiments, X 2 is the formula -(Y 2 ) q - (wherein q is an integer from 1 to 40, and Y 2 Each occurrence of represents a chemical bond, -CHR 21 -, NH-, -O-, -S-, -C(O)-, amino acid residues, and [ka] are independently selected from; Y 2 is only -NH- when adjacent to a -C(O)- group to form an amide; and R 21 is independently, at each occurrence, —H, —COH, or C1-C3 alkyl (preferably C1 alkyl), where each C1-C3 alkyl is optionally substituted with one or more phenyl or 3-indole, and is a linking moiety.
[0302] In some embodiments, Y 2 is an amino acid residue, Y 2 represents a naturally occurring L-amino acid residue. 2 is an amino acid residue, it can be oriented in any direction, i.e., —C(O)—CHR—NH— or —NH—CHR—C(O)—, where “R” represents the side chain of a naturally occurring amino acid.
[0303] In some embodiments, X 2 teeth, [ka] (wherein r is an integer of 1 to 8, preferably 1 to 4, more preferably 1 to 2; R 21 and R22 are independently —H or C1-C6 alkyl, preferably —H or C1-C2 alkyl, more preferably —H).
[0304] In some embodiments, X 2 teeth, [ka] (In the formula, r and s each independently represent an integer of 0 to 4, preferably 1 to 3, and more preferably 1 to 2; the sum of r and s is 7 or less; R 21 and R 22 are independently —H or C1-C6 alkyl, preferably —H or C1-C2 alkyl, more preferably —H).
[0305] In some embodiments, X 2 teeth, [ka] (In the formula, s and t each independently represent an integer of 0 to 4, preferably 1 to 3, and more preferably 1 to 2; the sum of r and s is 7 or less; R 21 , R 22 , and R 23 are independently —H or C1-C6 alkyl, preferably —H or C1-C2 alkyl, more preferably —H).
[0306] In some embodiments, X 2 teeth, [ka] (wherein r is an integer of 0 to 3, preferably 1 to 3, more preferably 1 to 2; s and t are each independently an integer of 0 to 2, preferably 0 to 1; the sum of r, s, and t is 6 or less; and R 21 and R 22are independently —H or C1-C6 alkyl, preferably —H or C1-C2 alkyl, more preferably —H).
[0307] In some embodiments, X 2 teeth, [ka] (wherein r and s are each independently an integer of 0 to 4, preferably 1 to 3, more preferably 1 to 2; the sum of r and s is 6 or less; R 21 , R 22 and R 23 are independently -H or C1-C6 alkyl, preferably -H or C1-C2 alkyl, more preferably -H). Preferably, the wavy line closest to the integer "r" is a PEG fragment (-[OCH2-CH2] m The wavy line closest to the integer "s" is the bond to the target fragment (L).
[0308] In some embodiments, X 2 teeth, [ka] (wherein r and s are each independently an integer of 0 to 4, preferably 1 to 3, more preferably 1 to 2; the sum of r and s is 6 or less; R 21 , R 22 , and R 23 are independently -H or C1-C6 alkyl, preferably -H or C1-C2 alkyl, more preferably -H). Preferably, the wavy line closest to the integer "r" is a PEG fragment (-[OCH2-CH2] m The wavy line closest to the integer "s" is the bond to the target fragment (L).
[0309] In some embodiments, X 2 teeth, [ka] (wherein r and t are each an integer of 0 to 3, and s is an integer of 0 to 3; preferably, r is 0, s is 2 or 3, and t is 2; the sum of r, s, and t is 5 or less; and R 21 , R 22 and R 23 are independently -H or C1-C6 alkyl, preferably -H or C1-C2 alkyl, more preferably -H). Preferably, the wavy line closest to the integer "r" is a PEG fragment (-[OCH2-CH2] m The wavy line closest to the integer "t" is the bond to the target fragment (L).
[0310] In some embodiments, X 2 teeth, [ka] (wherein r and t are each an integer of 0 to 3; s is an integer of 0 to 3; the sum of r, s, and t is 5 or less; and R 21 and R 22 are independently -H or C1-C6 alkyl, preferably -H or C1-C2 alkyl, more preferably -H). Preferably, the wavy line closest to the integer "r" is a PEG fragment (-[OCH2-CH2] m The wavy line closest to the integer "t" is the bond to the target fragment (L).
[0311] In some embodiments, X 2 teeth, [ka] (wherein r and s each independently represent an integer of 0 to 3, preferably 0 to 2; the sum of r and s is 5 or less; and R 21 , R 22 and R 23are independently -H or C1-C6 alkyl, preferably -H or C1-C2 alkyl, more preferably -H). Preferably, the wavy line closest to the integer "r" is a PEG fragment (-[OCH2-CH2] m The wavy line closest to the integer "s" is the bond to the target fragment (L).
[0312] In some embodiments, X 2 teeth, [ka] (In the formula, r and s each independently represent an integer of 0 to 4, preferably 0 to 2, more preferably 1 to 2; the sum of r and s is 5 or less; R 21 and R 22 are independently -H or C1-C6 alkyl, preferably -H or C1-C2 alkyl, more preferably -H). Preferably, the wavy line closest to the integer "r" is a PEG fragment (-[OCH2-CH2] m The wavy line closest to the carbonyl group is the bond to the target fragment (L).
[0313] In some embodiments, X 2 teeth, [ka] (wherein r and s each independently represent an integer of 0 to 4, preferably 0 to 2; the sum of r and s is 5 or less; and R 21 , R 22 and R 23 are independently -H or C1-C6 alkyl, preferably -H or C1-C2 alkyl, more preferably -H). Preferably, the wavy line closest to the integer "r" is a PEG fragment (-[OCH2-CH2] m The wavy line closest to the carbonyl group is the bond to the target fragment (L).
[0314] In some embodiments, X 2 teeth, [ka] [ka] (In the formula, r, s, t, and u each independently represent an integer of 0 to 6, preferably 0 to 4; v represents an integer of 0 to 10; and w represents an integer of 0 to 10; AA is an amino acid residue, preferably a naturally occurring amino acid residue; even more preferably, AA is an amino acid selected from Arg, His, Lys, Asp, Glu, Ser, Thr, Asn, Gln, Cys, Sec, Gly, Pro, Ala, Val, Ile, Leu, Met, Phe, Tyr and Trp; a is an integer of 0 to 10, preferably 0 to 6; more preferably 0 to 4; and R 21 , R 22 and R 23 are independently selected from -H, C1-C6 alkyl or (-COOH), preferably -H, C1-C2 alkyl or (-COOH), more preferably -H or (-COOH). Preferably, the wavy line on the left represents a PEG fragment (-[OCH2-CH2] m The wavy line on the right is the bond to the target fragment (L).
[0315] In some preferred embodiments, (AA) a comprises a tripeptide selected from Trp-Trp-Gly or Trp-Gly-Phe. In some preferred embodiments, (AA) a is Trp-Trp-Gly-Phe (SEQ ID NO: 2).
[0316] In some embodiments, X 2 teeth, [ka] [ka] (In the formula, r, s, t, and u each independently represent an integer of 0 to 6, preferably 0 to 4; v represents an integer of 0 to 10; and w represents an integer of 0 to 10; AA is an amino acid residue, preferably a naturally occurring amino acid residue; even more preferably, AA is an amino acid selected from Arg, His, Lys, Asp, Glu, Ser, Thr, Asn, Gln, Cys, Sec, Gly, Pro, Ala, Val, Ile, Leu, Met, Phe, Tyr and Trp; a is an integer of 0 to 10, preferably 0 to 6; more preferably 0 to 4; and R 21 , R 22 and R 23 are independently selected from -H, C1-C6 alkyl or (-COOH), preferably -H, C1-C2 alkyl or (-COOH), more preferably -H or (-COOH). Preferably, the wavy line on the left represents a PEG fragment (-[OCH2-CH2] m The wavy line on the right is the bond to the target fragment (L).
[0317] In some preferred embodiments, (AA) a is Trp-Trp-Gly-Phe (SEQ ID NO: 2).
[0318] In some embodiments, X 2 teeth, [ka] [ka] (In the formula, r and s each independently represent an integer of 0 to 4, preferably 0 to 2; w represents an integer of 0 to 10; and R 21 , R 22 and R 23are independently selected from -H or C1-C6 alkyl, preferably -H or C1-C2 alkyl, more preferably -H. Preferably, the wavy line on the left represents a PEG fragment (-[OCH2-CH2] m The wavy line on the right is the bond to the target fragment (L).
[0319] In some embodiments, X 2 teeth, [ka] [ka] (In the formula, r and s each independently represent an integer of 0 to 4, preferably 0 to 2; w represents an integer of 0 to 10; and R 21 , R 22 and R 23 are independently selected from -H or C1-C6 alkyl, preferably -H or C1-C2 alkyl, more preferably -H. Preferably, the wavy line on the left represents a PEG fragment (-[OCH2-CH2] m The wavy line on the right is the bond to the target fragment (L).
[0320] In some embodiments, X 2 teeth, [ka] [ka] (In the formula, r, s, and t each independently represent an integer of 0 to 4, preferably 0 to 2; w represents an integer of 0 to 10; AA is an amino acid selected from Arg, His, Lys, Asp, Glu, Ser, Thr, Asn, Gln, Cys, Sec, Gly, Pro, Ala, Val, Ile, Leu, Met, Phe, Tyr, and Trp; a is an integer of 0 to 10, preferably 0 to 6; more preferably 0 to 4; and R 21 , R 22 and R 23 are independently selected from -H or C1-C6 alkyl, preferably -H or C1-C2 alkyl, more preferably -H. Preferably, the wavy line on the left represents a PEG fragment (-[OCH2-CH2] m The wavy line on the right is the bond to the target fragment (L).
[0321] In an even more preferred embodiment, (AA) a is Trp-Trp-Gly-Phe (SEQ ID NO: 2).
[0322] In some embodiments, X 2 comprises or is a urea, carbamate, carbonate, or ester. In some preferred embodiments, X 2 teeth, [ka] Preferably, the wavy line on the left represents a PEG fragment (-[OCH2-CH2] m The wavy line on the right is the bond to the target fragment (L).
[0323] In a preferred embodiment, the X 2 teeth [ka] Preferably, the wavy line on the left represents the PEG fragment (-[OCH2-CH2] m The wavy line on the right is the bond to the target fragment (L).
[0324] In a further preferred embodiment, the X 2 teeth, [ka] and the L of the triconjugate is a DUPA residue (HOOC(CH2)2-CH(COOH)-NH-CO-NH-CH(COOH)-(CH2)2-CO-). Preferably, the wavy line on the left represents a PEG fragment (-[OCH2-CH2] m The wavy line on the right is the bond to the DUPA residue.
[0325] In a further preferred embodiment, the X 2 teeth, [ka] and L of the triconjugate is a DUPA residue (HOOC(CH2)2-CH(COOH)-NH-CO-NH-CH(COOH)-(CH2)2-CO-), wherein X 2 The amide group-bearing end of the PEG fragment (-[OCH2-CH2] m The terminal end is attached to a DUPA residue (HOOC(CH2)2-CH(COOH)-NH-CO-NH-CH(COOH)-(CH2)2-CO-).
[0326] In some embodiments, X 2 teeth, [ka] [where, X B is —C(O)NH— or NH—C(O)—, and Y 2 and R 21 is as defined above. Preferably, the wavy line on the left is selected from the PEG fragment (-[OCH2-CH2] m The wavy line on the right is the bond to the target fragment (L).
[0327] In some embodiments, X 2 teeth, [ka] [where, X B is —C(O)NH— or NH—C(O)—, and Y 2 and R 21 is as defined above. Preferably, the wavy line on the left is selected from the PEG fragment (-[OCH-CH] m The wavy line on the right is the bond to the target fragment (L).
[0328] In some embodiments, X 2 teeth, [ka] (SEQ ID NO:10, wherein SEQ ID NO:10 is defined as W1-Gly-Trp-Trp-Gly-Phe-W2, wherein W1 is [ka] and W2 is [ka] ), or [ka] (wherein Y 2 and R 21 is as defined above). Preferably, the wavy line on the left is selected from the PEG fragment (-[OCH2-CH2] m The wavy line on the right is the bond to the target fragment (L).
[0329] In some embodiments, X 2 teeth, [ka] (SEQ ID NO:14, wherein SEQ ID NO:14 is defined as W9-Gly-Trp-Trp-Gly-Phe-W10, wherein W9 is [ka] and W10 is [ka] and;R 21 is as defined above, preferably R 21 is selected from -H or CH2-NH2; more preferably -H). Preferably, the wavy line on the left represents a PEG fragment (-[OCH2-CH2] m The wavy line on the right is the bond to the target fragment (L).
[0330] In some embodiments, X 2 teeth, [ka] (SEQ ID NO:11, wherein SEQ ID NO:11 is defined as W3-Gly-Trp-Trp-Gly-Phe-W4, where W3 is [ka] and W4 is [ka] ), or [ka] (SEQ ID NO:14, wherein SEQ ID NO:14 is defined as W9-Gly-Trp-Trp-Gly-Phe-W10, wherein W9 is [ka] and W10 is [ka] Preferably, the wavy line on the left is a PEG fragment (-[OCH2-CH2] m The wavy line on the right is the bond to the target fragment (L).
[0331] In some embodiments, X 2 teeth, [ka] (SEQ ID NO:11, wherein SEQ ID NO:11 is defined as W3-Gly-Trp-Trp-Gly-Phe-W4, wherein W3 is [ka] and W4 is [ka] ), [ka] (SEQ ID NO:12, wherein SEQ ID NO:12 is defined as W5-Gly-Trp-Trp-Gly-Phe-W6, wherein W5 is [ka] and W6 is [ka] ), [ka] (SEQ ID NO:13, wherein SEQ ID NO:13 is defined as W7-Gly-Trp-Trp-Gly-Phe-W8, wherein W7 is [ka] and W8 is [ka] ), [ka] (SEQ ID NO:14, wherein SEQ ID NO:14 is defined as W9-Gly-Trp-Trp-Gly-Phe-W10, wherein W9 is [ka] and W10 is [ka] Preferably, the wavy line on the left is a PEG fragment (-[OCH2-CH2] m The wavy line on the right is the bond to the target fragment (L).
[0332] In some embodiments, X 2 teeth: [ka] is.
[0333] In some embodiments, X 2 teeth: [ka] (In the formula, X Bis -C(O)NH- or NH-C(O)-). Preferably, the wavy line on the left represents a PEG fragment (-[OCH-CH] m The wavy line on the right is the bond to the target fragment (L).
[0334] In some embodiments, X 2 teeth: [ka] (In the formula, X B is -C(O)NH- or NH-C(O)-). Preferably, the wavy line on the left represents a PEG fragment (-[OCH-CH] m The wavy line on the right is the bond to the target fragment (L).
[0335] In some embodiments, the composition has formula IA: [ka] , (Preferably, n is from about 280 to about 700 with a dispersity of about 3 or less, more preferably from about 350 to about 630 with a dispersity of about 2 or less, and also more preferably from about 400 to 580 with a dispersity of about 1.2 or less, and preferably m is from about 2 to about 80 repeat units with a dispersity of about 2 or less, more preferably from about 2 to about 70 with a dispersity of about 1.8 or less; also more preferably from about 2 to about 50 with a dispersity of about 1.5, or alternatively, m is a discrete number of repeat units, preferably m is 12 or 24) This includes conjugates of
[0336] In some embodiments, the composition has formula IA-1: [ka] , (Preferably, n is from about 280 to about 700 with a dispersity of about 3 or less, more preferably from about 350 to about 630 with a dispersity of about 2 or less, and also more preferably from about 400 to 580 with a dispersity of about 1.2 or less, and preferably m is from about 2 to about 80 repeat units with a dispersity of about 2 or less, more preferably from about 2 to about 70 with a dispersity of about 1.8 or less; also more preferably from about 2 to about 50 with a dispersity of about 1.5, or alternatively, m is a discrete number of repeat units, preferably m is 12 or 24) This includes conjugates of
[0337] In some embodiments, the composition has formula IA-2: [ka] , (Preferably, n is from about 280 to about 700 with a dispersity of about 3 or less, more preferably from about 350 to about 630 with a dispersity of about 2 or less, and also more preferably from about 400 to 580 with a dispersity of about 1.2 or less, and preferably m is from about 2 to about 80 repeat units with a dispersity of about 2 or less, more preferably from about 2 to about 70 with a dispersity of about 1.8 or less; also more preferably from about 2 to about 50 with a dispersity of about 1.5, or alternatively, m is a discrete number of repeat units, preferably m is 12 or 24) This includes conjugates of
[0338] In some embodiments, the composition has formula IA-3: [ka] , (Preferably, n is from about 280 to about 700 with a dispersity of about 3 or less, more preferably from about 350 to about 630 with a dispersity of about 2 or less, and also more preferably from about 400 to 580 with a dispersity of about 1.2 or less, and preferably m is from about 2 to about 80 repeat units with a dispersity of about 2 or less, more preferably from about 2 to about 70 with a dispersity of about 1.8 or less; also more preferably from about 2 to about 50 with a dispersity of about 1.5, or alternatively, m is a discrete number of repeat units, preferably m is 12 or 24) This includes conjugates of
[0339] In some embodiments, the composition has formula IA-3a: [ka] , (Preferably, n is from about 280 to about 700 with a dispersity of about 3 or less, more preferably from about 350 to about 630 with a dispersity of about 2 or less, and also more preferably from about 400 to 580 with a dispersity of about 1.2 or less, and preferably m is from about 2 to about 80 repeat units with a dispersity of about 2 or less, more preferably from about 2 to about 70 with a dispersity of about 1.8 or less; also more preferably from about 2 to about 50 with a dispersity of about 1.5, or alternatively, m is a discrete number of repeat units, preferably m is 12 or 24) This includes conjugates of
[0340] In some embodiments, the composition has formula IA-3b: [ka] , (Preferably, n is from about 280 to about 700 with a dispersity of about 3 or less, more preferably from about 350 to about 630 with a dispersity of about 2 or less, and also more preferably from about 400 to 580 with a dispersity of about 1.2 or less, and preferably m is from about 2 to about 80 repeat units with a dispersity of about 2 or less, more preferably from about 2 to about 70 with a dispersity of about 1.8 or less; also more preferably from about 2 to about 50 with a dispersity of about 1.5, or alternatively, m is a discrete number of repeat units, preferably m is 12 or 24) This includes conjugates of
[0341] In some embodiments, the composition has formula IA-3c: [ka] , (Preferably, n is from about 280 to about 700 with a dispersity of about 3 or less, more preferably from about 350 to about 630 with a dispersity of about 2 or less, and also more preferably from about 400 to 580 with a dispersity of about 1.2 or less, and preferably m is from about 2 to about 80 repeat units with a dispersity of about 2 or less, more preferably from about 2 to about 70 with a dispersity of about 1.8 or less; also more preferably from about 2 to about 50 with a dispersity of about 1.5, or alternatively, m is a discrete number of repeat units, preferably m is 12 or 24) This includes conjugates of
[0342] In some embodiments, the composition has formula IA-3d: [ka] , (Preferably, n is from about 280 to about 700 with a dispersity of about 3 or less, more preferably from about 350 to about 630 with a dispersity of about 2 or less, and also more preferably from about 400 to 580 with a dispersity of about 1.2 or less, and preferably m is from about 2 to about 80 repeat units with a dispersity of about 2 or less, more preferably from about 2 to about 70 with a dispersity of about 1.8 or less; also more preferably from about 2 to about 50 with a dispersity of about 1.5, or alternatively, m is a discrete number of repeat units, preferably m is 12 or 24) This includes conjugates of
[0343] In some embodiments, the composition has formula IA-4: [ka] , (Preferably, n is from about 280 to about 700 with a dispersity of about 3 or less, more preferably from about 350 to about 630 with a dispersity of about 2 or less, and also more preferably from about 400 to 580 with a dispersity of about 1.2 or less, and preferably m is from about 2 to about 80 repeat units with a dispersity of about 2 or less, more preferably from about 2 to about 70 with a dispersity of about 1.8 or less; also more preferably from about 2 to about 50 with a dispersity of about 1.5, or alternatively, m is a discrete number of repeat units, preferably m is 12 or 24) This includes conjugates of
[0344] In some embodiments, the composition has formula IA-4a: [ka] , (Preferably, n is from about 280 to about 700 with a dispersity of about 3 or less, more preferably from about 350 to about 630 with a dispersity of about 2 or less, and also more preferably from about 400 to 580 with a dispersity of about 1.2 or less, and preferably m is from about 2 to about 80 repeat units with a dispersity of about 2 or less, more preferably from about 2 to about 70 with a dispersity of about 1.8 or less; also more preferably from about 2 to about 50 with a dispersity of about 1.5, or alternatively, m is a discrete number of repeat units, preferably m is 12 or 24) This includes conjugates of
[0345] In some embodiments, the composition has formula IA-4b: [ka] , (Preferably, n is from about 280 to about 700 with a dispersity of about 3 or less, more preferably from about 350 to about 630 with a dispersity of about 2 or less, and also more preferably from about 400 to 580 with a dispersity of about 1.2 or less, and preferably m is from about 2 to about 80 repeat units with a dispersity of about 2 or less, more preferably from about 2 to about 70 with a dispersity of about 1.8 or less; also more preferably from about 2 to about 50 with a dispersity of about 1.5, or alternatively, m is a discrete number of repeat units, preferably m is 12 or 24) This includes conjugates of
[0346] In some embodiments, the composition has formula IA-4c: [ka] , (Preferably, n is from about 280 to about 700 with a dispersity of about 3 or less, more preferably from about 350 to about 630 with a dispersity of about 2 or less, and also more preferably from about 400 to 580 with a dispersity of about 1.2 or less, and preferably m is from about 2 to about 80 repeat units with a dispersity of about 2 or less, more preferably from about 2 to about 70 with a dispersity of about 1.8 or less; also more preferably from about 2 to about 50 with a dispersity of about 1.5, or alternatively, m is a discrete number of repeat units, preferably m is 12 or 24) This includes conjugates of
[0347] In some embodiments, the composition has formula IA-4d: [ka] , (Preferably, n is from about 280 to about 700 with a dispersity of about 3 or less, more preferably from about 350 to about 630 with a dispersity of about 2 or less, and also more preferably from about 400 to 580 with a dispersity of about 1.2 or less, and preferably m is from about 2 to about 80 repeat units with a dispersity of about 2 or less, more preferably from about 2 to about 70 with a dispersity of about 1.8 or less; also more preferably from about 2 to about 50 with a dispersity of about 1.5, or alternatively, m is a discrete number of repeat units, preferably m is 12 or 24) This includes conjugates of
[0348] In some embodiments, the composition has formula IA-5: [ka] , (Preferably, n is from about 280 to about 700 with a dispersity of about 3 or less, more preferably from about 350 to about 630 with a dispersity of about 2 or less, and also more preferably from about 400 to 580 with a dispersity of about 1.2 or less, and preferably m is from about 2 to about 80 repeat units with a dispersity of about 2 or less, more preferably from about 2 to about 70 with a dispersity of about 1.8 or less; also more preferably from about 2 to about 50 with a dispersity of about 1.5, or alternatively, m is a discrete number of repeat units, preferably m is 12 or 24) This includes conjugates of
[0349] In some embodiments, the composition has formula IA-6: [ka] , (Preferably, n is from about 280 to about 700 with a dispersity of about 3 or less, more preferably from about 350 to about 630 with a dispersity of about 2 or less, and also more preferably from about 400 to 580 with a dispersity of about 1.2 or less, and preferably m is from about 2 to about 80 repeat units with a dispersity of about 2 or less, more preferably from about 2 to about 70 with a dispersity of about 1.8 or less; also more preferably from about 2 to about 50 with a dispersity of about 1.5, or alternatively, m is a discrete number of repeat units, preferably m is 12 or 24) This includes conjugates of
[0350] In some embodiments, the composition has formula IA-7: [ka] , (Preferably, n is from about 280 to about 700 with a dispersity of about 3 or less, more preferably from about 350 to about 630 with a dispersity of about 2 or less, and also more preferably from about 400 to 580 with a dispersity ...
Claims
1. A composition comprising a conjugate, the conjugate comprising: a linear polyethyleneimine fragment comprising an alpha end and an omega end; a polyethylene glycol fragment comprising a first end and a second end; where the alpha terminus of the polyethyleneimine fragment is the initiating residue; The omega end of the polyethyleneimine fragment is linked to a covalent linking group -Z-X 1 -Z- is connected to the first end of the polyethylene glycol fragment by -Z-, where -Z- is not a single bond and -Z- is not an amide; 1 - is a divalent covalent linking moiety; A composition, wherein the second end of the polyethylene glycol fragment is capable of binding to a targeting fragment.
2. The conjugate is a conjugate of formula I*: R 1 - (NR 2 -CH 2 -CH 2 ) n -Z-X 1 -(O-CH 2 -CH 2 ) m -X 2 -L (formula I*); [In the formula, n is any integer from 1 to 1500; m is any integer from 1 to 200; R 1 is the initial residue, where preferably R 1 is -H or CH 3 and R 2 are independently —H or an organic residue, —(NR 2 -CH 2 -CH 2 ) n R in 2 at least 80%, preferably 90%, of is H; X 1 and X 2are independently a divalent covalent linking moiety; Z is a divalent covalent linking moiety, where Z is not a single bond and Z is not -NHC(O)-; L is preferably a targeting fragment capable of binding to a cell. or a pharma- ceutically acceptable salt, solvate, hydrate, tautomer or enantiomer thereof.
3. The conjugate is a conjugate of formula I: [Formula 1] [In the formula, [chemical 2] is a single bond or a double bond; n is any integer from 1 to 1500; m is any integer from 1 to 200; R 1 is the initial residue, where preferably R 1 is -H or CH 3 and R 2 are independently —H or an organic residue, —(NR 2 -CH 2 -CH 2 ) n -R in 2 at least 80%, preferably at least 90%, of are H; Ring A is one or more R A1 R is a 5-10 membered cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl optionally substituted with A1 But independently, C 1 ~C 6 Alkyl, C 1 ~C 6 alkoxy, oxo, or halogen; or two R A1 may be combined together with the atoms to which they are attached to form one or more fused C 6 ~C 10 Aryl, C 5 ~C 6 Heteroaryl, or C 3 ~C 6 Each fused aryl, heteroaryl, or cycloalkyl may be joined to one or more R A2 optionally substituted with; R A2 But independently, C 1 ~C 6 Alkyl, C 1 ~C 6 Alkoxy, halogen, -SO 3 H or OSO 3 H; X 1 is a divalent covalent linking moiety; X 2 is a divalent covalent linking moiety; and L is a targeting fragment, where preferably the targeting fragment is capable of binding to a cell.
3. The composition of claim 1 or claim 2, which is a pharma- ceutically acceptable salt, solvate, hydrate, tautomer or enantiomer thereof.
4. R 1 - (NR 2 -CH 2 -CH 2 ) n - moiety is a dispersed polymer moiety having about 115 to about 1150 repeat units n and a dispersity of about 5 or less, preferably about 280 to about 700 repeat units n with a dispersity of about 3 or less, and more preferably about 350 to about 630 repeat units n with a dispersity of about 2 or less, wherein preferably R 1 is -H or CH 3 The composition according to claim 2 or claim 3,
5. -(O-CH 2 -CH 2 ) m 5. The composition of any one of claims 2 to 4, wherein - is a dispersed polymer moiety having from about 2 to about 80 repeat units m and from about 2 to about 70 repeat units m with a dispersity of about 2 or less, preferably from about 2 to about 70 repeat units m with a dispersity of about 1.8 or less; more preferably from about 2 to about 50 repeat units m with a dispersity of about 1.5 or less.
6. -(O-CH 2 -CH 2 ) m The moiety comprises, and preferably consists of, a discrete number of repeating units m from 4 to 60, and is preferably -(O-CH 2 -CH 2 ) m A composition according to any one of claims 2 to 4, wherein the moiety comprises, preferably consists of, a discrete number of consecutive repeating units m between 4 and 60.
7. Ring A is an 8-membered cycloalkenyl, a 5-membered heterocycloalkyl, or a 7-8-membered heterocycloalkenyl, where each cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl is optionally substituted with one or more R A1 7. The composition of claim 3, optionally substituted with
8. Ring A is cyclooctene, succinimide, or a 7-8 membered heterocycloalkenyl, where the heterocycloalkyl or heterocycloalkenyl contains 1 or 2 heteroatoms selected from N, O, and S, and each cyclooctene, heterocycloalkyl, or heterocycloalkenyl contains, at any position, one or more R A1 wherein preferably R A1 is oxo or fluorine, or two R A1 combine to form one or more fused phenyl rings, preferably one or two fused phenyl rings, wherein each phenyl ring contains one or more -SO 3 H or OSO 3 8. The composition of claim 3, optionally substituted with H.
9. The conjugate of formula I is [C3] , [C4] , [C5] , [C6] , [C7] , [C8] , and [C9] The composition according to any one of claims 3 to 8, wherein the composition is selected from
10. The conjugate of formula I is [C10] , [C11] , [C12] , [C13] , [C14] , [C15] , and [C16] The composition according to any one of claims 3 to 9, wherein the composition is selected from
11. The conjugate of formula I is [C17] , and [C18] The composition according to any one of claims 3 to 10, wherein the composition is selected from
12. The conjugate of formula I is [C19] The composition according to any one of claims 3 to 10, wherein the composition is selected from
13. The conjugate of formula I is [C20] , and [C21] The composition according to any one of claims 3 to 10, wherein the composition is selected from
14. X 1 but, [C22] (In the formula, r is independently at each occurrence 0 to 6, preferably 0, 1, 2 or 5; more preferably 0; s is independently for each occurrence 0 to 6, preferably 0, 2, 3 or 4; more preferably 2 or 3; t is independently at each occurrence 0 to 6, preferably 0, 1, 2, 4; more preferably 2; R 11 and R 12 is independently each occurrence -H and C 1 ~C 2 alkyl, preferably -H; and R 13 is -H; preferably, the wavy line closest to the integer "r" is the bond to ring A, and the wavy line closest to the integer "s" or "t" is -[OCH 2 -CH 2 ] m - is a bond with The composition of any one of claims 3 to 13, wherein the composition is selected from
15. X 1 but, [C23] (In the formula, X A is -NHC(O)- or C(O)NH-; and [C24] Preferably, the wavy line on the left is a bond to ring A and the wavy line on the right is —[OCH 2 -CH 2 ] m The composition of any one of claims 3 to 13, wherein the bond is -.
16. X 1 but, [C25] Preferably, the wavy line on the left is a bond to ring A and the wavy line on the right is —[OCH 2 -CH 2 ] m The composition of any one of claims 3 to 13, wherein the bond is -.
17. X 2 but, [C26] wherein X is selected from the group consisting of B is —C(O)NH— or NH—C(O)—; Y 2 Each occurrence independently represents a chemical bond, -CR 21 R 22 -, N.R. 23 -, -O-, -S-, -C(O)-, an amino acid residue, a divalent phenyl moiety, a divalent carbocyclic moiety, a divalent heterocyclic moiety, and a divalent heteroaryl moiety, wherein each divalent phenyl and divalent heteroaryl is selected from one or more R 23 and each divalent heterocyclic moiety is optionally substituted with one or more R 24 optionally substituted with; R 21 , R 22 and R 23 each occurrence independently represents -H, -SO 3 H, -NH 2 , -CO 2 H or C 1 ~C 6 alkyl, where each C 1 ~C 6 Alkyl is one or more of -OH, oxo, -CO 2 H, -NH 2 , C 6 ~C 10 optionally substituted with aryl or 5-8 membered heteroaryl; R 24 is independently each occurrence -H, -CO 2 H.C. 1 ~C 6 alkyl or oxo; preferably the left wavy line is -[OCH 2 -CH 2 ] m The composition of any one of claims 3 to 16, wherein the wavy line on the right is the bond to L.
18. X 2 but, [C27] , [C28] , is selected from Y 2 Each occurrence independently represents a chemical bond, -CR 21 R 22 -, N.R. 23 -, -O-, -S-, -C(O)-, an amino acid residue, a divalent phenyl moiety, a divalent carbocyclic moiety, a divalent heterocyclic moiety, and a divalent heteroaryl moiety, wherein each divalent phenyl and divalent heteroaryl is selected from one or more R 23 and each divalent heterocyclic moiety is optionally substituted with one or more R 24 optionally substituted with; R 21 , R 22 and R 23 each occurrence independently represents -H, -SO 3 H, -NH 2 , -CO 2 H or C 1 ~C 6 alkyl, where each C 1 ~C 6 The alkyl group is one or more of -OH, oxo, -CO 2 H, -NH 2 , C 6 ~C 10 optionally substituted with aryl or 5-8 membered heteroaryl; R 24 each occurrence is independently -H, -CO 2 H.C. 1 ~C 6alkyl or oxo; preferably the left wavy line is -[OCH 2 -CH 2 ] m The composition of any one of claims 3 to 16, wherein the wavy line on the right is the bond to L.
19. X 2 but, [C29] , [C30] , [C31] , [C32] , and [C33] Preferably, the left wavy line is selected from -[OCH 2 -CH 2 ] m The composition of any one of claims 3 to 16, wherein the wavy line on the right is the bond to L.
20. X 2 but, [C34] and preferably the wavy line on the left is -[OCH 2 -CH 2 ] m The composition of any one of claims 3 to 16, wherein the wavy line on the right is the bond to L.
21. X 2 but, [C35] 17. The composition of any one of claims 3 to 16, wherein
22. The composition according to any one of claims 1 to 21, wherein the targeting fragment L is capable of binding to a cell surface receptor, preferably the targeting fragment is capable of specifically binding to a cell surface receptor.
23. 23. The composition of claim 22, wherein the cell surface receptor is selected from growth factor receptors, extracellular matrix proteins, cytokine receptors, hormone receptors, glycosylphosphatidylinositol (GPI)-anchored membrane proteins, carbohydrate-binding integral membrane proteins, lectins, ion channels, G protein-coupled receptors, and enzyme-linked receptors such as tyrosine kinase-coupled receptors.
24. 24. The composition of claim 22 or 23, wherein the cell surface receptor is selected from epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), prostate surface membrane antigen (PSMA), insulin-like growth factor 1 receptor (IGF1R), vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), asialoglycoprotein receptor (ASGPr) and fibroblast growth factor receptor (FGFR).
25. 25. The composition of any one of claims 1 to 24, wherein the targeting fragment L is capable of binding to a cell surface receptor, the targeting fragment being a peptide, a protein, a small molecule ligand, a sugar, an oligosaccharide, an oligonucleotide, a lipid, an amino acid, an antibody, an antibody fragment, an aptamer or an affibody.
26. The targeting fragment L is selected from the group consisting of an EGFR targeting fragment; a PSMA targeting fragment, preferably a DUPA residue; an anti-HER2 peptide, preferably an anti-HER2 antibody or an affibody; folic acid; a somatostatin receptor targeting fragment, preferably somatostatin and / or octreotide; an integrin targeting fragment, preferably an arginine-glycine-aspartic acid (RGD) containing fragment; a low pH insertion peptide; an ASGPr targeting fragment, preferably asialoorosomucoid; an insulin receptor targeting fragment, preferably insulin; a mannose-6-phosphate receptor targeting fragment, preferably mannose-6-phosphate; a mannose receptor targeting fragment, preferably mannose; a Sialyl Lewis x26. The composition of any one of claims 1 to 25, selected from an antigen targeting fragment, preferably E-selectin; a sigma-2 receptor agonist, preferably N,N-dimethyltryptamine (DMT), a sphingolipid-derived amine and / or a steroid, more preferably progesterone; a p32 targeting ligand, preferably an anti-p32 antibody or a p32-binding LyP-1 tumor homing peptide; a Trop-2 targeting fragment, preferably an anti-Trop-2 antibody and / or antibody fragment; insulin-like growth factor 1; vascular endothelial growth factor; platelet-derived growth factor; and fibroblast growth factor.
27. Target fragment L contains DUPA residues (HOOC(CH 2 ) 2 -CH(COOH)-NH-CO-NH-CH(COOH)-(CH 2 ) 2 The composition according to any one of claims 1 to 26, wherein the aryl group is -CO-.
28. 28. The composition of any one of claims 1 to 27, wherein the conjugate is selected from Compound 1a, Compound 1b, Compound 4a, Compound 4b, Compound 7a, Compound 7b, Compound 10a, Compound 10b, Compound 14, Compound 17a, Compound 17b, Compound 18, Compound 19, Compound 22a, Compound 22b, Compound 28a, Compound 28b, Compound 31a, Compound 31b, Compound 38a, Compound 38b, Compound 43, Compound 47a, Compound 47b, Compound 51a, Compound 51b, Compound 56a, Compound 56b, Compound 62a, Compound 62b, Compound 70a, Compound 70b, Compound 72a, Compound 72b, Compound 75a, Compound 75b, Compound 78a and / or Compound 78b.
29. 29. The composition according to any one of claims 1 to 28, wherein the composition further comprises a polyanion, preferably the polyanion is a nucleic acid, the polyanion is preferably non-covalently bound to the conjugate, and the polyanion and the conjugate form a polyplex.
30. 30. The composition of claim 29, wherein the polyanion is a nucleic acid, and the nucleic acid is a dsRNA or ssRNA.
31. The composition of claim 30, wherein the nucleic acid is a dsRNA.
32. 32. The composition of claim 31, wherein the dsRNA is polyinosinic:polycytidylic acid (poly(IC)).
33. The composition of claim 30, wherein the nucleic acid is ssRNA.
34. The composition of claim 33, wherein the ssRNA is mRNA.
35. 35. A polyplex of a conjugate and a polyanion as defined in any one of claims 1 to 34, wherein the polyanion is preferably non-covalently bound to the conjugate, and preferably the polyanion is a nucleic acid.
36. A polyplex comprising a conjugate of formula I, or a pharma- ceutically acceptable salt, solvate, hydrate, tautomer or enantiomer thereof, and a polyanion, preferably a nucleic acid, wherein the polyanion, preferably a nucleic acid, is preferably non-covalently bound to the conjugate: [C36] [In the formula, [C37] is a single bond or a double bond; n is any integer from 1 to 1500; m is a discrete number of repeat units m from 2 to 100, preferably a discrete number of repeat units m from 4 to 60; R 1 is the initial residue, where preferably R 1 is -H or CH 3 and R 2 are independently —H or an organic residue, —(NR 2 -CH 2 -CH 2 ) n -R in 2at least 80%, preferably at least 90% is H; Ring A may have one or more R A1 R is a 5-10 membered cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl optionally substituted with A1 is independently 1 ~C 6 Alkyl, C 1 ~C 6 alkoxy, oxo, or halogen; or two R A1 together with the atoms to which they are attached to form one or more fused C 6 ~C 10 Aryl, C 5 ~C 6 Heteroaryl, or C 3 ~C 6 can form a cycloalkyl ring, where each fused aryl, heteroaryl, or cycloalkyl is selected from one or more R A2 optionally substituted with; R A2 is independently 1 ~C 6 Alkyl, C 1 ~C 6 Alkoxy, halogen, -SO 3 H or OSO 3 H; X 1 is a divalent covalent linking moiety; X 2 is a divalent covalent linking moiety; and L is a targeting fragment, where preferably the targeting fragment is capable of binding to a cell.
37. 37. The polyplex of claim 35 or claim 36, wherein the polyanion is a nucleic acid, and the nucleic acid is RNA.
38. 38. The polyplex of claim 37, wherein the RNA is dsRNA or ssRNA.
39. 38. The composition of claim 37, wherein the RNA is a dsRNA.
40. 40. The composition of claim 39, wherein the dsRNA is polyinosinic:polycytidylic acid (poly(IC)).
41. 38. The composition of claim 37, wherein the RNA is ssRNA.
42. 42. The composition of claim 41, wherein the ssRNA is mRNA.
43. 43. A pharmaceutical composition comprising a composition according to any one of claims 1 to 34 or a polyplex according to any one of claims 35 to 42, and optionally one or more pharma- ceutically acceptable excipients and / or carriers.
44. Cancer, preferably EGFR; HER2; prostate specific membrane antigen; folate receptor; integrin, preferably RGD integrin; asialoglycoprotein receptor; insulin receptor; mannose-6-phosphate receptor; mannose receptor; glycoside, preferably Sialyl Lewis x 44. A composition according to any one of claims 1 to 34 or a polyplex according to any one of claims 35 to 42 or a pharmaceutical composition according to claim 43 for use in the treatment of a cancer characterised by cells that overexpress an antigen; a sigma-2 receptor; a p32 protein; or Trop-2.
